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Abstract 
'Cavity disease', defined as the rapid degradation of the sporocarps of white button 
mushrooms, is caused by Burkholderia gladioli pv. agaricicola, a member of 
Pseudomonaceae. The specific strain analysed in this thesis, BG 164, was isolated from 
New Zealand, but the disease has also been sporadically reported in Europe. 
Nine mutants that did not cause cavity symptoms ('no-cavity') were isolated by 
transposon mutagenesis of the BG 164 derivative, BG 164R. Eight mutants had altered 
flagella number, did not secrete protease, had a highly reduced capacity to secrete 
chitinase and did not degrade mushroom mycelia. All these eight mutations were 
clustered in the GSP (General Secretory ~athway) operon. A cosmid, carrying 23.4kb 
genomic DNA, pCosGSP, complemented all mutations, which along with mapping of 
the cosmid, confirms that the cosmid has most or all of the functional gsp operon. 
The ninth mutant, BGII-107, secreted protease, although it did not form cavity on 
mushrooms. The DNA sequence analysis suggests that the mutation is in a polyketide 
synthetase gene. Interestingly, the mutant can also be complemented by the gsp operon-
containing cosmid, suggesting the presence of a polyketide synthetase gene adjacent to 
the GSP genes. 
Cavity disease initiation, in contrast to most of the other diseases, requires a very high 
inoculum of the pathogen, suggesting a probable reason for the sporadic appearance of 
the disease. Studies on the indigenous non-pathogenic bacterial population of 
mushrooms led to the identification of a natural antagonist of BG I 64R, Ewingella 
americana (PRCl20), in the sporocarp tissue. Population studies indicated the 
involvement of polymicrobial interactions and a quorum sensitivity-dependent 
induction of Cavity disease expression. 
Chapterl 
Chapter I 
General Introduction. 
1.1. Introduction. 
"The distinct difference between commensal, opportunistic and pathogenic 
microbes is that pathogenic microbes have evolved the genetic ability to 
breach cellular and anatomic barriers that ordinarily restrict other micro-
organisms. Thus pathogens can inherently cause damage to cells to 
forcefully gain access to a new, lmique niche that provides them with less 
competition from other microorganisms, as well as with a ready new source 
ofnutrients"· Stanley Falkow (Falkow, 1998). 
Microorganisms were probably the first forms of life on earth. In the process of 
adapting to the changing environmental conditions over the past 3.8 billion years 
(Mojzsis et al., 1996; Nutman et al., 1997) they have evolved to be ubiquitous. 
Microbial populations play an important role in maintaining the ecological balance of 
nature, while primarily still being engaged in their struggle for existence. 
Microbial interactions in nature can be broadly divided into eight classes neutralism, 
amensalism, commensalism, synergism, mutualism, competition, predation and 
parasitism. All these interactions are widely evident in a variety of natural habitats. 
When living hosts serve as specific niches, and interactions between hoast and microbe 
cause damage to the host (Brogden & Guthmiller, 2003), the interactions are called 
"diseases" and the microbes are known as "pathogens". However, if we consider it from 
the point of view of the microbe, it could simply be stated as a strategy adopted for 
survival in a specific niche. 
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The term 'disease' implies to the 'manifestation of damage to host' resulting from host 
microbe interactions (Casadevall & Pirofski, 2000). The basic principle underlying 
disease expression is the 'genetic capacity' of a 'pathogen' to 'breach host's defence 
mechanisms' (Falkow, 1998). The ability of bacteria to elicit disease symptoms in a 
host is either an attribute of signals from a potential host or a strategy adopted by the 
pathogen to survive in the host. Thus, regardless of the initial cause, bacteria become 
pathogens by responding to stimuli and switching on certain gene(s) that is/are 
detrimental to the host, but beneficial to the pathogen. 
Disease is observed in all forms of living organisms, including bacteria, if we consider 
phage infections that lyse bacterial cells as viral diseases. Depending on the nature of 
the host, microorganisms adopt various strategies to optimise their interactions with the 
hosts in order to cause diseases. These' include production of a wide range of products 
including enzymes, toxins and secondary metabolites that are collectively known as 
virulence factors (Salmond, 1994; Finlay & Falkow, 1997). A basic theme of disease 
formation is the release of these virulence factors by the pathogen into the targeted host 
tissue. Thus, secretion of virulence factors forms an essential component of disease 
expression, especially in case of bacterial pathogens. This thesis describes an attempt to 
identify the virulence factors involved in the expression of 'Cavity disease' in white 
button mushrooms. 
In 1992, Gill and Cole reported a novel disease in white button mushrooms, Agaricus 
bisporus (Lange) Imbach, from a farm in New Zealand. The disease rapidly affected the 
sporophores resulting in marked tissue degradation, and in severe cases caused a deep 
cavity in the cap of mushroom fruit body. Due to the typical symptoms associated, the 
disease was named 'Cavity disease' (Figure 1.1.), and, was defined as the 'rapid 
degradation of the pileus tissue of white button mushrooms'. The causative organism 
was identified as Pseudomonas cepacia and the strain was designated CANU-PMS164 
(Gill & Cole, 1992). 
--... -------------------------------
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Figure 1.1: Cavity disease of button mushroom, [AJ diseased mushroom. [BJ healthy 
mushroom. [C] lateral view of a diseased mushroom cavity, showing unaffected gills. 
Unlike most of the predominant mushroom diseases causmg significant crop losses 
worldwide (discussed in section 1.3.4.), this disease is not associated with tissue 
browning of the mushrooms. The other characteristic feature of this disease is, the 
pathogen selectively degrades the pileus tissue (Figure 1.2.) of button mushrooms 
leaving the gills and the stipe intact. 
~S;:--I!!!!!!i!!!~~~ ~== Pileuspilei 
ttl. ~~-Pileus 
"'----Gill 
V"~----- Anulus 
~------ Stock 
Figure 1.2: Schematic representation of the parts of a mushroom sporocarp 
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1.2. Why study a mushroom disease? 
A. bisponls (Lange) Imbach, the common cultivated button mushroom, is grown 
worldwide. In Europe, the annual production of A. bisponls is 8-9 xl05 tonnes per year. 
The highest producers are France and the Netherlands, followed by the UK (Godfrey, 
2003). The New Zealand mushroom industry currently produces 7500 tonnes of button 
mushrooms per year (Buchanan & Barnes, 2002) for local consumption as well as for 
export, with an estimated value of five million dollars (New Zealand). Because the 
worldwide production of cultivated mushrooms continues to grow [(Courvoisier, 1999) 
cited by Godfrey 2003, (Royse, 1997)], mushroom farmers continuously face the 
challenge of protecting their crops from diseases and adverse factors that impede the 
maximum cropping yield. Consequently, the scientific community remains attentive to 
the problems. associated with the industry and interested in suggesting probable 
remedies. 
Problems associated with the yields of A. bisponls crops can be attributed to abiotic and 
biotic factors involved in mushroom cultivation. Abiotic factors for the commercial 
mushroom production include temperature, relative humidity (Godfrey, 2003) and 
compost composition (Ivors et al., 2000; Milenkovic et al., 2000) and depend on the 
specific type of mushroom cultivated. These are constant factors in mushroom 
cultivation, for which scientifically formulated conditions best suited for the specific 
type of cultivated mushroom can be adopted in modern mushroom fanns (Wong & 
Preece, 1980). In contrast, the biotic factors associated with decrease in cropping yields 
are variable and are continuously monitored by producers and scientists (discussed in 
section 1.3.3. and 1.3.4.). A virus resistant variant of A. bisporus, Agaricus bitorquis 
(Quelet) Saccardo, has been introduced in some commercial farms, particularly in 
tropical countries, and also in some New Zealand farms (Gill & Cole, 1992; Buchanan 
& Barnes, 2002) to prevent economic losses (Gill & Cole, 1992) due to viral infections. 
In spite of being virus resistant, A. bitorquis is susceptible to a range of bacterial 
diseases, especially diseases caused by Pseudomonas spp (Wong et al., 1982; Rainey & 
Cole, 1988; Geels et al., 1994; Moquet et al., 1996; Gill & Cole, 2000). Cavity disease 
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reported by Gill and Cole (1992) was one such pseudomonad disease, and the first 
example of a non-fluorescent pseudomonad associated with a mushroom disease. 
Although Gill and Cole named the disease as 'Cavity disease' in 1992, similar 
mushroom diseases had been reported earlier from the Horticultural Research 
International, Littlehampton, u.K. by Lincoln et al., in 1991 (Lincoln et al., 1991). 
They described the disease as 'Rapid soft rot disease of edible mushroom' and 
identified the causative organism as Pseudomonas gladioli pv. agaricicola. One ofthese 
isolates, strain RR3 was deposited in the National Collection of Plant Pathogenic 
Bacteria (accession number NCPPB 3850). The soft rot disease in mushrooms is stated 
to be less prevalent than most of the other Pseudomonad diseases in the mushroom 
industry. It is sporadically reported from farms in the UK and other European countries. 
However, when Cavity disease occurs, it causes devastating effects within very short 
periods of time. Thus it has received considerable attention from mushroom scientists, 
as a pathogen that has the potential to cause considerable crop losses to the mushroom 
industry (Fermor & Lincoln, 2001) (Lincoln et al., 1991; Gill & Cole, 1997). 
Intrigued by the rate and magnitude of tissue degradation of mushroom sporocarps by 
P. gladioli pv. agaricicola strain CANU-PMS164, the current project was initiated to 
study the molecular mechanism(s) by which the pathogen expresses Cavity disease 
symptoms on button mushrooms. A number of speculations on the probable mode of 
action of CANU-PMS 164 in the formation of Cavity disease was suggested by Gill and 
Cole, (1997) on the basis of biological experiments. It was shown that the strain 
produces a potent inhibitor of tyrosinase (Ferrar, 1995), which is the enzyme 
responsible for the browning of tissues in mushrooms and other plants. However, to 
date, genetic analyses directed towards identifying the actual gene(s) or gene product(s) 
of P. gladioli pv. agaricicola or P. cepacia CANU-PMSI64 responsible for disease 
expression have not been undertaken. Thus, molecular investigations addressing the 
gene(s) involved in expression of Cavity disease fonn the main theme of this thesis. 
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1.3. Literature review. 
1.3.1. Previous research on the causative agent of Cavity disease. 
In the first report of Cavity disease by Gill and Cole in 1992, the causative 
microorganism was designated as CANU-PMS164 and deposited in the culture 
collection of the Department of Plant and Microbial Sciences, University of Canterbury. 
In spite of a few differences with the type strain ATCC 25416, CANU-PMS 164 was 
identified as P. cepacia and was the first report of a non-fluorescent pseudomonad 
associated with mushroom disease. The range of symptoms observed in case of cavity 
disease varied from mild blotching to pitting of the fruiting body of mushroom 
sporocarp; and, in acute cases led to the complete degradation of the whole sporocarp 
(Gill & Cole, 1992). 
Young (1992) surveyed antifungal compounds produced by soil-inhabiting microbes. 
CANU-PMS 164 was one of the isolates investigated and showed that this strain 
inhibits the growth of filamentous fungi, Trichophyton and Fusarium. On the basis of 
some biochemical studies, including thin layer chromatography and UV absorption 
spectra, it was speculated that the inhibitory compound was pyrrolnitrin (a common 
antifungal antibiotic produced by Pseudomonas sp.), or a closely related compound for 
which biological activity is destroyed at temperatures above 40°C (Young, 1992). 
Ferrar (1995) also screened CANU-PMS164 when he was surveying phytopathogens as 
a source of novel diphenol oxidase (DPO) inhibitors. DPO is responsible for the 
browning of most fruits and vegetables. Ferrar demonstrated that CANU-PMS164 
causes 20% inhibition of the mushroom ortho-diphenol oxidase (o-DPO) or tyrosinase 
but does not inhibit the para-diphenol oxidase (p-DPO ) or laccase (Ferrar, 1995). 
Gill and Tsuneda (1997) investigated the pathogenicity of CANU-PMS164 on other 
varieties of economically important mushrooms in Japan such as Lentinula edodes, 
Pleurotus ostreatus, Flammulina veiupies, Pholiota nameko, Hypsizygus marmoreus 
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and Grifola frondosa . This study showed that pathogenicity of the organism has a 
broad host range and is can cause similar soft rotting symptoms in a number of 
commercially important mushrooms. However, the intensity of disease formation varies 
amongst the different species. Scanning electron microscopy revealed that damage to 
the host tissues of the different mushroom species was distinct for each type of 
mushroom used. The authors suggested that the pathogen damages the various 
mushroom fruit bodies and their different parts in two ways. Degradation of the hyphal 
wall layer followed by the degradation of chitin matrix of A. bisporus was suggested to 
be the first mode of action, while shrivelling of mushroom hyphae was the second. The 
other interesting observation about this pathogen was that it inhibited the mycelial 
growth in plate assays with mycelial cultures from the different mushroom species. 
Based on these observations Gill and Tsuneda (1997) speculated that the microorganism 
first secretes a toxin followed by induction of hyphae degrading enzymes (Gill & 
Tsuneda, 1997). 
In 1997, Gill and Tsuneda reported that the Cavity disease-causing isolate CANU-
PMS164 was compared to the mushroom soft rot pathogen P. gladioli pv. agaricicola 
(Lincoln et aI., 1991) and re-identified as P. gladioli pv. agaricicola (Gill & Tsuneda, 
1997). In 1992, Yabucchi et al. (Yabuchi et al., 1992), proposed a new genus name, 
Burkholderia, to include members of the "pseudomallei group", which were not true 
Pseudomonads. Based on their proposal, P. gladioli pv agaricicola CANU-PMS164, 
was transferred to the new genus and is presently known as Burkholderia gladioli pv. 
agaricicola. 
At the outset of this project, a 16s rDNA sequence analyses of CANU-PMS164 was 
carried out to confmn the taxonomic status. On the basis of the analysis and all the 
information available, the strain was re-designated as BG 164. BG stands for 
!l.urkholderia gladioli pv. agaricicola. The collection number, 164, as catalogued 
earlier, was retained. Subsequently, a spontaneous rifampicin resistant mutant strain of 
BG164 was generated (section 23.1) and this was used in the studies described in this 
thesis. This strain was identified as BG 164R, where R represents Rifampicin resistance 
inBGl64. 
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1.3.2. Nomenclature of Burkholderia gladioli pv. agaricicola. 
Burkholderia is a new genus name proposed by Yabucchi et al. in 1992 for the RNA 
homology group II Pseudomonads, in honour of the American bacteriologist W. H. 
Burkholder, who fIrst discovered the etiologic agent of rotten onion (Burkholder, 1950). 
The genus Pseudomonas consists of pathogenic bacteria, mainly plant pathogens and a 
few animal pathogens. Palleroni et al. in 1973 (Palleroni, 1984) divided the different 
species belonging to the genus Pseudomonas into fIve defInitive groups on the basis of 
rRNA/DNA homology. This system of classifIcation was confIrmed subsequently by 
several laboratories following several other approaches, including investigations on 
metabolic pathways and their regulatory mechanisms, determination of amino acid 
sequences of selected proteins, immunological studies, cell wall composition and 16S 
ribosomal RNA sequences (Palleroni, 1984). 
B. gladioli was originally identifIed as a phytopathogen of gladiolus (Mc Culloch, 
1921). The disease symptoms, although often confIned to the lower leaves of the plant, 
could occur in all parts of the foliage. The pathogen was particularly reported to be 
active under moist and humid conditions, and typical symptoms consisted of circular to 
elliptical rusty red lesions, which gradually turned dull brown to purple. Lucia Mc 
Culloch (1921) of the Bureau of Plant Industry in the u.s. Department of Agriculture 
first isolated the disease causing bacterium of gladioli and named it Bacterium 
marginatum. According to her report, the disease was especially prevalent in the 
District of Columbia where 80 to 90% of the crops were attacked, although it was found 
from Illinois to Califoruia. Mc Culloch initially isolated and described the 
phytopathogen, but, it was not chosen as the type strain. 
Previously, Severini reported a similar disease in gladiolus and named the causal 
organism as P. gladioli {Severini 1913}. Bacterium marginatum (Mc Culloch, 1921) 
and P. gladioli were considered synonyms. Strains with similar phenotypic 
characteristics have been reported to be pathogenic to iris, onion and gladiolus 
elsewhere but have mainly been described as P. marginata. Burkholder isolated another 
group of strains, exclusively pathogenic to onions, which was phenotypically very 
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similar to the strain described above, and named it P. alliicola (Palleroni, 1984). Young 
et al. (1978) proposed the inclusion of two pathovars within the species to designate the 
different pathogenic capacity (Young et aI., 1978). The two pathovars of P. gladioli 
suggested were pv. gladioli and pv. alliicola. The type strain ATCC10248 was chosen 
as a lectotype to represent P. galdioli pv. gladioli and the reference strain for P.gladioli 
pv. alliicola was ATCC19302 (Palleroni, 1984). The isolation of the mushroom soft 
rotting bacteria by Lincoln et al. in 1991 was the first report of any disease of fungi 
caused by the rRNA homology group II Pseudomonad. The isolate was compared to the 
above two pathovars of P. gladioli and the creation of a new pathovar, pv. agaricicola 
was proposed within the species P. gladioli, to accommodate this newly characterised 
pathogen. The literal meaning of the term "agaricicola" was "dwelling on the gill 
bearing fungi" (Lincoln et al., 1991). 
1.3.3. Chemical composition of mushroom sporocarps. 
Chemically, mushrooms are made up of 89-94% water; 2.6-4% protein, 2.5-5.8% 
carbohydrates, only 0.2-0.7% crude fat, 0.6-1 % fibre and just over 1% ash (Godfrey, 
2003). The fungal cell wall can be described as a ~-linked chitin and glucan skeleton 
embedded in an amorphous matrix made up mainly of water-soluble polysaccharides 
(Alexopoulos et al., 1996). The major carbohydrate is chitin, which is chemically 
defined as a ~-1-4 linked homopolymer of N-acetylglucosamine. Chitin is chemically 
unique to fungal cell walls and insects, and serves a vital role as the main structural 
component of the fungal cell walls. The glucans in the fungal cell wall are generally 
long chains of ~-1-3 linked glucose molecules with occasional ~-1-6 linkages found in 
the mature cell walls (Carlile et aI., 2001). Besides chitin and glucans, other 
components making up fungal cell walls consist of polysaccharides such as a-glucans 
and glycoproteins as well as lipids, melanins, D-galactosamine polymers and 
polyuronids (Alexopoulos et al., 1996). Fungi generally do not have cellulose, a cell 
wall component prevalent in plants, and pectins, with the exception of members 
belonging to Oomycetes (Carlile et aI., 2001). 
Mushrooms are a good source of nutrition for humans, because of their chemical 
composition (Vetter, 2003). Both the white and brown varieties of A. bisporus are 
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chemically similar, with chitin being the main source of dietary fibre. It has been 
estimated that chitin provides 27kcal of energy per 100g (Mattila et aI., 2002). The 
major soluble carbohydrates are mannitol, trehalose and glycogen. Sucrose, glucose, 
and hemicellulose are also present (Burton et al., 1994; Eastwood et al., 2000). 
Mushroom contains both saturated and unsaturated lipids, about 50% of which are 
neutral lipids (Godfrey, 2003). They also contain almost all amino acids, and the protein 
content in mushrooms has been found to be comparably higher than common fruit and 
vegetables (Zivanovic et al., 2003). Of the minerals, mushrooms contain large amounts 
of potassium, phosphorous, copper, iron and low concentration of sodium (Vetter, 
2003). Nutritionally mushrooms are very healthy and thus are a popular food item for 
human beings (Zivanovic et al., 2000). 
Parameters defining the quality of mushrooms in case of commercial production consist 
Of the colour, appearance, texture, aroma and flavour (Burton et al., 2000), which are, in 
tum, dependent on the chemical composition of mushrooms. An important aspect 
governing mushroom quality is the fact that mushroom sporocarps continue to grow and 
carry on their basic biological processes even after being harvested. It was demonstrated 
that during the first six days following harvest the mushroom sporocarps toughen in 
texture, gradually accompanied by softening (Zivanovic et al., 2000). Zivanovic et al. 
(2000), in their work on the textural changes in A. bisporus, have ascribed softening of 
mushroom tissues to the loss of total protein and polysaccharide content and shrinkage 
of hyphae, leading to an increase in intercellular spaces of pileus tissues, while the 
toughening was correlated to the increase in the chitin content of mushroom tissues on 
storage. The preferred colour of mushroom sporocarps is white. However, the most 
frequent problem associated with the mushroom industry is browning of mushrooms 
(Mamoun et aI., 2000a). 
Browning of the mushroom tissue, like most other fruit and vegetables, is a biochemical 
reaction, which has widely been accepted as a defence mechanism in plants against the 
pathogens (Walker & Ferrar, 1998). It is an enzymatic process catalysed by two major 
groups of enzymes, the diphenol oxidases (DPOs) and the peroxidases (Ferrar & 
Walker, 1999). In intact cells, both the enzyme and its substrates are present, but they 
are spatially separated, with the enzyme being cytosolic and the phenolic substrates 
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being present within the vacuoles (Walker & Ferrar, 1998). However, wounds cause a 
disruption of the vacuolar membrane, thereby bringing the enzyme and substrate into 
contact, catalysing the reaction and generation of reactive quinones by DPOs (Walker & 
Ferrar, 1998). These reactive quinones polymerise either with themselves or with 
amino acids or small peptides to give a characteristic brown colour (Walker, 1975). 
This protects the tissue: firstly, by sealing off the site of wound, forming a physical 
barrier and, secondly, by polymerising both the host's proteins and the toxic compounds 
produced by the pathogen, thereby rendering them inactive (Walker & Ferrar, 1998). 
DPOs are of two broad types: ortho-diphenol oxidases and para-diphenol oxidases 
(Walker, 1975). Although mushrooms have both o-DPO and p-DPO, their relative 
distribution in the skin layer (pileuspilei) and the soft flesh underneath (pileus tissue) 
are quite different. High levels of o-DPO activity are present in the skin of the 
sporocarp (Burton et al., 1993). 
Aldridge and Walker (1980) monitored the changes in the amino acid content during the 
developmental stages ofbasidiocarps in an attempt to find out the possible substrate for 
the activity of o-DPO. They found that there was a decrease in the content of tyrosine 
and phenylalanine and an increase in proline, histidine and threonine with the maturity 
of the sporocarps. These extracted amino acids were also challenged with the mushroom 
tyrosinase, but no obvious target could be identified by this approach (Aldridge & 
Walker, 1980). 
Sporophores of mushroom contain both active and latent or inactive tyrosinase (Burton, 
1988, Button et al., 1993). The effects of pre- and post-harvest development of 
mushroom tyrosinase at different stages as well as on the two different tissue types, 
namely the skin of the fruiting body (pileispileis) and flesh (pileus trauma) were 
investigated by Burton (Burton, 1988). He reported that there were no significant 
changes in the tyrosinase activity between the different harvests of the mushroom crop, 
but a major difference lies in the degree of activation of the latent tyrosinase during the 
pre- and post- harvest stages. Tyrosinase activity increases during the post harvest stage. 
It was suggested that this change in the tyrosinase activity was due to the increase in the 
protease activity in the post harvest senescence stage of the mushroom sporocarps. The 
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tyrosinase activity was found to be about 2 to 2.8 times higher in skin of the mushroom 
than in the flesh (Burton et aI., 1993). 
1.3.4. Mushroom diseases. 
The diversification of the mushroom industry, in terms of variety of mushrooms as well 
as production worldwide, has gained impetus since the 1980s (Royse, 1997). With the 
emergence of this agro-industry, the scientific community has become aware of the 
different diseases related to mushrooms. Moulds and fungi, viruses and bacteria all 
cause diseases in mushrooms, resulting in significant economic losses to the mushroom 
industry. 
Fungal diseases: 
Fungal diseases, which have been reported in the literature, include 'Cobweb disease' 
caused by Cladobotryum dendroids (Mc Kay et al., 1999), 'Green mould epidemic' 
caused by several strains of Trichoderma (Mamoun et al., 2000b), 'Wet bubble disease' 
caused by Mycogene perniciosa (Vmar et al., 2000), 'Dry bubble disease' caused by 
Verticillium species (Mills et al., 2000) and 'Shaggy stipe disease' caused by 
Mortierella bainieri (Fletcher, 1973). 
The 'Cobweb disease' is so named after the coarse mycelia covering the affected 
mushrooms, thereby giving the appearance of a cobweb. This is accompanied by 
spotting of the caps of the mushroom and is often mistaken for bacterial blotch of the 
mushrooms. The disease is best identified when conidia from the cobweb rapidly 
colonise the casing surface and eventually the affected mushrooms tum brown and rot 
(Mc Kay et al., 1999; Godfrey, 2003). 
The 'Green mould epidemic' (Mamoun et al., 2000b) is gradually becoming well 
known as a destructive disease of cultivated mushrooms, causing alarming crop losses 
in many regions of the world. The disease can easily be recognised by its dark green 
sporulation in the compost or in the casing layer. Mushrooms normally do not grow in 
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the affected compost. However, if the mould advances in a mushroom bed, they spot the 
mushrooms and show disease symptoms similar to 'Mild dew' . 
The 'Wet bubble disease' of mushrooms is caused by Mycogone perniciosa (Umar et 
01., 2000). The symptoms are characterised by severe developmental errors in the fruit 
body formation and acute malformation of the mushroom sporocarps. The disease is 
very contagious and results in severe crop loss. Although the pathogen grows 
superficially, it is associated with cytological changes within the host. This results in the 
exudation of teardrop like extracellular fluid from the infected host and hence the 
disease is commonly known as 'Wet bubble disease'. 
Members of the genus Verticillium are generally associated with the 'Dry bubble 
disease' (Godfrey, 2003), cap spotting and stipe blowout disease in crops of cultivated 
mushrooms. The disease process involves a complex interaction between the host tissue, 
spores and mycelium of the pathogen. Details of these interactions are not yet clearly 
understood (Mills et 01.2003). 
'Shaggy stipe disease' is caused by Mortierella bainieri, and is characterised by peeling 
of the stipe tissue of Agaricus mushrooms (Fletcher, 1973). The stipe and the cap are 
also discoloured in the course of infection. Generally a course grey mycelial growth 
similar to 'Cobweb disease' is also noticed on the infected sporocarp. The pathogen can 
attack mushroom sporocarps in all stages of growth. Some affected sporocarps are 
stunted in appearance and irregular in shape. Brown blotches are also observed on the 
surface of sporocarps in case of infection during the late stage of developments. The 
disease, although reported from some parts of England, is of little commercial 
importance. 
Viral diseases: 
The 'Mushroom bacilliform virus' causing 'La France disease' is the most well studied 
example of a double stranded RNA-virus causing disease in mushroom (Schisler et ai., 
1967; Zabalgogeazcoa et 01., 1995). Typical symptoms of this disease are cessation of 
sporocarp formation or malformation of sporocarps, followed by death, and also 
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disappearance of the mycelia from the compost bed. The disease is also known as 
dieback, watery stipe and brown disease of mushrooms (Godfrey, 2003). 
The only other viral disease, causing considerable concern in the mushroom industries 
of UK, is caused by an unidentified virus X (Gaze et al., 2000). Typical symptoms of 
this viral infection were non-productive beds of mushroom crops. The disease 
symptoms were reported 1996 onwards from different farms in England. The extent of 
disease formation appeared to be increasing each year. The variable symptoms in a 
typical bed affected by this virus ranged from small patches of non-productive zones in 
an otherwise normal cropping bed to predominant areas of no growth in the mushroom 
beds, with erratic growth of mushroom sporocarps in a non-productive bed. In the latter 
cases, the mushroom sporocarps usually appeared in clumps. In some cases, discoloured 
and distorted sporocarps have also been reported (Gaze et ai., 2000). 
Bacterial diseases: 
The most important bacterial pathogens of mushrooms belong to the genus 
Pseudomonas. The pseudomonad diseases in mushrooms are either associated with the 
formation of a characteristic blotch accompanied with a brown pigmentation or result in 
the formation of bacterial oozes from the infected areas. Brown blotch disease caused 
by Pseudomonas tolaasii (Moquet et al., 1996), ginger blotch caused by P. gingeri 
(Wong et ai., 1982) and the brown discolouration of mushrooms caused by P. agarici 
(Gee1s et al., 1994) are three distinct examples. 
Symptoms of P. tolaasii infection are the formation of brown depressed wet lesions on 
the cap tissue both during growth and storage, in contrast to the P. agarici infection, 
where only the outer covering of the cap develops a characteristic brownish marble 
appearance and a sticky surface which can easily be removed by gently rubbing the 
affected area. Another disease caused by P. agarici is 'drippy gill' disease (Gill & 
Cole, 2000). Symptoms of 'drippy gill' disease include the fonnation of bacterial ooze 
on the hymeneal lamellae, which at times coalesced to fonn ribbons of bacterial ooze. 
Rainey and Cole (1988) described an unnamed disease, which had the symptoms such 
as malformation of the fruiting body, a characteristic constriction in the gill region, and 
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marked tissue degeneration with bacterial ooze in the stock (Rainey & Cole, 1988). The 
latter disease-causing pathogen, designated as PMS-PV29, was compared to P. agarici 
and P. tolaasii, and distinct differences were found. However, this pathogen could not 
be assigned a distinct taxonomic status. 
Recently an enteric bacterium, Ewingella americana, has been found to be pathogenic 
to mushrooms. The disease is known as 'Internal §.tipe gecrosis' (ISN) and the pathogen 
is associated with limited collapse of the internal stipe (stalk) tissue. This disease is also 
accompanied by variable browning in the centre of the stipe (Inglis et al., 1996). E. 
americana is associated with the production of chitinase, in the presence of glucose and 
N-acetyl glucosamine, in the absence of chitin, as the strain does not utilise chitin as a 
carbon source. Another recently reported pathogen of brown mushroom, causing soft 
rot symptoms somewhat sinIilar to B. gladioli pv agaricicola, is Janthinobacterium 
agaricidamnosum (Lincoln et aI., 1999). The host pathogen relation and the mechanism 
of disease formation have not yet been established. 
P. tolaasii is associated with the production of a toxin, tolaasin. Tolaasin results in the 
activation of an enzyme, tyrosinase, which is responsible for the browning of the 
mushroom tissue (Soler-Rivas et ai., 1997). However, it was suggested that the 
production of tolassin is not the only factor related to the formation of disease 
symptoms (Moquet et ai., 1996). P. tolaasii is the most discussed problem in the 
mushroom industry, as it has been estimated to be responsible for 8-10% of crop loss 
(Moquet et ai., 1996; Godfrey, 2003). 
Several research programmes have been undertaken to look at means of preventing the 
tissue browning associated with these diseases. One example is the use of a cell free 
extract containing a lipodepsipeptide produced by P. reactans to inhibit browning 
caused by P. tolaasi (Soler-Rivas et al., 1999). This lipodepsipeptide reacts with 
tolassin, the toxin responsible for the browning of mushroom tissues. The reaction 
results in the precipitation of a characteristic white compound. The diffusible 
lipodepsipeptides produced by P. reactans are known as white line inducing nrinciple 
(WLIP) and has been proposed as the potential inhibitor of brown blotch disease (Soler-
Rivas et aI., 1999). Another putative bio-control strain of brown blotch bacteria was 
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isolated from rotting cultivated mushrooms, Pleurotus ostreatus and A. bisporus by 
Tsukamoto et al., (1998) (Tsukamoto et al., 1998). The strain 9405 is a Gram-positive, 
saprophytic bacterium, which does not produce tyrosinase and inhibits brown blotch 
symptoms in vitro. In vivo inhibition of brown blotch was not as apparent, but its 
candidature as a bio-control agent should be further evaluated, especially in relation to 
whether the strain has any adverse effects on mushrooms or humans. 
1.3.5. Burkholderia and pathogenesis. 
The genus Burkholderia, (Yabuchi et al., 1992), consisted of three plant pathogens (B. 
caryophylli, B. gladioli and B. solanacearum), and four species known to be pathogenic 
to humans (B. mallei, B. pseudomallei, B. cepacia and B. pickettii). In 1995, Yabucchi 
and his colleagues (Yabuchi et al., 1995) proposed the transfer of B. pickettii and B. 
solanacearum to a new genus, Ralstonia. Presently, the genus Burkholderia consists of 
five species, three human pathogens and two plant pathogens. 
Although B. cepacia has long been known to be a phytopathogen responsible for soft rot 
of onion, it is now an increasingly recognized pathogen among immuno-compromised 
patients, particularly those with chronic granulomatous disease and cystic fibrosis 
(Govan et al., 1996; Revets et al., 1996). Its potential role in declining pulmonary 
function and other associated fatal outcome has caused widespread concern (petrucca et 
a!., 2003; Mahenthiralingam et al., 2002; Ross et al., 1995; Simpson et al., 1994). The 
most common diseases in patients with chronic granulomatous disease are pneumonia, 
bacteraemia, skin abscesses, and cervical adenitis. The organism's innate resistance to a 
number of antibiotics and disinfectants, and capacity to colonise a wide variety of 
nutritional substrates, means that the epidemic strains are easily transmitted within the 
cystic fibrosis community. The disease outcome in about 20% of such infections are 
generally described as a rapid decline in clinical status known as 'cepacia-syndrome', 
leading to septicaemia and death of individuals. Recently, a natural outbreak of 
subclinical mastitis caused by B. cepacia complex in milking sheep was reported in 
Spain (Berriatua et al., 2001). This was the first report of B. cepacia infection in 
animals. 
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B. pseudomallei is commonly lmown as the pathogen causing melioidosis and is 
endemic to southern Asia and northern Australia (Dorman et al., 1998). The disease 
varies from asymptomatic infection to fulminant sepsis. Although well Imown as a 
tropical disease, Dorman et al. (1998) has reported a fatal B. pseudomallei infection in 
America, in a Puerto Rican patient with X-linked chronic granulomatous disease. Other 
predisposing conditions that enhance the severity of melioidosis are impaired cellular 
immunity, pre-existing renal failure or diabetes mellitus (Schwarzmaier et al., 2000). 
Glanders is a contagious disease caused by the bacterium B. mallei, attacking hoofed 
animals. Humans may also be infected. Horses usually develop a chronic form of the 
disease with infected nodules and lesions in the respiratory tract and the skin. Although 
this disease has been nearly eradicated from the world, it is still prevalent in some 
enzootic areas of Asia and Africa (Galan & Arceiz, 1997). 
Of the plant pathogenic speCIes of Burkholderia, B. caryophy/li is a pathogen of 
carnations (Dianthus caryophyllus). Disease symptoms vary from stunting and wilting 
to cracking of stems of the infected plants (Lelliott & Stead, 1987). In Japan, B. 
caryophylli is the most damaging disease of carnations, which results in massive crop 
losses, especially in the warm districts of the country. The pathogen can attack almost 
all cultivars of B. caryophylli. Although the pathogen is mostly associated with 
Dianthus spp., Liu in 1990 described a similar wilting disease in Gypsophila panieulata 
and identified the causal organism as B. earyophyl/i (Liu, 1990). 
Initially identified as a phytopathogen of gladiolus, several strains of B. gladioli 
pathogenic to a number of other plants as onions, iris, freessia, dendrobium, cymbidium, 
tulip, green gram and rice have been isolated and identified (Mat suyama, 1998). Disease 
symptoms vary from spotting of foliar parts to scabbing and rotting of storage tissues. 
Although primarily a phytopathogen, B. gladioli has gained much more attention since 
the last decade, as it has been found to cause severe pulmonary infections in cystic 
fibrosis and other immuno-compromised patients (Simpson et al., 1994; Ross et ai., 
1995). The expanding spectrum of human disease symptoms associated with B. gladioli 
includes bacteremia (Shin et aI., 1997), septicaemia and empyema (Khan et al., 1996). 
Graves et al. 1997 reported the association of bacteremia, pneumonia and cervical 
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adenitis in immuno-compromised patients with B. gladioli infections (Graves et aI., 
1997). 
1.3.6. Common virulence factors identified in pathogenic Burkholderia spp. 
Like all other pathogenic bacteria, Burkholderia elicit disease symptoms by production 
of a range of virulence factors. In theory, any molecule produced by bacteria, presented 
either on the cell surface or secreted to the external environment, by virtue of which 
bacteria colonise and destroy a specific host could act as a virulence factor (Salmond, 
1994). In the case of plant pathogens, the extracellular virulence factors include plant 
cell wall degrading enzymes, toxins, hormones, siderophores, DNA molecules and 
signalling factors. The cell surface associated virulence factors are exemplified by 
structures like pili, flagella, lipopolysaccharides, exopolysaccharides and outer 
membrane bound proteins (Salmond, 1994). Over the past decade, virulence factors 
associated with the various members of the genus Burkholderia have been explored in 
relation to the diseases outlined above. Examples of such virulence determinants are 
presented below. 
1.3.6a. Cell surfact;l associated virulence factors. 
Among the surface associated virulence factors, roles of flagella have been extensively 
studied in the two human pathogens, B. pseudomallei and B. cepacia. Chua et al. 
(2003), in their study on the aflagellate, non motile mutants of B. pseudomallei in the 
BALB/c mice model, have shown that flagella facilitate spread throughout the 
respiratory tract and adhesion to the host cells, but do not have any role in the invasion 
of host cells (Chua et al., 2003). In contrast, flagella mediated motility of B. cepacia has 
been demonstrated to be the major contributory factor in the invasion of human alveolar 
epithelial carcinoma cell line A549 (Tomich et al., 2002). The result published by Chua 
et ai. (2003) contradicted previously published work of De Shazer et al. (1997) in which 
no differences could be detected in the virulence properties of non-motile aflagellate 
mutants of B. pseudomallei (1 026b) in diabetic rat and Syrian Hamster models of 
infection. Such mixed results indicate that virulence determinants can be specific to the 
model system being used for the particular analysis. This was also noted by Gan et al. 
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2002, who proposed Caenorabrhabditis elegans as a model system for the study of 
melioidosis (Gan et al., 2002). 
In 2001, DeShazer et al. identified a gene for capsular polysaccharide protein in B. 
pseudo mallei (1 026b) with homology to glycosyltransferase gene, wbpX, of 
Pseudomonas aeruginosa. They demonstrated that transposon insertion in the gene 
renders the pathogen avirulent in the Syrian Hamster model for study of acute 
septicemic melioidosis (Reckseidler et al., 2001). Sokol et al. (1999) have characterised 
an omibactin biosynthesis gene, pvdA, which plays a significant role in the synthesis of 
pyoverdine type siderophores, in B. cepacia strain K-56, and have demonstrated its role 
in respiratory infection in a rat modeL From their data, they suggest that the omibactin 
biosynthesis and uptake plays a role in the early stages of lung colonisation in the case 
ofB. cepacia infection (Sokol et al., 1999). 
1.3.6b. Extracellular/secreted virulence factors. 
Lee and Liu (2000) identified a novel serine metalloprotease MprA, with significant 
sequence similarity to the subtilisin family of serine proteases, as a virulence 
determinant of B. pseudomallei (Lee, 2000). Gan et al. (2002) demonstrated a 
correlation of the virulence of clinical isolates of B. pseudomallei to the production of 
diffusible toxins by the strain, using their proposed Caenorabrhabditis elegans model 
for melioidosis. The potential toxin(s) were not identified in the report, however, their 
diffusible nature was established by filter assay techniques, and the gene sequence of 
three mutants indicated the isolation of novel proteins with significant sequence 
similarity to hypothetical proteins P A2762, and PA2945 of P. aeruginosa and a 
hypothetical 37.5kD protein in agai-mtr intergenic region of E. coli K-12 (Gan et aI., 
2002). 
In case of plant pathogenic Burkholderia, it was found that most of the strains of B. 
gladioli produced the phytotoxin toxoflavin, while the other species of the genus 
Burkholderia were associated with the production of tropolone (Iiyama et al., 1998). 
The relationship between the production of phytotoxins and pathogenicity of B. gladioli 
in rice seedlings and onion tubers was tested in a number of strains of the pathogen. 
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The authors suggest that the pathogenicity of the different species of Burkholderia 
involved other unidentified factors besides phytotoxins. 
Apart from the diffusion of toxins identified by Gan et al. (2002), export of the 
virulence-associated factors is generally dependent on the different secretion systems 
present in Gram-negative bacteria. Tomich et al., (2003) used a murine model to 
demonstrate a direct association of type III secretion system with the virulence of B. 
cepacia. They identified the genes in B. cepacia with significant similarity to type III 
secretory proteins and demonstrated that a null mutation in bscN gene, encoding an 
ATP binding protein of the type III secretion, resulted in the attenuation of the strain 
(Tomich et al., 2003). The mprA serine metalloprotease gene described by Lee and Liu 
(2000) has also been reported to have a signal sequence, thereby suggesting the role of 
sec-dependent transport of the mature protein (Lee & Liu, 2000). Thus, the different 
protein secretion systems have also been suggested to play significant roles in the 
pathogenesis of bacteria. 
1.3.6c. Gene induction. 
It is often evident that a pathogen has to reach a threshold density before expressing 
virulence. This is because, the regulation of genes responsible for the production of 
certain virulence factors depends on the concentration of signalling molecules (Lewenza 
et al., 1999; Anand & Griffiths, 2003; Jude et at., 2003), which in tum depends on the 
concentration of bacteria. Such density dependent induction of genes is popularly 
known as 'Quorum sensing'. Bacteria generally continuously produce diffusible 
signalling molecules at a basal level into its surrounding environment. With the increase 
in the quorum of bacterial cells, the concentration of such molecules in the immediate 
environment increases. At certain threshold concentrations, detected by specific 
receptors, transcriptional regulators activate specific genes. The key role in the process 
is thus played by the small diffusible signals well known as the 'autoinducers', which 
interact with their specific cognate transcriptional regulators. 
The most well documented autoinducers present in the different species of bacteria are 
acylated homo serine lactones (Fuqua & Greenberg, 1998). A study on the distribution 
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of quorum sensing genes in the different members of Burkh0 Ideria cepacia complex has 
revealed the production of N-octanooyl-L-homoserine lactone and N-hexanoyl-L 
homoserine lactone, in most members of the complex (Lutter et aI., 2001), although, 
presence of additional acyl-HSLs including decanoyl-HSl has been reported in B. 
vietnamiensis (Conway, 2002). These systems regulate the production of virulence 
factors like protease, lipase and siderophore in the different species of Burkholderia. 
The, PmlI-PmIR, and CepIR quorum sensing signals have been associated with the 
production of virulent metalloproteases, MprA in B. pseudomallei and ZmpA in B. 
cenocepacia (Sokol et al., 2003; Valade et al., 2004), thus indirectly implicating 
quorum sensing in the disease process. 
1.3.7. 'Soft Rot' disease. 
Cavity disease has been described as 'Soft rot' disease of mushrooms (Gill & Tsuneda, 
1997). Bacterial soft rot disease in plants is loosely defined as the degradation of tissues 
by extracellular enzymes produced by pathogenic bacteria (Barras et al., 1994). Cavity 
formation in mushrooms involves extensive tissue degradation of mushroom sporocarps 
and is hence quite naturally described as a 'Soft rot' disease of mushrooms. 
Depolymerisation of the cell wall components forms the main aspect of tissue 
maceration in the case of 'Soft rot' disease. Thus, extracellular enzymes serve as the 
major pathogenic factor in disease development in the case of 'Soft rot' diseases. Of the 
many soft rot diseases investigated in plants, studies on Erwinia carotovora and 
Erwinia chrysanthemi exemplify the most well documented 'Soft rot' pathogen. These 
species are responsible for causing tissue-macerating diseases in a variety of plants and 
in different plant parts (Barras et al., 1994). 
The virulence determinants of Erwinia include lipopolysaccharides (Schoonejans et al., 
1987), iron uptake systems (Expert & Toussaint, 1985), flagella (Mulholland et al., 
1993), global repressor gene rsmA that controls the production of extracellular enzymes, 
quorum sensing signals like N-(3-oxohexanoyl)-L-homoserine Lactone (Cui et al., 
1995), proteases (Martis et al., 1999) and secondary metabolites (Chatteljee, et al. 
1996). The extracellular enzymes associated with pathogenesis of these bacteria are 
mainly pectin degrading enzymes, besides cellulases and proteases (Barras et aI., 1994) 
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(Martis et al., 1999), which together degrade the plant cell walls. Production of 
extracellular pectinases and cellulases has been established to be the principal 
pathogenic factor in the soft rot diseases (Barras et al., 1994). Of the different 
extracellular enzymes secreted by Erwinia spp., the proteases are secreted by the type I 
secretion pathway while secretion of the range of pectin degrading iso-enzymes and 
cellulase depends on the general secretory pathway. Thus, the general secretory 
pathway has been suggested to play an essential part in the pathogenesis of the most 
well studied members of soft rot bacterium Erwinia spp. 
The following section is hence dedicated to provide a brief overview of the different 
secretion systems found in Gram-negative bacteria, with special emphasis on the Type 
II secretion system. 
1.3.8. Secretion systems present in Gram-negative bacteria. 
Unlike eukaryotic cells, each bacterial cell can be conceived as a compartmentalised 
self-sufficient entity, with either a single membrane (Gram-positives) or double 
membranes (Gram-negatives) delimiting the cellular contents from the environment. 
The secretion systems in Gram-negative bacteria can be divided into two broad classes 
depending on the process by which proteins get exported across the inner membrane 
after being synthesised in the cytoplasm (Stathopoulos et al., 2000; Pugsley, 1993; 
Wandersman, 1996; Pugsley et al., 1997b; Thanassi & Hultgren, 2000). 
(i) The sec-dependent protein export systems, in which the secretion of proteins 
across the inner membrane is mediated by membrane embedded translocation 
complex and the export specific chaperone made up of a group of proteins 
called the 'sec' proteins. 
(ii) The sec-independent protein export systems, in which the proteins are secreted 
directly across both the inner and outer membranes through special apparatus 
spanning both the membranes. 
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In the sequential passage of compounds across the cell membranes the most commonly 
used system in crossing the inner membrane is the sec-system, also known as the 
general export pathway (GEP). This is the most prevalent secretory system present in 
Gram-positive bacteria (Driessen et ai., 1998). Recently, a second secretion pathway 
known as the Iwin-Arginine-Iransport (TAT) pathway, originally identified as a 
protein transport route into the thylakoid of chloroplast (Hutcheon & Bolhius, 2003), 
has been identified in both gram-negative and gram-positive bacteria (Berks, 2000) and 
members of archae bacteria (Hutcheon & Bolhius, 2003). Proteins to be secreted 
undergo sorting and are directed to the respective transport apparatus in the cytoplasmic 
face of the bacterial inner membranes. To facilitate identification, the proteins being 
secreted by both the sec-system and the TAT pathway have N-terminal signal 
sequences. The sec pathway signal peptides are approximately 24 amino acids in length 
which can be divided in three distinct regions: an N-terminal positively charged region 
(n-region), a hydrophobic a-helical region (h-region) and a c-domain which has the 
signal peptidase cleavage site. The TAT pathway recognise proteins by the presence of 
a conserved (S/T)-R-R-x-F-L-K sequence motif at the n-regionlh-region boundary of 
the polypeptide, with consecutive invariant arginine residues (Berks et al., 2000). The 
other major difference between proteins that are transported by the TAT pathway and 
the sec-system is that the former transports proteins in a folded form while the later 
transports linear polypeptides (Berks et ai., 2000; Hutcheon & Bolhius, 2003). 
Transport across the outer membrane is mediated by a number of systems, and each 
secreted protein seems to have a specific pre-destined system for its transport. Thus, the 
specific recognition of the secretory substrates by the specific secretin is dependent on a 
second group of well-defined signals as outlined below. 
As presented in figure 1.3., secretion systems in Gram-negative bacteria will be divided 
into two broad classes in this review, essentially categorised by their dependence on the 
sec-system for transport of proteins across the inner membrane. 
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Figure 1.3: General overview of the different secretory systems present in Gram-negative 
bacteria . 
1.3.8a. The sec-dependent secretory systems: 
The four types of secretion pathways, which facilitate transport from the periplasm to 
the external milieu, are categorised as: 
(i) Type II secretion : responsible for the secretion of extra cellular enzymes and 
toxins. 
(ii) Type IV secretion : a system adapted to function in the transport of diverse 
substrates such as DNA in bacterial conjugation and T -DNA into the plant 
cells and delivery of a variety of effector proteins produced by pathogenic 
bacteria into the target eukaryoti c cells. 
(iii) Type V secretion: secretes proteins with diverse functionalities as proteases, 
toxins, adhesions and invasions . 
(iv) Chaperone lUsher Pathway: mainly responsible for the secretion of the 
different kinds of pili that enable adhesion of pathogenic bacteria to the 
respective host cell types. 
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Type II secretion system: 
The type two-secretion system is the main terminal branch of two-step secretion 
processes. It generally consists of 12 proteins spanning the cell envelope to form the 
core of the secreton, besides some associated proteins present in specific cases for the 
efficient functioning of the secretory machinery (Peabody et al., 2003). The type two 
secretion apparatus has been studied and identified in a range of Gram-negative bacteria 
including B. cepacia (Kimoto & Nakazawa, 2000; Fehlner-Gardiner et aI., 2002) and B. 
pseudomallei (DeShazer et al., 1999), and is popularly known as the General.s.ecretory 
fathway (GSP) of protein secretion. Most type II systems secrete more than one 
structurally divergent protein through the same set of secretion machinery (Pugsley et 
al., 1997b). An exception is Klebsiella oxytosa, which secretes only one enzyme, 
pullulanase (Pugsley et al., 1997a). 
The different components of the type II secretion system consist of GspD (Figure 1.4), 
which is the only outer membrane associated protein forming the secretin in the outer 
membrane. Proteins GspG, H, I, J have periplasmic domains and major similarities to 
type IV pili proteins for which they are also know as the pseudopilins (Peabody et al., 
2003). Another subset of inner membrane bound proteins is present, (GspC, F, K, L, M, 
N) which also have periplasmic domains but do not show any sequence similarities to 
the pili proteins. GspE is the only cytoplasmic protein, and possesses a conserved ATP-
binding motif thereby providing an autokinase activity; evidently it energises the 
secretion process or assembly of the secretory apparatus (Thanassi & Hultgren, 2000). 
Apart from these, two other GSP proteins are often found in the systems and known as 
GspM and GspL (Peabody et al., 2003). The latter is known to be the responsible for the 
association of GspE to the membrane, while the former is known to be the stabiliser for 
GspE. In some cases, a periplasmic protein GspS is also found, and is believed to act as 
a molecular chaperone in guiding the secretory substrates to the secretin, GspD. 
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Figure 1.4: Diagrammatic representations of Type II and Type IV secretion systems found in 
gram-negative bacteria (Thanassi & Hultgren, 2000). 
The GSPs in the different bacterial systems have distinct signals, which are recognised 
specifically by the outer membrane pore forming protein GspD, although no specific 
domains on the secreted polypeptides could be designated as a signal sequence in any of 
the secreted products. However, specific relationship between the folding of 
polypeptides in the periplasmic space (Nakazawa & Mitsuko, 1996; Stathopoulos et af., 
2000) and their ability to be secreted across the outer membranes has been reported in 
many cases (Pugsley et aI., 1997b). It is envisaged that the accurate folding of 
polypeptides expose certain motifs which are recognised by the chaperones and act as 
the signals necessary for the recognition of candidate proteins to be secreted by the type 
II machinery and moved across the outer membrane of the cell (Stathopoulos el 01., 
2000). 
The secretion machineries in the different systems studied shows a high specIes 
specificity and generally cannot functionally complement gsp operon of a closely 
related species (Pugsley el 01. , 1997b). However, deGroot e/ 01. (2001) have recently 
shown that the recognition of substrates by the GSPs of two closely related species can 
be exchanged (de Groot el aI., 2001). The pullulanase secretion of Klebsiella ()xy tosa, 
Chapter 1 27 
was the first studied type II secretion apparatus and is considered to the prototype of the 
GSP in Gram-negative bacteria (Pugsley et ai., 1997a). 
Pullulanase, product of pulA gene, is a 120kD oligomeric lipoprotein that is secreted by 
K. oxytosa only when grown in media containing starch, maltose or intermediate size 
dextrines (Pugsley et al., 1997a). The enzyme cleaves 0.-1,6 linkages in maltodextrin 
polymers thereby liberating linear dextrins, which can then be utilised by the bacterial 
cells. Secreted PulA is temporarily anchored to the cell surface of the bacteria by the N-
terminal fatty acid moiety before being released into the media. The secretion of PulA 
requires 14 specific gene products, which form the 'pullulanase secreton' and the DsbA 
protein (Stathopoulos et aI., 2000). The secreton is made up of a cytoplasmic protein, 
PulE, which consist of an ATP binding site and a tetra cysteine motif (Possot & Pugsley, 
1997), and functions as the potential energiser of the system. The integral inner 
membrane proteins PuIC, PulM, PulN, PulK and PulF form the basal body of the 
secretion apparatus and are anchored to the periplasmic side of the inner membrane. 
They are generally attached to the inner membrane by a single N-terminal domain 
followed by a large C-terrninal domain. PulC is suggested to form a bridge between the 
components situated in the two membranes. The four pilin like proteins PuIG,H,I and J 
possess prepilin peptidase cleavage and methylation sites, localised in the periplasm 
and has been suggested to form a secretion channel for the passage of PulA 
(Stathopoulos, 2000). In addition to these four perpilin peptidases, the pullulanase 
secretion system consists of a pilin-like signal peptidase, which is an absolute necessity 
for the secretion ofpullulanase (Pugsley et ai., 1997a). PulD forms the outer membrane 
bound secreton consisting of 10-14 multimers spanning the membrane. PuIS serves as a 
molecular chaperone for the pullulanase secretion system and is responsible for the 
targeting of PulA to the PulD secretin by interaction with the C-terminal domain. The 
N-terminal domain of PulD is suggested to be responsible for the substrate recognition 
and also interaction of PuIC. PulL is a monotopic imler membrane bound protein that 
interacts with the energiser molecule of the system, PulE (Stathopoulos et aI., 2000). 
Possot and Pugsley (1997) have shown that the tetracysteine motif of PulE is essential 
for the effective functioning of the secreton in the pullulanase secretion. They have also 
compared the PulE homologues present in a nmnber of other Gram-negative bacteria, 
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EpsE of Vcholerae, QutE of chlysanthemi, XcpE in P. aureginosa and XpsE in 
Xanthomonas campestris. With the exception of Xanthomonas, all the PulE homologues 
investigated had the 4 cysteine motif (possot & Pugsley, 1997). 
In 1996, Sauvonnet and Pugsley demonstrated that the two non-adjacent regions at the 
N-terminal region of PulA, were together necessary and sufficient for the efficient 
secretion of the pullulanase. Absence of either one of the regions reduced the secretion 
of pullulanase and secretion was completely abolished in the absence of both. They 
created a series of deletion strains from the C-termmal end of the pullulanase gene, 
fused ~-lactam to each of the truncated genes and monitored the secretion of BlaM. 
Two regions, were identified as A and B, which were 78 and 80 amino acids in length 
and present in the N-tenninal end that served as the secretion signal for PulA 
(Sauvonnet & Pugsley, 1996). Lu and Lory 1996 applied a similar ~-lactam fusion 
approach to the exotoxin A of P. aeruginosa and identified a 60 amino acid signal 
sequence at the N-terminal region of toxin A (Pugsley et al., 1997b). 
GSP apparatus in different Gram-negative bacteria have been found to consist of 
homologues to the Pul proteins. In P. aeruginosa, it is known as the 'xcp gene' cluster 
and is associated in the secretion of toxin A (Mc Yay & Hamood, 1995), elastase, LasA, 
alkaline phosphatase, lipases and phospholipaseC (Sandkvist, 2001). In members of 
Erwinia spp it is known as the 'out' gene cluster and is associated with the secretion of 
pectinases, cellulase (Barras et al., 1994) and polygalacturonase (Sandkvist, 2001). In 
Vibrio cholereae it is known as the 'eps' system and is responsible for the secretion of 
the cholera toxin (Sandkvist et al., 1997), neuraminidase, lipase (Sandkvist, 2001), 
protease as well as an endochitinase (Connell et al., 1998). InXanthomonas campestris, 
the cluster is known as the 'xps' gene cluster and is associated with the secretion of 
polygalacturonate lyase, a-amylase, protease and endogluconase (Sandkvist, 2001). In 
Aeromonas hydrophila the general secretory pathway is designated as the 'exe' and is 
involved in the secretion of toxin, aerolysin, amylase, phospholipaseC, proteases and 
DNAse (Sandkvist, 2001) and cell surface structures (Howard & Meiklejohn, 1995). 
Generally, the genes of the pathway are clustered in one single region of the 
chromosome (Pugsley et al., 1997b). The gsp cluster has recently been found to be 
present in E. coli K-12 and has been associated with the secretion of endogenous 
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extracellular protein ChiA (Francetic et aI., 2000) . DNA sequence analyses of the 
proteins constituting the GSP secretion machinery (Figure IA.) in the different species 
of bacteria studied so far reveal 30-60% identity at the protein level. Most of the genes 
in the gsp gene cluster of the different species are organised in a single operon with an 
exception observed in case of P. aeruginosa, (Figure 1.5) which has two diverging 
operons. Minor variations in the organisation of the genes are sometimes observed at 
the 5' or the 3' termini of the gene cluster (Sandkvist, 2001). The gspC gene in 
Bpseudomallei I 026b gsp operon is transcribed in a direction opposite to the rest of the 
genes (De Shazer et aI., 1999). 
B. I'selldo/'/wllei ~SIJ 
P. (lerugi i7{)sa xep 
X . c;al1ll'esfris xps 
Eeo/; K 12 gsp 
P.pllrido xel' 
·\':FI.5flciios« gsp 
K.oxyroco plI! 
Figure 1.5: Alignments of the genes encoding type II secretion pathways studied in some 
bacteria. The individual species with the names of their secretion genes are presented on the 
left side. The figure represents a schematic diagram of the genes from A to 0 , each colour 
represents a specific gene and its homologue in case of P. aeruginosa.(Figure adopted from 
Sandkvist, 2001) 
The gsp gene cluster in E. coli K-12 has been designated 'cryptic' (Francetic & Pugsley, 
1996) as under normal laboratory conditions the strain does not secrete any proteins to 
the extracellular media. As a result, initially, the system could not be traced in E.coli K-
12 for a long time. The first indication of the system being present in E. coli came from 
partial sequence analysis of a protein which had homology to the MTB protein 0, and 
the entire operon was identified following the sequencing of the E. coli K-] 2 
chromosome (Francetic & Pugsley , 1996). Sequence data reveal the presence of a full 
complement of the pul genes , puIC-O, present in E. coli K-12 , namely gspC-O. 
Generally, the secretion apparatus in most of the members of Gram-negative bacteria 
consist of all the proteins stated in case of pullulanase secretion . However occasionally, 
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some proteins may be present, an example is the absence of the xepK (gspK) homologue 
in type II system of P. putida (de Groot et al., 1999). 
The type IV secretion system is homologous to the virB system in A. tumefaeiens 
dedicated to the transport of oncogenic T-DNA into plant cells (Dang et al., 1999; 
Seubert et al., 2003). Examples of protein secretion by this machinery are CagA protein 
secretion by Helieobaeter pylori into the infected gastric epithelial cells, secretion of 
multicomponent Bordatella petrusis toxin secreted by the Ptl system (Seubert et al., 
2003) and secretion of a toxin by Legionella tern/dot involved in phagosome trafficking 
and macrophage killing while residing in the eukaryotic vacuoles (Dang et al., 1999). 
Although the best studied secretion apparatus in case of type IV system is the virB 
systems of Agrobaeterium, Figure 1.4. represents the P. aeruginosa type IV pili 
synthesis system, to depict the degree of similarity to the type II secretion apparatus 
(Thanassi & Hultgren, 2000). 
The type IV pili or the secretion apparatus are polarly localised and play an important 
part as the virulence determinants in bacteria, by enhancing adherence to the target cells 
and also mediating a specific kind of motility known as twitching motility 
(Stathopoulos, 2000). Secretion and assembly of the type IV apparatus also require 14 
proteins, some of which have similarities to the type II systems (Stathopoulos et aI., 
2000). In the case of type IV pili, the pili subunits get cleaved off the signal sequence at 
the cytoplasmic face of the inner membrane, in contrast to that of the periplasmic face 
in case of all the other mentioned systems (Stathopoulos et al., 2000). Translocation of 
the pili subunits to the membrane surfaces in case of P. aeruginosa and N gonorrhoeae 
is facilitated by PilQ, which forms the secretion channeL However, in case of virB 
system, no such outer membrane associated secretin is found (Thanassi and Hultgren, 
2000). In P. aeruginosa and N gonorrhoeae there are three energy transducer systems 
present in the cytoplasmic face. The first one is Pil B, a mutation in which results in the 
loss of surface pili; the other two are Pil T and Pil U, mutations in either one of which 
results in hyper-pilinated strains, although they still remain devoid of the capacity of 
twitching motility (AIm & Mattick, 1997). 
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Type V secretion system: 
Some proteins get transported across the outer membrane either with the help of certain 
domains present as a part of their structures (known as the autotransporter family) or, 
aided by helper protein(s) (consisting of two types, the two-partner systems and 
Oligomeric foiled coils !!dhesin or the Oca Family) (Desvaux et al., 2004). Together, 
these systems are categorised as the Type V secretion system. The self promoted extra 
cellular secretion system found in Neisseria and Haemophilus for the secretion of 
immunoglobulin A protease is generally taken as the prototype for the autotransporter 
secretion pathway. Examples of the two-partner system are extracellular release of the 
mature filamentous haemagglutinin (FHA) of B. petrusis and, Serratia marcescens 
hemolysin secretion system. While the prototype of Oca family of secretin is the YadA 
secretion in Yersinia enterocolitica (Desvaux et al., 2004). 
The characteristic feature of proteins secreted by the autotransporter system is the 
presence of a few distinct domains in the periplasmic precursor polypeptides, other than 
the N-terminal signal sequence. These domains help in either the recognition of the 
helper proteins or in the passage of the proteins across the outer membrane after the 
polypeptides are autocatalytically cleaved off their signal sequence at the periplasmic 
face of the inner membrane (Thanassi & Hultgren, 2000). In contrast, in case of the 
twine partner system, the exoprotein and the p-barrel forming proteins are separately 
translated as two distinct proteins, while the members of the Oca family have six 
different domains, as exemplified by in the YadA secretion in Y. enterocolitica 
(Desvaux et al., 2004). 
The Neisseria and Haemophilus immunoglobulin A protease splits the hinge region of 
the human IgA (Wandersman, 1996). Such proteins that support self-transport are 
characterised by the presence of a distinct C-terminal domain, which enables them to 
anchor themselves in the outer membrane and then gradually get secreted through a 
barrel-like pore formed by the P barrel domain of the protein (Figure1.6B left). The 
mature protein, in this case, gets folded into the secondary structure before being 
secreted into the external milieu, and is auto-proteolytic ally cleaved off the C-terminal 
sequence after being docked into the periplasmic face of the outer membrane. The other 
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accessory domains (n and -I) also get cleaved off before the mature protein is liberated 
into the ex ternal environment (Desvaux et ul, 20(4). 
"r- t ' . L 
Figure 1.6: Diagrammatic representations. [AJ Chaperon Usher pathway (The alphabets 
representing the respective Pap proteins of the P pili). {BJ Type \I secretion systems present in 
Gram-negative bacteria (Thanassi & Hultgren, 2000). 
The ,,),. 1II01,("(' S('(,I1.\ pore forming hemolysin, ShlA is secreted across the outer membrane 
in thc prcsence of a single separate helper protein, ShlB. The activation of ShlA 
depends on its interaction with the helper protein. ShlB not only facilitates secretion 
across the outer membrane. but also helps in processing of the precursor protein. The 
site of interaction of these two proteins lies in the N-terminal rcgion of ShIA. Cleavage 
of 149 amino acid residues from the N-tcrminal l'nd of ShlA protein renders it inactive 
and incapable of being activated by ShlB. thereby suggesting the presence of an 
actlvation domain of ShlB in ShlA (Wancersman, 1')')6). Pm/ellS miru/Ji/is haemolysin 
and H. jJefl'llssis l:haH proteins have similar secretory systems (Thanassi & Hultgren . 
20()O) . 
'haperon/Usher Pat]1\vay: 
The production of P pili and the type I pili are good examples to illustrate the 
chaperon/usher pathway . whieh is an alternative tcmlinal branch of protein secretion 
tound in (iram-negative bacteria (Stathopoulos cf ul. 20(0). The components or the 
secretion machinery is characterised by the presence of a peri plasmic chaperon. which 
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plays multifunctional roles of facilitating the release of the polypeptides from the sec 
apparatus, enabling the proper folding of the periplasmic intermediate, and the guided 
movement of the secretory protein to the inner face of the usher, or the secretin on the 
outer membrane (Thanassi & Hultgren, 2000). As represented in Figure 1.6A., PapD 
plays the role of the periplasmic chaperone, while PapC is the outer membrane usher, 
forming a ring shaped multimeric component on the membrane surface (Thanassi et al., 
1998). Apart from the chaperon and the usher, the system also requires the products of 
six genes - PapA, the major pilin; PapE, the minor pilin and generally present at the tip 
of the composite pili; PapG, which forms the adhesin and is involved in the recognition 
of the Gala moieties of the kidney cells (Thanassi et al., 1998); PapF which forms the 
adapter moiety of the PapG to the PapE; and PapK, products of which link the minor 
pili fibrils to the PapA rod. The rod is terminated by PapH, which also plays the role of 
an anchor to the membrane. The chaperon directs the polypeptides to the secretin and 
once the substrates reach the usher, PapC, the chaperone, dissociates. The pathway does 
not require input of external energy for the secretion of proteins across the outer 
membrane, and the movement of the pilin subunits are supposed to take place by 
diffusion across the usher (Stathopoulos et al., 2000). 
1.3.8b. The sec-independent secretory systems. 
The ABC transport systems and the type III secretion system, which have major 
structural similarities to the flagella apparatus, exemplify the sec-independent protein 
transport systems. In both these cases the proteins get transported directly into the 
external surface without the formation of any periplasmic intermediate. 
ABC Transport System 
The ABC transporters are associated with the transport of a wide variety of substrates 
from the cell to external environment in both eukaryotes and prokaryotes. Examples of 
proteins transported by the ABC transport system are include a-haemolysin by E. coli, 
metalloproteases by E. chrysanthemi and S. marcesence, alkaline protease by P. 
aureginosa, hemoprotein (HasA) by S. marcescens, leucotoxin by Pasteurella 
hemolytica, toxin adenyl cyclase (CyaA) by B. petrusis (Wandersman, 1992) and 
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Colicin V by E. coli (Zhang et al., 1995). In gram-negative bacteria, the ABC proteins, 
in conjunction with other proteins are also involved in the uptake of certain specific 
substrates like maltose, histidine, iron chelating siderophore and oligopeptide 
complexes (Wandersman, 1996). 
The main characteristic of this system is the presence of a membrane bound ATPase as 
an inner membrane component of the secretion apparatus. Essential characteristics of 
ATPases are the presence of a hydrophobic domain, which spans the membrane six 
times, and a nucleotide binding cytoplasmic domain. The cytoplasmic domain forms a 
fairly conserved cassette while the hydrophobic domains are not conserved. In general, 
the secretion signal of the proteins secreted by the ABC transporters is situated close to 
the C-terminal end of the polypeptides being secreted (Thanassi & Hultgren, 2000). 
However, an exception to this is found in case of Colicin V secretion in E. coli which 
has an amino terminal secretion system (Zhang et al., 1995). 
The first protein exporter system identified was the a-hemolysin transporter of E. coli 
and is presented in Figure 1.7. The secretory apparatus consists of three components. 
The inner membrane bound ABC transporter, the hiller membrane fusion protein or the 
MFP and the outer membrane protein (OMP), which in case of hemolysin transport is 
ToIC. The outer membrane protein forms a barrel that spans the outer membrane and 
extends into the periplasm. The membrane fusion protein is generally trimeric and 
traverses the periplasmic space linking the OMP to the ABC transporter. The ABC 
protein having the nucleotide-binding site acts as the energizer for the whole system 
(Thanassi & Hultgren, 2000). 
Generally, the ABC transporters are associated with the export of either one specific 
protein or with the secretion of a group of isoenzymes, thereby indicating high 
specificity. However, the secretion systems of E. coli hemolysin, E. chfysanthemi and 
P. aeruginosa metalloproteases have been reconstituted in E. coli. 
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Figure 1.7: Diagrammatic representations of Type I secretion system (Left) and Type III 
secretion system of Yersinia sp. (Right).( Thanassi & Hultgren, 2000) 
Type III secretion: 
The type III secretion apparatus is the most sophisticated system that connects secretion 
to pathogenesis (Comelis & Van Gijsegem, 2000). It generally enables the pathogenic 
bacteria adhering to the surface of the eukaryotic cells to inject bacterial proteins into 
the host cells across three membranes, two present in bacteria and the host cell 
membrane. The system consists of a secretion apparatus and an assortment of secreted 
proteins, some of which act as effectors by directly affecting the target cells, while 
others are trans locators that enable the passage of effectors across the eukaryotic cell 
membranes. Type III secretory systems are present both in animal and plant pathogens. 
In the latter case, they are responsible for elicitation of disease or hypersensitive 
reactions. The effector proteins in plant pathogens belong to two classes, harpins and 
avirulence proteins. The well known animal pathogens exhibiting type III system 
mediated diseases are Yersinia, Shigella, Salmonella, Bordetella, Pseudomonas 
(Thanassi & Hultgren, 2000), Burkholderia cepacia (Tomich et aI., 2003), 
enteropathogenic and enterohemorrhagic E.coli and express diseases ranging from fatal 
septicaemia to mild dian'hoea and from fulgurant diarrhoea to chronic lung infection 
(Comelis & Van Gijsegem, 2000) . Well-documented examples of plant pathogenic 
bacteria exhibiting disease through type lli secretion system include Erwinia 
amy/ovora, Pseudomonas syringae, Ralstonia so/anacearum and Xanthomonas spp. 
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The Yersinia type III secretion machinery was the fIrst studied apparatus and still 
remains the classic example for the system. The Yersinia ysc operon consists of 29 
genes involved in the secretion of the Yersinia outer membrane proteins or the Y ops. 11 
out of the 29 ysc genes have homologues in most of the other type III systems. The ysc 
C gene product is a member of the secretin group of proteins (Figure 1.7) and is 
responsible for the formation of the outer membrane bound ring shaped structure 
facilitating the passage of macromolecules and fIlamentous phages. The four Y sc 
proteins, YscD, YscR, YscU and YscV span the inner membrane. YscS and YscT have 
also been predicted to be inner membrane bound. The energiser for the system is YscN, 
which has the ATP binding motifs. YscJ is a lipoprotein and has not been localised in 
the Yersinia secretion apparatus, but its counterpart in Pseudomonas spans across the 
inner and the outer membranes. The other two conserved proteins in the type III system 
are Y scL and Q. Amongst the non conserved proteins in the system are Y sc W, which 
helps in the proper insertion of Y scC proteins in the outer membrane and the Y scO and 
P proteins which are released upon calcium chelation, and is thus suggested to belong to 
the external part of the apparatus (Comelis & Van Gijsegem, 2000). 
The well-known effectors in Yersinia are Y opR and YopE proteins (Wandersman, 
1996). Both serve as cytotoxins, with the former exhibiting a tyrosine phosphatase 
activity, while the latter is involved in the disruption of the actin microfIlament 
structure. The translocation of the YopE and Y opR Tequire their secretion and also the 
secretion of Y opB and Y opD proteins, which act as the translocators for the system. 
The Y opB and YopD proteins have hydrophobic domains, thereby suggesting a 
transmembrane location (Comelis & Van Gijsegem, 2000). 
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1.4. Rationale for investigating this disease mechanism. 
Mushrooms have a characteristic cell wall composition (section 1.3.3) distinct to plants 
and animals, in which Burkholderia has previously been shown to cause disease. The 
initial characterisation of the pathogen has shown that it causes deep pitting of the 
sporocarp tissue. This suggests a rapid disintegration of the fungal mycelia aggregated 
in the formation of mushroom sporocarps. Another interesting aspect of the disease is 
that pitting of the sporocarp tissue is not associated with tissue browning. 
The ability of the genus Burkholderia to colonise both animal and plant tissues has 
made it an interesting organism to study in relation to host pathogen interactions. 
Different strains of Burkholderia have been found to be associated with the degradation 
of a variety of chlorinated hydrocarbon compounds (Shields et al., 1995; Dubras et al., 
1996). P. gladioli B-1 is a strain that has the ability to form and cleave C-P bonds 
(N akashita & Seto, 1991). It has been demonstrated to cleave the C-P bond of 2-amino-
3-phosphopropanoic acid while the ability to produce the enzyme phosphoenolpyruvate 
phosphomutase provides it with the capacity to form C-P bonds (Nakashita et al., 1992). 
Species of the genus Burkholderia possess multiple chromosomes and a very interesting 
genomic organisation, consisting of an array of insertion sequences (Lessie et al., 1996). 
It has been suggested that these insertion sequences promote the genomic variability of 
the genus. Some species of the genus Burkholderia have also been found to harbour a 
considerable amount of extrachromosomal DNA elements, including a number of 
transposons. Some of these transposons carry genes that are responsible for the 
degradation of chlorinated hydrocarbons (Xia et al., 1998). Insertion elements in the 
genome of Burkholderia have also been found to be associated with the activation of 
various operons, at different times, thereby leading to the capacity of the genus to 
metabolise a wide range of hydrocarbons (Johnson & Ronald, 1997). Burkholderia 
species have also been reported to possess multiple pathways for the direct metabolism 
of the catechols (Johnson & Ronald, 1997). In an attempt to establish the role of the 
different phytotoxins in the pathogenesis of Burkholderia spp., Iiyama-Kazuhiro et al., 
1998 (Iiyama et al., 1998) have found that species of Burkholderia are associated with 
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the production of tropolone and toxoflavin. Tropolone is a potent tyrosinase inhibitor 
and inhibits the enzyme by a so-called non-classical mechanism, where by the enzyme-
inhibitor complex undergoes a relatively slow reversible reaction (Ferrar & Walker, 
1999). 
Taking into consideration all these issues, it was hypothesised that Burkholderia 
gladioli pv agaricicola produced some kind of inhibitor of mushroom tyrosinase, 
followed by the production of cell wall degrading enzymes. It is possible that the 
inhibitory compounds and the cell wall degenerating compounds are either produced 
and function separately or have a synergistic effect, thereby causing the massive 
degradation of the tissue. Initial studies with B. gladioli have also revealed that the 
microorganism inhibits a range of other phytopathogenic filamentous fungi, yeast and 
the anaerobic bacterium Lactobacillus. This suggests that the strain is associated with 
the production of either more than one' toxic compound or a broad-spectrum toxin. In 
addition, the strain has been reported to be causing acidification of the media. This 
could also be a reason for inhibition of tyrosinase. It was predicted that at least two 
groups of compounds are involved in the pathogenesis of the species, one of which 
paralyses the host's defence mechanism and the other then starts the degradation of the 
mushroom mycelia, there-by causing the pitting. Thus, a wide range of possibilities 
arises by which BG164R causes Cavity disease in white button mushrooms. This 
project was hence initiated to try and elucidate the mechanism of disease formation by 
identifying the genes involved in the process. 
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1.5. Thesis objectives and aims. 
Cavity disease appears sporadically, but poses a massive threat to the mushroom 
industry. Previous work has not significantly advanced our understanding of how 
BG 164 causes Cavity disease. This thesis is hence the first attempt to defme the 
genetics of virulence and propose probable models involving the sequential stages of 
Cavity disease fonnation by BG 164. The presented research was initiated with two 
broad objectives: 
Objective!: To identify the gene(s) of BG164R involved in the expression of Cavity 
disease of white button mushrooms and to identify the mechanism(s) by which they 
cause the rapid degradation of mushroom tissues. 
Objective 2: To study the host pathogen relationships of B. gladioli pv. agaricicola, 
involved in the expression of Cavity disease in Agaricus bisporus. 
To address the two objectives several aims were set at the outset of the project. 
Objective 1 aims: 
1) Generate antibiotic resistance profile of BG 164 and identify/create a marker that 
would enable us to identify the strain in the gene manipulation experiments. 
2) Establish an efficient mutagenesis system for BG 164. 
3) Isolate virulence genes using a novel mushroom bioassay. 
4) Identify the nature of the gene product(s) involved m the initiation of the 
disease. 
5) Investigate whether the antifungal compound( s) produced by BG 164 is involved 
in the degradation of mushroom mycelia. 
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Objective 2 aims: 
1) IdentifY the endogenous microbial population prevalent in button mushrooms. 
2) Define the minimum infectious unit of the pathogen required to initiate Cavity 
disease in button mushroom. 
3) Find out whether initiation of the disease process is dependent on the presence 
of inducing signals, as an attempt to identifY a reason for the sporadic 
appearance of the disease. 
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1.6. Presentation overview. 
The results presented in this thesis have been divided into six chapters. The present 
Chapter, has broadly introduced the host and the pathogen involved in this study, and, 
provided a general idea about the different mechanisms by which Gram-negative 
bacteria cause disease. 
The first part of Chapter Two describes the establishment of an efficient bioassay 
system and the isolation of a spontaneous rifampicin resistant mutant strain of the 
pathogen. These two essential components were used subsequently in the genetic 
analyses of the disease causing genes of B. gladioli pv. agaricicola, strain BG164. 
Molecular experiments aimed at targeting, identitying and isolating the genes of 
BG164R responsible for the formation of cavity disease are also described in Chapters 
Two, Three and Four. Preliminary biochemical experiments attempted to co-relate the 
genetic findings to the biological experiments has been described in Chapter Three. 
Occasional connections with the biological work have been made throughout the thesis, 
since biological assays formed guidelines to genetic manipulations and in some cases 
play an important role in confirming data obtained by the molecular experiments. 
The second part of the thesis, Chapter Five, addresses some biological questions and 
describes experiments carried out purely on the basis of host pathogen relationships. 
Their probable interactions appear to play a vital part in the initiation of disease, as 
evidenced from the data presented. 
In the concluding chapter, Chapter Six, results of the key findings in the project are 
summarised, probable models describing the mechanism(s) by which BG164R causes 
cavity disease in button mushrooms are suggested and ways to test the models are 
proposed. 
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Chapter 11 
Isolating avirulent mutants ofBG164R .. 
2.1. Introduction. 
Bacterial virulence arises from a wide range of biochemical and physiological processes 
taking place within the pathogen. The capacity to cause disease is ultimately based on 
the sequential regulation and expression of gene(s). The biggest challenge in studying 
host pathogen relationships is to identify the precise order in which virulence factors are 
regulated. Identification of the potential pathogenic genes, irrespective of the temporal 
nature of their expression, forms the preliminary basis of studying host-pathogen 
interactions. Such investigations are generally approached by creation and identification 
of null mutations that knock out the virulence properties, followed by the establishment 
of Molecular Koch's (Falkow, 1988) postulate which involves isolating and restoring 
the virulence properties by an intact copy of the knocked out gene. This fundamental 
approach forms the basis of studying the genetic mechanism(s) of Cavity disease 
formation by BG164 in this study. 
Both targeted gene mutations and random mutagenesis can be used to identify putative 
virulence genes. When predetermined genes with well-defmed phenotypes are targeted, 
site-directed mutagenesis and chemical mutagenesis are useful. However, when 
identification of a gene is based on tracing the position of the specific mutation 
following random mutagenesis of the bacterial chromosome, transposons are generally 
the method of choice. Transposons provide the primary advantage of encoding an easily 
followed selectable marker, which allows identification of the mutated genes. In the 
previous reports on Cavity disease, propositions about the possible gene products 
involved in the pathogenesis of BG 164 have been put forward by Gill and Tsuneda 
(1997). Their list may not be comprehensive, so in this study a new search was initiated 
using random (transposon) mutagenesis. 
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This chapter mainly describes an attempt to target the genes of B. gladioli pv. 
agaricicola, involved in causing cavity disease in mushrooms. At the beginning, this 
required construction of strains to be used in the analyses. Random transposon 
mutagenesis using mini-Tn5KmlacZ2 (deLorenzo et aI., 1990) was used to introduce 
the mutations. The chapter also describes phenotypic characterisation of the mutants 
and discusses the results in light of the objectives of this research and also in relation to 
other research involving host pathogen interactions. 
2.2. Material and Methods. 
2.2.1. Bacterial strains and plasmids used. 
Strains Genotype or description 
and plasmids 
Burkholderia gladioli pv.agaricicola. 
BG164 
BG164R 
BG4-12 
BG12-88 
BG12-147 
BG15-40 
BG15-87 
wildtype, cav+, Af+, Ri:f 
wildtype, cav+, Af+, Ri~, Prot+ 
BG 164R gspF: :mini-Tn5KmlacZ2,Ri~,KmR, 
cav-,Af+, Prot-
BG 164R gspK: : mini-Tn5KmlacZ2 ,Ri~,KmR, 
cav-,Af+, Prot-
BG164RgspK::mini-Tn5KmlacZ2,Ri~,Knl, 
cav-,Af+, Prot-
BG 164R gspE: :mini-Tn5KmlacZ2 ,Ri~,KmR, 
cav-,Af+, Prot-
BG 164R gspD: :mini-Tn5KmlacZ2,Ri~,KmR, 
cav-,Af+, Prot-
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BG16-787 BG 164R gspE::mini-Tn5KmlacZ2,Ri~,KmR, 
cav-,Af+, Prot-
BG4-127 BG 164R::mini-Tn5KmlacZ2,Ri~,KmR,cav-
BG9-130 BG 164R: :mini-Tn5KmlacZ2 ,Ri~,KrnR ,cav-
BG9-481 BG 164 R: :mini-Tn5KmlacZ2 ,Ri~,KmR,cav-
BG14-48 BG164R::mini-Tn5KmlacZ2,Ri~,Knl,cav-
BG14-127 BG164R::mini-Tn5KmlacZ2,Ri~,KmR,cav-
BG14-722 BG164R::mini-Tn5KmlacZ2,Ri~,KrnR,cav+, 
Prot+ 
BG110 BG164R::mini-Tn5KmlacZ2,Ri~,KmR,cav+, 
A~ 
Esherichia coli. 
S17-1(A.pir) thi pro hsdR- hsdM+ l::..recA RP4-2::TcMu-
Km::Tn7 
MC4100 araD13911(lacl PO ZYA-argF) U169 rpsL 
thi recA-56 
Pseudomonas aureofaciens 
PA147-2 
PAE639 
wildtype, Af+, Bfm+, Ri~, CmR,(lO).Lg/mL) 
PA147-2 yeiJ::mini-Tn5KmlacZ2,Af+,Bfm-, 
Fla-, Mot-, Ri~, KmR 
Pseudomonas cepacia. 
BIll wild type, Chi-
Pseudomonas putida 
P.putida wild type, Prot-
Serratia entomophila 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
Simon et al.1983 
Casadaban 1976 
Carruthers et 
al. 1994 
MondsMSc 
Thesis 2000 
A.L.J.Cole 
H.K.Mahanty 
Lab Collection 
Derivative of Al wild type, AmpR , Chi+ ,path+ Upadhyay et al. 
1999 
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Plasmids used: 
pUTZ2 pUT containing mini-Tn5KmlacZ2 deLorenzo et 
al.1990. 
Table 2.1. List of Strains and plasm ids used in the experiments described in Chapter 2 
2.2.2. Media, reagents and antibiotics. 
45 
All media and reagents used in this study were prepared as described in Appendix I and 
II. Concentrations of the antibiotics used to maintain the selective pressure on the 
strains or the strains containing plasmid or cosmid constructs are as mentioned in 
Appendix I, unless otherwise stated. 
2.2.3. Basic bacteriological methods. 
B. gladioli pv. agaricicola, Pseudomonas and Serratia strains were grown under 
aerobic conditions, in a 30°C incubator. To isolate individual colonies of Burkholderia 
and Pseudomonas strains, plates streaked with bacteria on the selective plates had to be 
incubated for 36-40hr, while for Serratia, 20hr incubation yielded single colonies. E. 
coli strains were incubated aerobically at 37°C for 18hr. Well shaken liquid culture of 
the different strains grown in their respective temperature (mentioned above) for 18hr 
till the culture reached a stationary phase, were used as 'overnight culture' unless 
otherwise stated. For everyday use, plates containing strains were stored at 4°C and re-
used for seven days. For long term storage, freezer stocks of strains and the constructs 
were made by growing bacteria overnight in LB supplemented with appropriate 
antibiotics, 1.5mL cultures were harvested by centrifugation at 7,OOOrpm for 2min at 
4°C, resuspended in 800flL of fresh LB supplemented with 15% glycerol and stored at-
80°C. 
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Disc diffusion assay to test the antibiotic susceptibility of BG 164. 
BG 164 was isolated from rotten mushrooms and purified cultures were stored in the 
culture collection of School of Biological Sciences at the University of Canterbury, 
Christchurch, New Zealand. No previous work on this strain included a description of 
genetic markers, such as antibiotic resistance. 
In the assay, 50flL overnight culture of the test strain was aseptically spread on an LB 
plate, dried briefly in a sterile biohazard cabinet and impregnated with sterile antibiotic 
discs containing the concentration of antibiotics to be tested. The plates were incubated 
at 30°C for 24hr before scoring the susceptibility of the strains for the respective 
antibiotics. The assay was repeated at least twice in all cases. 
2.2.4. Growth analysis of the strains. 
F or all the growth analysis experiments, 1: 100 dilutions of overnight cultures of the test 
strain were grown in LB supplemented with or without antibiotics, as required for the 
specific experimental set up, incubated in shaking water baths, as mentioned in section 
2.2.3. At regular intervals, 500flL aliquots of cultures were aseptically removed in 
replicates from the growing culture and the optical density of the culture at the specific 
time was measured at 260nm with a LKB Ultraspec® Plus spectrophotometer. When the 
viable cell counts at the various stages of growth were monitored, 500flL aliquot was 
removed and used as the stock sample to make serial dilutions. For enumerating the 
viable cells present in the individual dilutions, three aliquots of 5JlL from each dilution 
were spotted on selective plates and incubated for 30hr at 30°C in case of all 
Burkholderia and Pseudomonas samples, unless otherwise stated. 
Mushroom bioassay system. 
The bioassay system established was an amendment of the basic technique implemented 
by Doreen G. Gandy in 1968, in which he had used blocks of mushroom tissue on wet 
paper towels maintained at 25°C in a Petri dish (Gandy, 1968). In routine assays, fresh 
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mushrooms supplied by a specific mushroom farm in Christchurch were washed thrice 
in sterile distilled water, cut into slices of approximately 1.S to 2mm in width, with a 
sterile cut throat razor, and immersed immediately in ice cold water to prevent tissue 
browning. These pieces of mushrooms were aseptically transferred to sterile lunch 
boxes lined with wet paper towels, sterilized under a UV lamp for lSmin and inoculated 
with the test bacteria, either as fixed volumes of sterile suspensions or as single 
colonies. The inoculated mushrooms were incubated for 16hr at 30DC. Within the time 
frame, the wild type bacteria caused distinct holes of approximately 4-Smm diameter on 
the mushroom pieces. 
When growth of bacteria was monitored on mushroom slices, the mushrooms were cut 
into small pieces of approximately O.Scm x 1.0cm and about 4mm thick, inoculated 
with the test bacteria. At regular intervals the pieces of mushrooms were taken out from 
the experimental set up with sterile forceps, vortexed for 2min in a sterile Eppendorf 
tube with lOOf-tL of 1 x MS. The supernatant was used to make serial dilutions and three 
a1iquots of Sf-tL from each dilution were spotted on selective plates and incubated for 
30hr at 30DC. 
2.2.6. Mutagenesis. 
Mini-TnSKmlacZ2 (deLorenzo et al., 1990) has been used to generate random 
insertional mutants, primarily because of the kanamycin resistance marker that could be 
easily traced in BG 164R apart from some other salient features. This TnS derivative is 
capable of fusing lacZ to whatever gene it disrupts. The lacZ gene lacks both 
transcriptional and translational signals, and the lacZ fusion protein created in each case 
of successful mini-TnSKmlacZ2 transposition in the right reading frame of a gene is 
separated from the target gene by 49 nuc1eotides. Additionally, the transposon has a 
functional kanamycin gene, which facilitates the one step selection of the mutants in 
vitro. The transposon has been successfully used in creating random protein fusions in 
P. putida (deLorenzo et al., 1990), and in some other enteric and soil borne Gram-
negative bacteria (Monds et al., 2001; Giddens et al., 2002). 
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The delivery vehicle used for the transposon mini-Tn5KmlacZ2 is pUTZ2, which has 
been constructed in the plasmid vector pUT (Herroro et al., 1990), a pGP704 derivative. 
pUT plasmid has the 1t protein dependent RK6 origin of replication. As a result, it 
serves as a suicide vector when conjugated into strains that lack chromosomally borne 1t 
protein. It also has an RP4 origin of transfer (oriT) and so it can be mobilised only when 
conjugated from an E. coli (Eg: S17-1 A pir) strain that supplies the RP4 conjugative 
functions in trans. The transposase gene required for transposition of mini-Tn5 is also 
supplied in trans' by the vector. Once integrated into the target gene, the transposon is 
stably maintained without any further transposition event. 
2.2.6a. Conjugation protocol used for the generation of mutants. 
The transposon mini-Tn5KmlacZ2 borne by pUTZ2, maintained in E. coli S17-1 (A-pir) 
was introduced into the recipient, BG 164R, by conjugation. Overnight cultures of the 
donor E.coli S17-1 (A-pir) (Simon et al., 1983) containing pUTZ2, and the recipient 
strain, B. gladioli pv.agaricicola BG164R were washed with fresh LB broth to remove 
the respective antibiotics from the media, the recipient was heat shocked at 43°C for 
l5min and mixed with the donor in a ratio of 4: 1. The mixture was spotted on LB plates 
without any antibiotics and incubated at 30°C for 4hr, after which the cells were 
recovered from plates by washing with fresh LB broth and centrifuged. The resulting 
pellet was resuspended in 200/lL of fresh LB broth and 100/lL aliquots were spread on 
selection plates consisting of rifampicin, kanamycin and chloramphenicol (15/lg/rnL) to 
select for BG 164R transconjugants. It was observed that the transconjugants started 
appearing on the plates after about 30hr of incubation, but to get colonies of reasonable 
size, which would be easy to screen on mushroom assays, the plates had to be incubated 
for at least 36hr. 
2.2.6b. Screening and isolation of mutants with 'no-cavity' phenotype. 
Transconjugants ansmg from independent conjugations were screened for the 
transposition events of the miniTn-5 resulting in 'no-cavity' phenotypes using the 
mushroom assay described in section 2.2.5, as well as on minimal agar plates to test the 
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number of auxotrophic mutants to test the randomness of the transposition events of the 
transposon in the chromosome. 
2.2.7. Phenotypic characterisation of mutants. 
2.2.7a. Preparation of samples for Transmission Electron Microscopy (TEM). 
TEM grids were prepared by scraping 24hr old bacterial cells from plates supplemented 
with appropriate antibiotics, re-suspended in 100f-LL of sterile distilled water and two 
drops of this 1 % phosphotungstic acid, and spotting onto TEM grids. Extra solution was 
drained off by capillary action from the grids by using a filter paper. Stained bacteria 
were observed under bright field either in a Hitachi H-600 Electron microscope in the 
Mechanical Engineering Department or with a JEOL JEM-1200EX Electron 
mlcroscope available in the School 'of Biological Sciences, at the University of 
Canterbury. 
2.2.7h. Motility Assay. 
The capacity of movement in the different species of bacteria is generally tested by 
spotting test bacterium on plates supplemented with low percentage of agar. Motility 
agar plates supplemented with 0.3% agar as stated in Appendix I were used for the 
assay. Motility in such cases was defined by the capacity of the test bacteria to move 
away from the point of inoculation on the plate, thereby forming a colony, which 
appears more like a halo around the central inoculation point. Strains were assessed 
non-motile when there was no halo formation around the central inoculation site. 
2.2.7c. Biofilm Assay. 
The assay conditions standardised after assessing the biofilm forming capacity of wild 
type strain in different media and with varying hours of incubation were: 16hr 
incubation of 1 :50 dilution of stationary cultures of wild type and mutant cells at 30°C 
in 100f-LL of mushroom extract media (Appendix I) in 96 well microtitre dishes or 1mL 
of media in borosilicate glass test tubes. Biofilms were visualised after staining with 
crystal violet for 20min at room temperature, followed by rigorous washing under 
flowing water and drying by tapping on paper towels. 
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2.2.7rl. Scanning Electron Microscopy (SEM). 
Mushroom slices were inoculated with the test bacteria growing on LB plates with 
respective antibiotics and incubated for 16hr as per the established mushroom bioassay 
conditions. After the required incubation times, the mushroom slices were washed with 
phosphate buffer (Appendix II) to remove excess loosely bound bacterial cells, frozen in 
liquid nitrogen, sprayed with gold dust and observed under Leica s440 SEM, available 
in the department. 
2.2.7e. Chitinase Assay. 
Chitin plates prepared according to the method stated in Appendix I were used in the 
assay procedure. The test bacteria were spotted on the plates and incubated at 30°C for 
4days before scoring the ability of the bacteria to produce chitinase. Production of 
chitinase was determined by the clearing of colloidal chitin around the colonies spotted 
on the plates. 
2.2.7f. Protease Assay. 
The ability of test bacteria to produce protease was tested by transferring the colonies 
onto 1 % skim milk agar plates (Appendix I) and checking the capacity of the strains to 
clear casein around the test colonies. The plates were incubated at 30°C for 24hr before 
noting the ability of the test bacteria to degrade casein. 
2.2.7g. o-DPO inhibitions Assay. 
The o-DPO assay was adopted from the method standardised by Ferrar in 1995 (Ferrar, 
1995), whereby commercially available mushroom o-DPO was used as the enzyme, and 
was allowed to react with a substrate DOPA (dihydroxyphenylalanine). The reaction 
resulted in the formation of a coloured product DOPA -chrome and could be measured at 
OD 452 nm. The intensity of the colour produced was taken as a measure of the amount 
of active tyrosinase present in the reaction. The culture extract from the potential 
microorganisms were used to test the presence of potential inhibitory compounds. In the 
assay, 50)lL of the enzyme (0.252AU at 452nM) was added to 100)lL O.2M phosphate 
buffer pH7.0 and 50)lL of 10mM DOPA in a 96 well microtitre dish. To this, 100)lL of 
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the test supernatant was added and incubated for 20min at 30°C. After the required 
incubation time the OD at 452nm was read on a multiscan reader available in the 
department. 
2.2.7h.ln vitro antifungal phenotype. 
The method used was an adaptation of the method stated by Carruthers et al. 1994 
(Carruthers, 1994). Plugs of agar containing actively growing fungal mycelia were 
inoculated at the centre of PDA plates (Appendix I) and incubated at 23°C for 2 days 
until the radius of the freshly subcultured test fungus was about 3.0cm. Colonies of test 
bacteria were streaked with a sterile loop approximately lcm away from the growing 
mycelia tip and the plates were further incubated for 2 days before checking the extent 
of inhibition in comparison to the growth of fungal mycelia on a plate which did not 
have any bacteria growing on it. 
2.3. Results. 
2.3.1. Describing the genotype of BG 164 
The antibiotic resistance profile of BG 164 was determined because the genotype of the 
strain was previously unknown and was essential for gene manipulation experiments. 
BG 164 was susceptible to a number of commonly used antibiotics as detennined by 
disc diffusion assay technique, (Table 2.2). To select the strain in subsequent analyses, 
a rifampicin resistant derivative was isolated. 
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Susceptible to: Resistant to: 
Ampicillin lOOJ,lg/mL Chloramphenicol50J,lg/mL 
Nalidixic acid l5J,lg/mL Polymyxin 300J,lg/mL 
Tetracycline 30J,lg/mL Erythromycin 15J,lg/mL 
Rifampicin 50J,lg/mL Vancomycin 30J,lg/mL 
Kanamycin 50J,lg/mL Penicillin 10J,lg/mL 
Gentamycin 50J,lg/mL Streptomycin 50J,lg/mL 
Table 2.2: Antibiotic susceptibility of BG164. 
Spontaneously arising rifampicin-resistant BG 164 colonies were isolated by plating 
IOOI-tL of 1: IOOI-tL of overnight culture of BG 164 cells containing approximately 106 
cells, on LB plates supplemented with rifampicin (50I-tg/mL) and incubating them at 
30°C for 48hr. Eight spontaneous rifampicin-resistant colonies initially appeared on the 
selection plates. All the colonies were further tested by re-streaking on to LB plates 
supplemented with 50l-tg/mL Rifampicin. Four representative colonies out of the 8 
spontaneous mutants were grown in liquid cultures to test the capacity of growth in 
antibiotic supplemented liquid media. Mter 18hrs of growth, 3 out of the 4 colonies 
tested, grew to a unifonn Optical Density (OD) at 260nm wavelength (OD26o= 1.7). To 
further test the stability of the marker in the strains, two representative colonies growing 
in rifampicin supplemented LB broth were subcultured (1:100 dilution) in LB broth 
without any antibiotics, serially diluted and all dilutions plated in triplicate on LB plates 
with and without antibiotics. Colonies arising on the plates were enumerated for 
comparison (Table 2.3). 
CFU/mL 
Strain OnLB On LB +Rif late 
BG164-3 
BG164-5 7.l5XI09 
Table 2.3: Stability of the Rifampicin resistant BG164 strains created. 
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There was no major difference (Table 2.3) in the number of colonies appearing on either 
of the plate types indicating that the spontaneous mutation was stable. Eventually, 
BG 164-5 was designated as BG 164R, and used in all the experiments described 
henceforth . 
2.3.2. Introduction of Rifampicin resistance in BG 164R does not affect virulence. 
The virulence of BG 164 and BG 164R was compared by monitoring Cavity disease 
symptoms on mushrooms in two parallel experiments. In the first experiment, overnight 
cultures of BG 164 and BG 164R were re-suspended in sterile distilled water to a 
concentration of 1 X 1 09 cells/mL. AI iquots of 2~lL and 4~L were randomly spotted onto 
mushroom caps, which were then incubated for 20hr at 30De. In a second setup, 
colonies were transferred by toothpicks onto the surface of mushroom caps and 
incubated at 30De for 20hr. No difference was observed between the strains in the 
development of symptoms by either set-up (Figure 2.1). BG 164R was thereafter 
selected for use as the test strain for further studies. 
The primary objective was to identify the genetic mechanism(s) by which B. gladioli 
pv .agaricicola causes cavity disease in mushrooms. The strategy adopted to identify the 
genes involved was random mutagenesis screens, which were followed by the isolation 
of mutants unable to form cavities on mushrooms. In order to trace such phenotypes in 
A B 
,/ 
Figure 2.1A: Inocula consisting of liquid suspensions in water. Top left 2~L of BG164 inocula . 
Top right 2~L of BG164R. Bottom left 4~L BG164 suspension and bottom right 4~L of BG164R. 
In 2.1B: Inocula consisting of toothpicked colonies; left BG164 colony and right BG164R colony . 
Arrows indicate sites of control inoculations with water (A) and blank toothpick marks (B). 
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VIVO, a large number of random mutants would need to be screened, for which the 
establishment of an efficient bioassay system with conditions best suited for proper 
representation of the disease was essential. 
2.3.3. Establishment of bioassay system to study Cavity Disease. 
Initially, whole mushroom sporocarps without the stock were surface sterilised, placed 
in a moist chamber and inoculated with B. gladioli pv.agaricicola to test for 
pathogenicity. However, to screen large numbers of mutants, an assay using whole 
sporocarps was not practical. Therefore, a wide range of incubation times and 
mushroom pieces (Figure 2.2.) of different sizes were tested to best represent Cavity 
disease and to serve our purpose of screening maximum number of mutants per set up. 
A 
Figure 2.2: A representative mushroom bioassay used for the screening of mutant bacteria. [AJ 
Control Slice. [BJ Mushroom slice with cavity formed by BG164R under the defined assay 
conditions. 
For screening of mutants, mushroom pieces were lined in 4 columns of 7 rows in each 
lunch box. On each piece of mushroom four colonies of test bacteria could be patched. 
A total of 100 colonies could be tested for the desired phenotypes, in each lunch box 
used, with the appropriate negative and positive controls. 
2.3.4. Establishment of the mutagenesis system. 
Mutations in the virulence genes of BG 164R were created by mini-Tn5KmlacZ2 
mutagenesis. In an effort to get the maximum number of transconjugants, two 
parameters had to be optimised. Firstly, the time of incubation of conjugants and 
secondly, the ratio of donor to recipients to yield maximum number of transformants for 
a given incubation time. 
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In a series of preliminary experiments, the two variables were measured by mixing 
conjugants in different proportions and incubating mixtures for various times. To 
establish optimum ratio of donor to recipients, respective strains were mixed in ratios of 
1:1, 1:2, 1:3 and 1:4; and, to establish the best suited incubation period, 1hr, 2hr, 4hr 
and 6hr were tested. Cells were recovered from the test plates by washing with fresh LB 
broth, centrifuged and the pellet was plated on selection plates. Transconjugants started 
appearing on the plates after about 30hr of incubation. Incubation periods of 36hr were 
necessary to get colonies large enough for further work. However, by that time 
spontaneous rifampicin-resistant donors also began to arise on the control plates, 
making it difficult to select true transconjugants from the conjugation plates. To 
circumvent this problem, the selection plates were supplemented with chloramphenicol 
(15mg/mL). The optimal conditions established for the experiment were 250JlL of 
overnight culture of donor to be mixed with ImL of heat shocked overnight culture of 
recipient and conjugated for Ahr at· 30°C. The transconjugants were selected on 
rifampicin, kanamycin and chloramphenicol supplemented LB plates and incubated for 
a further 36hr before screening for mutants. 
2.3.5. Selection of 'no-cavity' mutants. 
Approximately 10,000 transconjugants arising from 66 independent experiments carried 
out in 16 attempts were screened for the transposition of the miniTn-5, resulting in 'no-
cavity' phenotypes using the mushroom assay described in section 2.2.5, as well as on 
minimal agar plates to test the number of auxotrophic mutants. On average, 1.5% of the 
transconjugants were auxotrophs, thereby suggesting that the transposition events in the 
chromosome were randomly distributed. 
Twenty 'no-cavity' forming mutants were selected after testing each putative BG164R 
mutant three times on mushroom slices. Of these 20 mutants, 6 were prototrophic 
(Figure 2.3.) and the remaining 14 were unable to grow on minimal media. The 
genotypes of the 6 prototrophic mutants isolated have been described in Tablel.I. 
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Figure 2.3: Mushroom Bioassay to compare between the wild type, BG164R and the mutants 
selected for no cavity phenotype. [A] Control prick, [B] BG164R, [C] BG4-12, [D] BG12-88, [E] 
BG12-147, [F] BG15-40, [G] BG15-87 and [H] BG16-787 
Was the ' no-cavity ' phenotype, evident in the mutants isolated, due to the inability of 
the mutant strains to grow on the mushroom slices? In the formation of Cavity disease, 
BG 164R has to establish itself amongst endogenous mushroom bacteria before causing 
disease, as will be described in chapter 5. lfmutants have growth defects, they might be 
less able to compete with the endogenous bacteria (refer section 5.3.4). This could lead 
to the no-cavity phenotype and not be an effect of a mutation in a virulence gene . Thus , 
to test the ability of mutants to grow on the mushroom slices, growth rates of the 
mutants were compared to that of the wild type. 
2.3.6. Comparison of the rate of growth of mutants with the wild type. 
The growth rate of the wi Id type and the mutants were monitored over 12hr in LB broth 
supplemented with required antibiotics, by measuring the optical density of the cells at 
600nm at a regular interval (section 2.2.4). The viable counts of the bacteria were also 
monitored over time, by serially diluting the cultures and plating them on the respective 
selection plates . Data arising from triplicate sets of independent readings were used to 
draw the growth curves and calculate standard errors. 
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Figure 2.4.A: Comparative growth (OD600 values) of the mutants with the wild type strain, 
BG164R, in LB broth . 
The mutants and the wild type grow at nearly the same rates (Figure 2.4.A). At the end 
of 12hr, most of the strains grew up to an 00600 of 2.0. Among the different mutants, 
the patterns of growth observed in the case of BG4-12, BG 15-40 and BG 12-147, were 
similar to that of the wild type , BO 164R. The other three seemed to be growing slower, 
with BO 15-87 being the slowest. BO 15-87 grew only to an 00600 of 1.2. Evidently, this 
strain also shows a gradual decline in the CFU/mL (Figure 2.4B.). 
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Figure 2-4-8: Comparative growth (viable cell counts) of the mutants and the wild type strain, 
BG164R in LB broth. 
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This could be attributed to the initial difference in the viable cell counts at the start of 
the experiment (Figure 2.4.B), which shows the trend of growth calculated as viable cell 
counts over a 12hr period. The growth rates, as evident from viable cell counts are very 
distinct for each strain tested. This could partially be due to sampling errors or 
genuinely due to the effects of mutation. It was difficult to conclude at that stage 
without having an idea of the genes that have been disrupted in each case. 
In order to monitor the rate of growth of the mutants on mushroom slices, two separate 
experiments were set up. The growth of a representative auxotrophic and a 
representative prototrophic mutant in comparison to that of the wild type strain was 
monitored over a 16hr period. In both the experiments, IO!lL aliquots of 1: 1 00 dilution 
of an 18hr culture of the wild type, and the two different mutants were spotted onto 
mushroom slices and incubated for 16hr at 25°C. At regular intervals, the bacteria were 
retrieved from the mushroom slices by agitating the slice in IOO!lL ofLB for 30sec in a 
vortex mixer, serially diluted and plated on selection plates. The data presented in 
Figures 2.5.A and B are the average number of cells retrieved from slices taken from 
three separate samples. The auxotrophic mutant grows in the initial 6hr, but thereafter 
does not show any increase in CFU/mL over a period of 16hr on the mushroom slices 
(Figure 2.5.A). In fact, there was a very slow decline in the population of the 
auxotrophic mutants compared to wild type observed over time in the mushroom 
background, which shows a clear trend of increase in the population with time. In 
contrast, the prototrophic mutants showed clear evidence of gradual increase in number 
of cells, which was comparable to that evident in the case of BG 164R. In the figures, a 
difference in the number of cells is observed in case of the initial inoculum and the 
number of cells retrieved after 4hr incubation on the mushroom slices. This was because 
of the technical problems associated with retrieving live cells from the mushroom 
tissues after inoculation. This problem has been consistently observed in case of all 
experiments, which involved extraction of live cells from mushroom tissues. The 
proportion of cells that could be extracted from mushroom slices immediately after 
inoculation was estimated. Approximately 25-30% of the population was lost in each 
case. 
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Figure 2.S.A: Comparative growth rates of BG164R against the auxotrophic mutant BG4-127 
on mushroom slices. 
r 
10 Conc of starting cells 
I Cells retrieved after 4hr 
I 
o Cells retrieved after 6hr 
o Cells retrieved after 
12hr 
DCelis retrieved after 
16hr 
13 ,-------------, 
12 
11 
10 
9 
8 
7 
6 
0, 5 
.£ 4 
3 
2 
1 
o 
BG164R BG4-12 
Strains tested 
Figure 2.S.B: Comparative growth rates of BG164R against the prototrophic mutant BG4-12 on 
mushroom slices. 
The 'Do-cavity' phenotype observed in the auxotrophic mutants could thus be due to the 
mutation itself or due to the inability of the strain to grow on mushrooms . Analysis of 
the auxotrophic mutants in relation to no-cavity phenotype would have been interesting, 
but, since the main objective of the research was to identify the genes that directly had a 
role in the formation of cavity disease, it was decided to focus on and analyse the 
prototrophic mutants. 
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The ability of a pathogenic bacterium to cause disease has been well documented to be 
associated with certain macromolecular bacterial surface components like flagella 
(Tomich et aI. , 2002; Chua et aI., 2003), pili (O'Toole & Kolter, 1998b; Pratt & Kolter, 
1998; O'Toole et aI. , 2000), and capsular polysaccharides (DeShazer et aI., 2001). 
These structures can be observed easily under the microscope or analysed 
phenotypically by simple assays. These techniques were therefore used to look for 
obvious changes in the mutants in comparison to the wild type. 
2.3.7. Transmission Electron Microscopy. 
To find out whether the mutations had any effect on the morphology of the cell surface, 
transmission electron microscopy was used to observe the physical appearance of the 
mutants as compared to that of the wild type strain. Entire surfaces of the grids 
containing samples prepared according to the method mentioned in 2.2.7a were scanned 
under different magnifications and representative pictures of the entire field are 
presented in Figure 2.6. 
Figure 2.6: Transmission electron micrographs of the mutants and the wild type cells. [Aj 
BG164R, [Bj BG4-12, [C] BG12-88, [.oj BG12-147, {Ej BG15-40, [Fj BG15-87, [Gj BG16-787 
Magnification is = X30, 000, except C and G, where the magnification is = X60, 000 
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The wild type strain has 5 polar flagella. Four out of the six mutants have a single polar 
flagellum, while two strains BG12-88 and BG12-147 had two visible polar flagella. 
Apart from the changes in flagella number, no major change in the morphology on the 
cell surface was observed. 
Flagella are organelles required for motility and chemotaxis of the cell (Macnab, 1992), 
however, having them has also been correlated with the ability to form biofilms 
(O'Toole & Kolter, 1998b; Pratt & Kolter, 1998; Watnick & Kolter, 1999) and for 
virulence (LiIlehoj et al., 2002; Tomich et al., 2002; Chua et aI., 2003). Flagella-
mediated motility has been associated with pathogenicity in P. aeuntginosa (Lillehoj et 
al.,2002), Campyiobacter jejuni, Helicobacter pylori, Vibrio cholerae (Dasgupta et ai., 
2000), B. pseudomallei (Chua et al., 2003), Proteus mirabiiis, C. jejuni and B. cepacia 
(Tomich et al., 2002). Studies on the mechanisms by which flagella effect virulence and 
pathogenicity of the different bacterial species have been made by comparing either 
aflagellate, non-motile mutants, or mutants that over-produce flagella. In the case of 
Cavity disease, the 'no-cavity' mutants of BG164R had a reduction in the number of 
flagella. So, the probability of alteration in the motility of BG 164R due to reduction in 
the flagella number was addressed, as, differences in motility could ultimately affect the 
capacity of disease formation. 
2.3.8. Motility Assay. 
Motility in strains belonging to the family Pseudomonaceae have generally been tested 
in plates made with 0.25% to 03% agar (Dasgupta et al., 2000; Monds, 2000; Tomich 
et al., 2002; Chua et aI., 2003). Non-motile mutants of Burkholderia sp., have been 
tested on 0.25% and 03% agar and clear differences in the phenotype could be 
observed. On the basis of these published data, 'no cavity' mutants of BG 164R, with 
reduced numbers of flagella, were initially tested by transferring individual colonies of 
the different mutants on motility agar plates (section 2.2.7b.). No difference in the 
colony morphology was observed in any of the mutants when compared to the wild type 
strains, although, clear differences were observed in the control PA147-2 (Carruthers, 
1994) wild type motile and the control non-motile mutant strain, PAE639 (Monds, 
2000). The motility ofBG164R on 0.3% agar was prolific and within 18hr of incubation 
the cells spread widely on the agar plates, making big diffused colonies. Thereafter, 
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plates with varying proportions of agar ranging from 0.2% to 0.8% were tested to check 
for any visible differences in the motility patterns of wild type and mutants. In none of 
these cases changes in the capacity of swimming of the mutants were observed, when 
compared to the wild type. 
Flagella mediated motility have been co-related to the formation of bacterial biofilms in 
E. coli, P. aeuruginosa and P. aureo/aciens (O'Toole & Kolter, 1998b; Pratt & Kolter, 
1998; Monds et aI., 2001). Most of these reports are based on results of studying 
aflagellate mutants of the wild type strain. Whether reduction in the number of flagella, 
as observed in case of the 'no-cavity' mutants of BG 164R, had any effect on its 
capacity to form bacterial biofilms was thus an interesting feature to trace in the mutants 
2.3.9. Biofilm Assay. 
Bacterial biofilms are defmed as "matrix enclosed bacterial populations adherent to 
each other and lor to surfaces" (Pratt & Kolter, 1998). Pathogenic bacteria form and live 
within such sessile communities on the surface of living tissues. Apart from possessing 
flagella, a number of other features (O'Toole & Kolter, 1998b; Pratt & Kolter, 1998; 
Monds et al., 2001), like the formation of type I and type IV pili, production of 
exopolysaccharides and certain environmental cues based mainly on the availability of 
nutrients (O'Toole et al., 2000) have been found to be associated with the formation of 
bacterial biofilms. 
Although under natural conditions bacterial biofilms develop on biotic surfaces, 
laboratory based research on biofilm studies are generally done by growing bacterial 
cells on different hydrophobic abiotic surfaces, such as plastics made of polyvinyl 
chloride (PVC), polycarbonate and polypropylene or on hydrophilic surfaces as 
borosilicate glass (O'Toole & Kolter, 1998a). Laboratory studies have demonstrated that 
although the extent of biofilm formation by the wild type P. jluorescens strain WCS365 
varies on different hydrophobic surfaces, a comparative study based on biofilm 
formation by the wild type and no biofilm forming mutants yield similar results in all 
the model hydrophobic surfaces tested (O'Toole & Kolter, 1998a). However, in such 
comparative assays with wild type strains and mutants, differences could be observed 
on the capacity ofbiofilm formation on hydrophobic and hydrophilic surfaces. 
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The main purpose of studying biofilm forming capacity in case of the Cavity disease 
pathogen was to find out any possible observable differences in the capacity of biofilm 
formation by the non-cavity fomling mutants in comparison to that of the wild type. 
Thus, although the study was carried out using abiotic surfaces, in an effort to imitate 
the nutritional conditions present in mushroom, biofilm studies on the mutants and wild 
type was done with mushroom juice extract media (Appendix J). Initially, a whole range 
of media and two types of abiotic surfaces, hydrophobic PVC and borosilicate glass 
were tested, and the assay conducted according to the conditions stated in section 
2.2 .7c. 
A 13 c D E F c 
Figure.2.7: Biofilm formation by wild type BG164R and its Cavity minus mutants. [A] BG164R, 
[B] BG4-12, [C] BG12-88, [D] BG12-147, [E] BG15-40, [F] BG15-87, [G] BG16-787, [H] Media 
control. 
On PVC plastic hydrophobic surfaces, the biofilm fOm1ation was weak and no 
differences could be noticed when the mutants were compared. Of the different media 
tested and the surfaces tested, best biofilm formations were observed in borosilicate 
glass test tubes and in mushroom juice extract media (Figure 2.7.) . There was no 
distinct difference in the intensity of crystal violet staining of the biofilms, as a measure 
of biofilm fOm1ation capacity, fOm1ed by the mutants in comparison to the wild type on 
the hydrophilic surface. 
2.3.] O. Scanning E lectron Microscopy. 
Electron microscopy was used to visualise the effect of growth of the wild type and 
mutant bacteria on the morphology of mushroom tissues. Mushroom slices were 
inoculated with bacteria and incubated for l6hr prior to preparing samples for the 
microscope (2 .2.7d) . 
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Figure 2.8: S!;:M of mushroom tissues inocul'ated with the wild type and mutant bacteria. [A] 
Control mushroom slice without any bacteria showing intact mushroom mycelia, [B] Degraded 
mycelia on being challenged with the wild type strain BG164R, [C-H] Mushroom slices 
challenged with mutants. [C] BG4-12, [0] BG12-40, [E] BG12-88, [F] BG15-40, [G] BG15-88, [H] 
BG16-787 
In general, the mutants (Figure 2.8.C-H) formed a continuous sheath on the surt~lce of 
the mushroom pieces. with occasional breaks under which the mushroom hyphae were 
visible. In comparison, mushroom slices inoculated with the wild type bacteria 
remained attached to (Figure 2XB) skeletal remains of degraded hypha I filaments. 
Mycelial filaments associated with the mutants were shrivelled under the bacterial 
sheaths (Figure 2.~F-H) . Filamentous strands of bacterial cells appeared in the breaks of 
the bacterial sheath (Figure 2XC-E), although they cannot be associated with the 
degraded masses of hyphae as observed in case of the wild type strains. Thus, under the 
standardised assay conditions, it was concluded that mutants hlil to degrade the hyphae 
of mushrooms, but, were able to shrivel mushroom mycelia . The wild type strain. 
however, clearly degraded mushroom tissue and , to degrade fungal cells, bacteria would 
have to secrete certain degradative enzymes. 
The production of enzymes that degrade mushroom tissue could be the explanation for 
the effect of the wild-type strain on the mushroom tissue. BG 164R has been associated 
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with the production of both chitinase and r->-glucanase, as well as other bioactive 
compounds , essentially toxins (Gill & Tsuncda, 1997). [n combination, chitinase and 
glucanase act as powerful degraders of mushroom tissue, but if present singly, tissue 
degradation is not as extensive (Gill & Tsuneda, 1997). Gill and Tsuneda (1997) 
proposed the necessity of combined action of both the enzymes since, chitin and ~­
glucan are inextricably covalently linked in case of fungal cell walls (Sietsma & 
Wessels' 979, cited by Gill & Tsuneda 1997}, with chitin forming the inner skeleton 
and ~-glucans fomling the matrix. Thus, in order to degrade fungal mycelia, 
depolymerisation of chitin would be a key component. Although Gill and Tsuneda 
(1997) reported the production of chitinase by the strain, other researchers working on 
this strain (Young, '992) could not observe chitinase activity when pure colonies 
growing under laboratory conditions were tested . 
2.3.11. Chitinase Assay. 
The capacity of BG 164R and the mutants to degrade colloidal chitin were tested using 
the plate assay technique stated by Gill & Tsuneda (' 997) and described in section 
2.2.7e. In comparison to the wild type (Figure 2.9), the mutants had a highly reduced 
capacity to degrade colloidal chitin. The effectiveness of the assay was confirmed using 
Serratia entomophila strain A,M02 as positive control and P. ccpacia strain B III as a 
negative controL 
Figure 2.9: Chitinase assay. [A] Serratia entomophila strain A1M02 Chi+(Positive control) [B] 
BG164R [C! P.cepacia strain B111 (negative contra.l) [0] BG4-12, [E ~ BG12-88, [F] BG12-147, 
[G] BG15-40, [H] BG15-87, [I] BG16-787. 
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Soft rot causing bacteria in higher plants have been associated with the production of 
proteinases apart from pectinases and cellulase. A mushroom soft rot pathogen was thus 
quite naturally expected to produce chitinase; that would degrade the structural 
component of mushroom tissue. It is evident that a chitin degrading enzyme is produced 
by the strain. The other common group of enzyme produced by soft rot pathogens is 
protease and so, the abi lity of mutants to degrade mi lk protein was tested thereafter. 
2.3.12. Protease Assay. 
Protease production was tested using a standard in vitro assay (2.27f). Colonies of the 
wi .ld type and the mutant strains were transferred onto 1'% skim milk agar plates and 
incubated for 24hr at 30"e. No protease activity was detected by this assay using tbe 
mutant strains (2.10). 
Figure 2.10: Protease assay on milk agar pllates. [A] BG164R Wild type strain, [B] BG4-12, [C] 
BG12-88, [0]1 BG12-147, [E] BG15-40, [F] BG15-87, [G]8G16-787, [H] P.putida (-ve cantra ll). 
Protease secretion, rather than production explains the protease minus phenotype In 
rnembers of the closely related pathogenic Burkhulderia sp. Generally, in the case of 
secretory mutants, protease secretion is a lso linked to the capacity to secrete a range of 
vimlence t~lctors. The mutants described here could, therefore, have insetiions in genes 
for secretion. I f they were secretory mutants, then it could be expected that the secretion 
of other vindence factors were also effected. The wild type strain is known to secrete an 
inhibitor of urthu-Diphenol oxidase (o-DPO), an enzyme associated with host defence 
(Aldridge & Walker. 1980). The next question that was addressed was whether the 
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Cavity disease mutants of BG l64R lost the capacity of production or secretion of this 
inhibitor. 
2.3.13. o-OPO inhibition assay. 
The o-OPO inhibition assay (2.2.7g) was used to check any difference in the capacity of 
the various mutants to inhibit mushroom o-OPO. The positive control strain, BG 1 64R, 
in contrast to that reported by Ferrar (1995) did not produce a detectable inhibitor of 0-
OPO over an incubation time of 20min. The assay was repeated with a reduced 
incubation time of lOmin. Even with the reduced time of incubation, only 10% 
inhibition of tyrosinase was observed in comparison to 20% reported by Ferrar (1995). 
Oespite these inconsistencies between the published observations and those reported 
here, the supernatants from the mutants were compared in the assay. There was also an 
inhibition of 10% enzyme activity, suggesting that the mutations did not affect the 
production or secretion of the tyrosinase inhibitor produced by the wild type strain. 
Variation in the data reported earlier and the data obtained could be attributed to the 
difference in the batches of the commercial enzyme used in the assay. Although, any 
difference in the secretion of tyrosinase inhibitor was not detected in the supernatants, 
secretion of other mycelia degrading compounds could have been affected by the 
mutations. 
Gill and Tsuneda (1997) designated B.gladioli pv. agaricicola, BG164R as a 'novel 
mushroom pathogen' based on their fmding that the cavity disease pathogen produces 
both toxins and degradative enzymes that degrade mushroom mycelia. They associated 
the production of toxins by the strain with the capacity to inhibit fungal mycelia. To test 
whether the mutants had any change in the ability to inhibit fungal mycelia, actively 
growing mycelia were challenged with the mutant bacteria. 
2.3.14. in vitro antifungal phenotype. 
An in vitro antifungal inhibition assay was set up to test whether the mutants lost the 
capacity to inhibit fungal mycelia. Initially, growing mycelia of Gaeumanomyces 
graminis were tested because BG164R was the strongest inhibitor (2.2.7h) of it. 
('ha/)/er // 
Thereafter. the observa tion was 'xtended to the capacity of inhibition or mushroom 
mycelia un C 1A platcs by two representative mutants, T he no-cavity causing mutants 
were still able to inhibit the grow ing mushroo m mycelia (F igure 2.11). S imilar 
Figure.2 ,11: Inhibition of Gaeumanomyces graminis mycelia by wild type BG164R, and its 'no-
cavity' causing mutants. [A] BG164R, [B] BG4-12, [C] BG12-88, [0] BG12-147, [E] BG15-40, [F] 
BG15-87, [G] BG16-787, [H] Eco/i S-17 (negative control). 
observation was noted in case of mushroom mycelia (Figure 2,12), indicating that the 
antifungal compound produced by He; I fl4R is possibly distinct, and not involved in the 
expression of Cavity disease in mushrooms, 
To furth e r tes t this hypothesis. a genetically undefined mutant of B(; I 64H. \vith highly 
reduced capacity to inhibit fungal mycelia, BCi 1\ OAf-, \vas tested for its ability to 
induce disease symptoms on mushroom slices, The mutant d emonstrated the ability to 
cause ea"ity disease by this assay (Figure 2, \3.A and 8). 
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Figure.2.12: Inhibition of Agaricus bisporus mycelia by wild type BG164R, and representative 
'no-cavity' causing mutants. [A) BG164R, [B) BG4-12, [C] BG12-147, [D) PA147-2 (-ve control) 
13 . 1 ' .• j{) 
Be, 1 "-III Rl d I(lAt~ 13(, I(.-1 R 
I~ Ci I 1 O!\ I· 
2.13. 2.13.B 
------
Figure 2.13: Antifungal [A) and mushroom bioassays [B] with antifungal reduced mutant 
(BG11OAf-) and a representative no-cavity forming (BG15-40) mutant, in comparison to the wild 
type strain BG 164R 
2.4. Discussion. 
In the experiments described above, the Cavity disease pathogen, BG 164, was prepared 
for gene manipulation experiments, randomly mutated, and 'no-cavity' mutants were 
isolated using a mushroom bioassay system. In the process of preparing BG 164 for 
gene manipulation experiments, initially the genetic markers present in the strain were 
defined by identifying its innate antibiotic resistance and susceptibility profiles . 
Thereafter, the spontaneous rifampicin-resistant mutant BG 164R was further 
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mutagenised. The 6 prototrophic mutants derived from BG164R by mini-Tn5 insertion 
mutagenesis were found to differ from BG 164R in regard to the flagella numbers, had a 
reduced capacity to degrade colloidal chitin, and lost the capacity to degrade protein on 
milk agar plates. 
Growth curves were developed to compare the rate of growth of mutants to that of the 
wild type. All the prototrophic mutants isolated had similar rates of growth in the LB 
broth. The main objective of the growth experiments was to test whether capacity of 
growth of the mutants was linked to the inability of bacteria to cause cavity on 
mushroom slices, in the next set-up, the growth rates of a representative prototrophic 
and a representative auxotrophic mutant was monitored on mushroom slices over time. 
This clearly indicated that the population of the auxotrophic mutants gradually 
decreased on the slice of the mushroom tissues, while the population of the prototrophic 
mutants steadily increases overtime. The 'no cavity' phenotype observed in case of the 
auxotrophic mutants could thus be due to the mutation itself, or due to the inability of 
the strain to grow on mushrooms. To identify the genes that had a role in the 
development of Cavity disease, it was decided to analyse the prototrophic mutants first. 
Surface components in a bacterium often contribute to the virulence properties, besides 
serving as the main connection with the external environment (Stathopoulos et al., 
2000). Surface appendages like flagella and pili are essential for the colonisation of host 
surfaces, which serves as the initial stage in disease formation, both in the case of plants 
and animal pathogens (Lillehoj et al., 2002; Tomich et al., 2002; Chua et al., 2003; 
Tans Kersten et aI., 2001; Ichinose et al., 2003; Mulholland et aI., 1993). In Vibrio 
cholerae, flagella enable the bacterial cells to swim to intestinal mucosa in order to 
escape the peristaltic action of the intestine. Chua et al. (2003) in their study on the 
aflagellate, non-motile mutants of B. pseudomallei in the BALB/c mice model have 
demonstrated that flagella are virulence determinants. They facilitate the spread of B. 
pseudomallei throughout the respiratory tract and mediate adhesion to the host cells, but 
they do not have any role in the invasion of host cells. In contrast, flagella-mediated 
motility of B. cepacia has been proven to be the major contributory factor in the 
invasion of human alveolar epithelial carcinoma cell line A549 (Tomich et al., 2002). In 
P. aeruginosa, flagella facilitates adhesion to the respiratory epithelial cells by binding 
Chapter II 71 
to a receptor of mucin, Mud, secreted by the respiratory cells (Lillehoj et al., 2002). In 
the case of plant pathogens like Erwinia, Xanthomonas and P. syringae, any mutation 
leading to aflagellate, non-motile phenotype has been demonstrated to be accompanied 
by the loss of pathogenicity (Ichinose et al., 2003; Mulholland et al., 1993; Tans 
Kersten et al., 2001). Ichinose et al., 2003 have reported that mutations in genes coding 
for flagellin protein, FliC, and the flagella cap protein, FliD, leads to reduced 
pathogenicity of P. syringae pv. tabaci on tobacco leaves and the mutants also had a 
reduction in the invasion capacity of the host tissue. In contrast, the pathogen Ralstonia 
solanacearum, requires flagella in the initial colonisation of the host by switmning 
towards to the host surface. Once internalised into the host tissue, flagella does not play 
any role in the production of disease symptoms (Tans Kersten et al., 2001). Thus, 
flagella have been associated with pathogenicity of bacteria in different ways. All 
studies stated above have been analysed in light of the mutations that led to the loss of 
flagella formation in bacteria. The no-cavity forming mutants isolated in the course of 
this study were associated with the reduction in the flagella number and retained the 
capacity of migration very similar to that of the wild type. In P. aeruginosa, the jleN 
gene product regulates flagella number by acting as a negative regulator of jleQ, the 
transcriptional activator for the flagellar synthesising genes (Dasgupta et ai., 2000). 
Dasgupta et al. (2000) have demonstrated that in the jleN mutants of P. aeruginosa 
strains P AK and P AO 1, motility was impaired although there was an increase in flagella 
number. Alternatively, there are reports of multiflagellate mutants of P. aureginosa that 
swarm better. The mutations mapped to the jla locus of the chromosome which carries 
genes for basal body formation of the flagella (Suzuki, 1980). Dasgupta et ai. (2000) 
proposed that phenotypes of motility and flagella number are not linked. Motility assay 
results presented in this chapter support the proposition of Dasgupta et al. (2000). 
Flagella-mediated motility and chemotaxis forms a complex subsystem consisting of 
flagella and the sensory apparatus that controls its operation. The process of flagella 
biosynthesis and the controlled movement of the bacterial cells in response to 
environmental cues are controlled by a set of 40 genes in E. coli and Salmonella 
typhimurium spread over in 3 contigs within the bacterial chromosome (Macnab, 1992). 
Of these 40 gene products, the general secretory pathway secretes only two genes 
necessary for the formation of the flagella basal body while the flagella apparatus 
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secretes the rest. The two proteins secreted by the general secretory pathway of protein 
secretion in bacteria form the P and L rings in the basal body of flagella. The P and the 
L rings of flagella basal body have been associated with the maintenance of integrity of 
the rod in basal body structure and in no way linked to the possible control of the 
flagella number. Dasgupta et al. (2000) published the first report on the gene, JleN, 
controlling flagella number. Although majority of the genes in the complex flagella 
operon have' been identified and the complex process of regulation of the different 
operons deciphered, the role of some genes still remain unknown. It has been presented 
in this chapter that the no-cavity mutants have a reduction in the number of flagella, 
while still retaining the capacity of motility. It is thus tempting to speculate at this stage 
that the mutants by some unknown mechanism have a role in the regulation of flagella 
number. 
Interestingly, Cavity disease mutants 'in general do not show any difference in the 
capacity of biofilm formation under the defined assay system. One of the main features 
governing the formation of biofilms is availability of nutrients (O'Toole et aI., 2000). In 
the assay described, the media used was mushroom extract media, formulated 
specifically to best represent the nutritional conditions in the mushroom tissues. Apart 
from environmental cues regarding availability of nutrients, other factors have been 
associated with biofilm formation, such as possessing flagella, formation of type I and 
type IV pili, production of exopolysaccharides (O'Toole & Kolter, 1998b; Pratt & 
Kolter, 1998; Monds et al., 2001). Common factors such as the ability of bacteria to 
swim and adhere to the target substratum and thereby multiply on them to form micro-
colonies, have been found to be necessary in the formation of bacterial biofilms and in 
the virulence of pathogenic bacteria; however, the exact molecular mechanism involved 
in biofilm formation still is unknown. O'Toole and Kolter in their work on initiation of 
biofilm formation in P. Jluorescens WCS365 (O'Toole & Kolter, 1998a) have 
demonstrated that extra cytoplasmic proteins take part in biofilm fonnation. In their 
rapid attachment assay they have demonstrated that in the presence of pronase E, the 
cells loose the capacity of adhering to abiotic surfaces. They have suggested that 
surface-attached proteins playa role in the biofilm formation, and hence in the presence 
of proteases, the initiation of biofilm formation is hampered. One of the phenotypic 
characters that distinguish the Cavity disease mutants from the wild type is the inability 
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to secrete proteases. However, no differences in the capacity of biofilm formation were 
observed in case of the mutants. Perhaps, inability to form biofilm in the presence of 
protease is a feature observed in case of only some specific proteases. Although there is 
a growing list of genes now known to be involved in biofilm formation, no study 
described so far has addressed the role of secretory proteases in the prevention of 
biofilm formation. From the results presented, it can be concluded that in the case of 
cavity disease, biofilm formation possibly does not play any significant role. Although, 
in order to confirm this hypothesis, biofilm fonnation by BG 164R and the mutants on 
mushroom tissues need to be tested in vivo. 
BG164R has a capacity to degrade colloidal chitin. Gill and Cole (1992) have reported 
the ability of BG 164R to metabolise N-acetyl glucosamine, the monomer of chitin. The 
results presented in this chapter are consistent with Gill and Cole's observation. The 
mutants have a highly reduced ability to degrade colloidal chitin, in spite of not being 
able to form cavity on mushroom slices. Recently, a strain of Burkholderia gladioli 
(CHBI0l) that does not show any chitinase activity against colloidal chitin has been 
reported to produce chitosanase A. The enzyme hydrolyses glucosamine oligomers 
larger than pen tamers (Shimosaka et aI., 2000), thus cannot degrade colloidal chitin on 
plate assays, which involves liberation of the monomers from oligomers and making 
them available to the bacteria to metabolise. Chemically chitin, is a ~-1-4 linked 
polymer of N-acetyl glucosamine and for the bacteria to metabolise N-acetyl 
glucosamine, it has to make the monomer available in its immediate environment. 
Perhaps such sequential degradation of chitin takes place in case of BG 164R, firstly 
hydrolysis of glucosamine oligomers into smaller units take place which is followed by 
the cleavage of the glycosidic bonds to liberate N-acetyl glucosamine, which is then 
metabolised by BG164R. Mutations interfere with one of the products involved in the 
sequential degradation of mushroom chitinase, as a result of which the mutants do not 
completely lose the capacity of degrading colloidal chitin Alternately, the mutations 
interfere with the secretion of chitin degrading enzymes of BG 164R. 
The bioassay system proved to be efficient for the purpose of screening mutant bacteria 
and testing an 'all or none' effect of cavity formation. However, slices obtained from 
different sporocarps varied in the intensity of disease manifestation under the 
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standardised assay conditions. Since colonies of the strain tested in the bioassay system 
were transferred onto mushroom slices with toothpicks, size of the initial inoculum used 
could possibly have been the explanation for such variation in the expression of disease 
symptoms. Alternatively, there could have been involvement of other intrinsic factor(s) 
in the expression of Cavity disease by BGl64R on mushroom tissues, as will be 
discussed in chapter 5. 
2.5. Concluding Remarks. 
In summary, the mutants, in comparison to the wild type, have reduced number of 
flagella and have highly reduced capacity to degrade colloidal chitin, are unable to 
degrade milk proteins and associated with the shrinkage of mushroom mycelia. These 
could possibly imply that the same gene or different genes of a specific operon has been 
mutated in case of all the mutants. Identification of the gene( s) disrupted by transposon 
insertion in case of the mutants is most likely to provide possible explanations of the 
phenotypes noticed in the mutants. Thus, identification of the mutated genes was 
essential. The next chapter describes the cloning of mutants and identification of the 
genes that have rendered the pathogen avirulent. 
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Chapter III 
Identifying the gene(s) ofBG164R involved 
in the manifestation of Cavity disease 
synlptonls. 
3.1. Introduction. 
Cavity disease is a 'soft rot' disease of the mushroom sporocarp. As such, BG164R is 
expected to produce and secrete mushroom cell wall depolymerisation enzymes. The 
characteristic difference between the cell walls of plants and mushrooms is the presence 
of specific components like chitin and glucan, which make up the skeletal structure of 
the mushroom mycelia (Alexopoulos, 1.996). The observed phenotypic differences 
(presented in section 2.3.7, 2.3.11 and 2.3.12) between the wild type and mutants of 
BG 164R isolated in the mutagenesis screens were a reduction in the flagella number, 
inability to degrade protein on milk agar plate and highly reduced capacity to degrade 
colloidal chitin. Identification of the genes mutated in the avirulent derivatives of the 
pathogen appeared to be the best approach to relate the genetic mechanism(s) of 
BGl64R involved in the expression of Cavity disease. 
This chapter describes the cloning of chromosomal regions to which these mutations 
map. Cloned genes adjacent to the insertion points of the transposon were sequenced. A 
genomic library of BG 164R was constructed; putative cosmids capable of 
complementing the null mutants were isolated and used to complement the mutants. 
Attempts made to identify the active products involved in Cavity disease are also 
described. In the last section, the role of BG164R protease(s) in Cavity disease 
manifestation is discussed. 
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3.2. Material and Methods. 
3.2.1. Bacterial strains, plasrnids and cosmids either created or used in the 
course of the study. 
Strains Genotype or description References 
and plasmids 
Burkholderia gladioli pv.agaricicola. 
BG164R wildtype, cav+, Af+, Rif, Prot+ This study 
BG4-12 BG 164R gspF: :mini-Tn5KmlacZ2 ,Ri~,KmR, 
cav-,Af+, Prot- This study 
BG12-88 BG 164R gspK::mini-Tn5KmlacZ2,Ri~,KmR, 
cav-,Af+, Prot- This study 
BG15-40 BG 164R gspE: :mini-Tn5KmlacZ2,Ri~,KmR, 
cav-,Af+, Prot- This study 
BGProt-123 BG164R gspL::mini-Tn5KmlacZ2,Ri~,KmR, 
cav-,Af+, Prot- This study 
BGProt-125 BG 164R gspF: :mini-Tn5KmlacZ2 ,Ri~,KmR, 
cav-,Af+, Prot- This study 
BG4-12Cos BG4-12 complemented with cosmid 
pCosGSP, Ri~ KanR, TetR ,cay + This study 
BG12-88Cos BG 12-88 complemented with cosmid 
pCosGSP, RitRKanR, TetR ,cav+ This study 
BG15-40Cos BG15-40 comllemented with cosmid 
pCosGSP, Ri KanR, TetR ,cav+ This study 
BG-LAF3 BG164R with pLAFR3, Ri~,TetR, cav+, 
Prot+ This study 
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BG4-12LAF3 BG4-12 with pLAFR3 Ri:f,KanR, TetR, 
cav-, Prot-
Eschericia coli 
DH5a 
HBlOl 
supE44 AlacU169 (~801acZAM15) hsdR17 
thi-1 relA1 recA1 
supE44 hsdS20 (rB-mB-) recA 13 ara-14 rspL20 
proA2lacY1 galK2 xyl-5 myl-l 
Plasmids and constructs 
pSPRC12 8.5kb SalI fragment containing gspF: :mini-Tn5 
KmlacZ2 from BG4-12 in pBluescript KS+, 
ApR,KanR. 
pSPRC40 5Akb SalI fragment containinggspE::mini-Tn5 
KmlacZ2 from BG15-40 in pBluescript KS+, 
A R R p ,Kan. 
pSPRC87 6.0kb Sail fragment containing gspD::mini-Tn5 
KmlacZ2 from BG 15-87 in pBluescript KS+, 
ApR, KllnR. 
pSPRC88 5 .2leb Sail fragment containing gspK: :mini -Tn5 
KmlacZ2 from BG 15-88 in pBluescript KS+, 
ApR, KanR. 
pSPRC147 5.3leb Sail fragment containing gspK::mini-Tn5 
KmlacZ2 from BG12-147 in pBluescript KS+, 
ApR, KanR. 
pSPRC787 5Aleb Sail fragment containing gspE::mini-TnS 
KmlacZ2 from BG 12-787 in pBluescript KS+, 
A R R p ,Kan. 
pBGProt-123 6.6kb SalI fragment containing gspL: :mini-TnS 
KmlacZ2 from BGProt-123 in pBluescript KS+, 
ApR, KanR. 
pBGProt-125 8.3kb Sail fragment containing gspF: :mini-Tn5 
KmlacZ2 from BGProt-125 in pBluescript KS+, 
A R R p ,Kan . 
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This study 
Hanahan 1983 
Boyer 1969 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
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pROBE 
pCosGSP 
Vectors. 
1.5kb NotI fragment containing the kanamycin 
gene from mini-Tn5KmlacZ2blunt end cloned 
into the EcoRV site of pBluescriptKS-;ApR 
23.4kb Sau3AI partial fragment containing GSP 
gene cluster from BGl64R into pLAFR3. 
pBluescript ColEl ori lacZafKS poly linker, T3/T7.ApR 
(KS,MI3+) 
pBR322 ColEl ori ApR TcR. 
pLAFR3 pRK290 derivative;RP4(IncP-l) ori, ACOS, 
pUC9 multicloning site and lacZa,TcR 
Table 3.1. List of Strains used in the experiments described in Chapter 3. 
3.2.2. Media, reagents and antibiotics. 
78 
S.R.Giddens 
This study 
Stratagene 
Bolivar et al. 1977 
Staskawicz et al. 
1987 
All media and reagents used in this study were prepared as described in Appendices I 
and II. Concentrations of the antibiotics used to maintain selective pressure on either 
strains or plasmids/cosmids within a strain are as described in Appendix I, unless 
otherwise stated. 
3.2.3. Bacteriological methods and mushroom bioassay system. 
The bacteriological methods and the culture conditions used are stated in section 2.2.3. 
All mushroom bioassays were carried out according to the method stated in section 
2.2.5. 
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3.2.4. DNA manipulation and cloning techniques. 
3.l.4a. Preparation of Genomic DNA (Pitcher et al. 1989) 
The method used was adopted from Pitcher et al. (1989), whereby 1.5 mlliquid cultures 
of 16hr old cells were harvested by centrifugation at 7,000rpm for 2min and the pellet 
was resuspended in 1I15th vol (100~L) of Tris-EDTA buffer. Bacterial lysis was 
mediated by the addition of 5 volumes (500~L) GES solution (Appendix II), followed 
by thorough mixing and incubation at 65° C for 15min. Cold 7.5M ammonium acetate 
(Appendix II) was added, at half the volume of the GES added (250~L), and the 
solution mixed thoroughly before being incubated on ice for 10 min. Proteins were 
extracted by addition of double the volume of ammonium acetate (500)lL) of 
chloroform: isoamyl alcohol (24: 1). Aqueous and organic phases were mixed and 
separated by centrifugation at 12,000rpm for 3min. DNA was precipitated from the 
aqueous phase by addition of 0.54 volumes of isopropanol, mixing with care by 
inversion and incubation at room temperature for 15min. The dehydrated filaments of 
DNA were recovered by centrifugation, rehydrated by washing thrice with 70% ethanol, 
air dried and resuspended in 50)lL of T lOE! Buffer (Appendix II). 
3.lAb. Plasmid DNA preparation (Sambrook et al., 1989) 
Plasmid DNA was prepared by the standard alkaline lysis method derived from 
Brinboim and Dolly (1979), as stated by Sambrook et al. (1989). For routine analysis of 
plasmid DNA, cells from 1.5mL of a 16-18hr old culture were harvested by 
centrifugation at 7,000rpm for 2min at room temperature and the supernatant was 
removed by aspiration. The cells were resuspended in 1I15th volume (100)lL) of 
solution I (Appendix II) and incubated for 10min on ice. Double the existing volume of 
freshly prepared solution II (Appendix II) (200)lL) was added and mixed gently until 
the solution became viscous and clear, indicating complete lysis of cells had occurred. 
Following this, half the total existing volume of ice-cold solution III (Appendix II) 
(150~L) was added and mixed vigorously until a white precipitate appeared. The 
solution was incubated on ice for 10min, followed by centrifugation for 10min at 
13,000rpm at 4°C. The supernatant was decanted into a fresh Eppendorf tube, and half 
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the existing volume of ice-cold isopropanol (250j.lL) was added in order to dehydrate 
the DNA molecules. After incubation on ice for further 10min the DNA was 
precipitated and collected at 13,OOOrpm for 10m in at 4°C. The DNA pellet was washed 
once with 70% ethanol at RT, which partially re-hydrates DNA. The DNA was then air-
dried and resuspended in 200j.lL of TlOEJ buffer. Double the volume (400IlL) of 100% 
ice-cold ethanol was added, to re-precipitate the DNA, and held on ice for 10 min 
before centrifugation at 13,000 rpm at 4°C for 10min. The DNA collected was washed 
thrice in 70% ethanol, air-dried and resuspended in sterile distilled water. The volume 
of the sterile distilled water used to resuspend the DNA extracted, depended on the copy 
number of the plasmid DNA being extracted. For high copy plasmid DNA like 
pBluescript and its derivatives, the DNA was generally resuspended in 50j.lL of TlOEl, 
for medium copy number plasmid like pBR322 or low copy number pLAFR3 based 
cosmid constructs, 20llL TlOEJ was used. DNA concentration was estimated (3.2.4c) 
and the working DNA solutions were normally diluted to a concentration of 
approximately 500ng/j.lL before being stored at -20°e. 
3.2.4c. Estimation of DNA concentration (Sambrook et ai., 1989). 
The concentration of various DNA samples was determined by measuring the ratio of 
absorbance at 260nm relative to the absorbance at 280nm using a deuterimn lamp LKB 
Ultraspec ® Plus spectrophotometer. DNA was generally diluted to 1: 100 and the 
relative absorbance measured. The concentration of the DNA sample was calculated 
from the standard 10D 260 "" 50ng of nucleic acid. 
3.2.4d. Preparation of sequencing/cloning gualitv DNA (Sambrook et al., 1989). 
An essential criterion in sequencing or cloning reactions is the quality of the DNA 
template. Thus, plasmid DNA prepared by the alkaline lysis method (stated in section 
3.2.4b) and required for further manipulation was re-suspended in 200j.lL of TlOEJ and 
subjected to further purification. This included a lithium chloride treatment for the 
precipitation of high molecular weight RNA and an RNAse treatment for the 
elimination of low molecular weight RNA, followed by a phenol chlorofonn extraction 
to remove all protein contaminants. 
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Briefly, to 200f..lL of DNA (extracted by the alkaline lysis method) an equal volume of 
ice-cold 5M LiCh solution was added. The solution was mixed and incubated on ice for 
10min followed by centrifugation at 13,OOOrpm, 10min at 4°C. The supernatant, 
containing the DNA and small molecular weight RNA molecules, was transferred to a 
fresh tube. An equal volume of ice-cold isopropanol was added, followed by incubation 
for 10min on ice. The nucleic acid was collected by centrifugation (13,OOOrpm, 
incubated on ice for 10min at 4°C), rinsed in 70% ethanol at RT, air dried and re-
suspended in 200f..lL of TlOEI. RNA was removed by the addition of 2f..lL of 10mg/mL 
RNAse solution and incubation at 37°C for 25min. The DNA was subsequently purified 
by adding equal volumes of phenol and chloroform:isoamyl alcohol. mixture was 
centrifuged to sepamte the aqueous and the organic phases at 12,000rpm for 3min at 
RT. The aqueous phase, containing the DNA, was collected and the DNA was 
precipitated by adding 1I10th volume of 3M sodium acetate and 2 volumes of 100% ice-
cold ethanol. The solution was mixed well and incubated on ice for 10min. The DNA 
was recovered by centrifugation at 13,OOOrpm for lOmin, washed thrice in 70% ethanol 
at RT and re-dissolved in sterile distilled water to give a fmal concentration of 100-
500ng/f..lL. 
3.2.4e. Restriction digestion of DNA. 
Restriction digests were set up according to the manufacturer's recommendations. 
Digestions were routinely carried out in a final volume of 10)lL and incubated at 37°C 
for 1-3hr. For digestions that required more than one restriction enzyme, a buffer best 
suited for all the enzymes were used. Alternatively, the digestion was carried out in 
more than one step, separated by thermal denaturation of the enzyme at 80°C for 15min 
and precipitation of the DNA. 
3.2.4f. Agarose gel electrophoresis ofDNA(Sambrook et al., 1989). 
DNA fragments digested with restriction enzymes were analysed by agarose gel 
electrophoresis. The agarose gel was prepared with 1 x TAE buffer (Appendix II) at a 
concentration varing from 0.5% to 0.9% depending upon the size of the expected DNA 
fragments to be separated. The resolved DNA fragments were stained for 10min with 
0.5ng/mL ethidium bromide solution prepared in 1 x TAE. Generally, an aliquot of A 
DNA digested with HindIII was used as the standard against which the size of the DNA 
Chapter III 82 
fragments being electrophoresed were estimated. Following the staining of DNA, gels 
were de stained in 1 x TAB for 5 mins before visualisation at a wavelength of256nm on 
a Sigma T2210 UV trans-illuminator. The DNA gels were photographed using the 
Kodak Electrophoresis Documentation and Analysis System 120. 
3.2.4g. Elution of DNA from agarose gels. 
The desired DNA fragments were eluted from agarose gels with the "Prep-a-Gene" 
DNA purification kit from Bio-Rad® using the manufacturer's protocol. The DNA was 
eluted from the matrix using sterile distilled water. 
3.2.4h. Calf intestinal phosphatase CCIP) treatment of DNA (Sambrook et aZ. 1989). 
To enhance the chances of ligation of insert DNA to the vector, unless otherwise stated, 
the vector DNA was treated with calf intestinal phosphatase (CIP) prior to ligation. The 
basic principle of the reaction is removal of the terminal 5' phosphate from the digested 
DNA by treatment with phosphatase. This reduces the chances of self-ligation of the 
vector DNA. 
The DNA to be CIP treated was precipitated and re-suspended in 49f.l,L of 1 x 
dephosphorylation buffer (from the lOx stock provided by Boehringer Mannheim) and 
1 unit of CIP (Boehringer Mannheim). The reaction was incubated at 37°C for 30min 
before being terminated by addition of EDT A (Appendix II) pH 8 (to make fmal 
concentration of the solution 5mM) at 75°C for lOmin. Following the required 
incubation period, the volume of the DNA was made up to 200f.l,L, and extracted with 
phenol and chloroform using the method stated in section 2.3.4d. The DNA was re-
dissolved in 10f.l,L of sterile distilled water. 
3.2.4i. DNA ligation (Sambrook et aZ., 1989). 
Estimated quantities of the vector and insert DNA, in the ratio of 1:3 respectively 
(unless otherwise stated), were transferred into an Eppendorf tube and precipitated by 
addition of 1/8th volume of 2M potassium acetate pH 8, and double the volume of 100% 
ice-cold ethanol. The mixture was incubated at -80°C for 20min and the DNA 
recovered by centrifugation at 13,OOOrpm for 10min at 4°C. The precipitated DNA was 
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re-suspended in III-lL of sterile distilled water, heated at 45°C for 5min and crash 
cooled to separate any annealed cohesive end ligation. To this 31-lL of 5 x ligation buffer 
and 2 units of T4DNA ligase (GIBCO BRL) was added and incubated at RT for 16hr 
(unless otherwise stated). At the end of the required incubation period, an aliquot was 
run on an agarose to check the efficiency ofligation, re-precipitated with 2M potassium 
acetate as stated above and dissolved in sterile distilled water at a final concentration of 
50ng/l-lL. 
3.2.4j. Cloning of transposon tagged genes from the genomIc DNA of BG164R 
(Sambrook et al., 1989). 
Generally, 81-lg of genomic DNA and 21-lg of vector DNA were digested to completion 
with 5 units and 1 unit of the appropriate enzyme respectively. Following digestion, an 
aliquot of both the insert and vector DNA was checked on an agarose gel, the enzymes 
were thermally denatured, and the final volume of DNA was made up to 200l-lL with 
sterile distilled water. DNA was precipitated by the addition of 1I10th volume of 3M 
sodium acetate, double the final volume of 100% ice-cold ethanol, and incubated at -
800e for 20 min prior to centrifugation at 13 OOOrpm for 10 min at 4°C. This DNA 
served as the digested stock, and ligation was set up with 21-lg of insert DNA and 500ng 
of vector DNA for 18 to 20hr at room temperature with 4 units of T 4 DNA ligase. 
Following ligation for 20hr, aliquots of the ligated DNA were checked on a 0.9% 
agarose gel prior to re-precipitation as described above with sodium acetate. 
Approximately, 100ng of ligated DNA was used for electro-transformation of E. coli 
DH5a electro-competent cells according the method stated in section 3.2.5. 
3.2.5. Electro-transformation. (Dower et al.1988; Zabarovsky and WinbergI990). 
3.2.5a. Preparation of Electro-competent E. coli cells. 
The method used was as recommended by the Bio-Rad pulse controller instruction 
manual. One hundred mL of an exponentially growing culture of E. coli, starting from a 
1 :100 dilution of 18hr old stationary phase culture, was grown to an OD6oo of 0.5 to 0.7. 
The culture was chilled on ice for 30min and cells were harvested by centrifugation at 
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5,000rpm for 5min at 4°C. The cells were washed by resuspending in 100mL of ice-cold 
sterile distilled water and centrifugation at 5,000rpm for 5min at 4°C. This was followed 
by a second wash in half the volume of ice-cold sterile distilled water and a third wash 
in one fourth volume of ice-cold 10% sterile ice-cold glycerol. The cells were thereafter 
resuspended in 500)lL of 10% sterile ice-cold glycerol, and 40)lL aliquots were 
transferred to sterile and cold Eppendorf tubes. The cells were either freshly used or 
stored in -80°C for use up to 3months. 
3.2.5b. Electroporation of ligated DNA into competent E. coli cells. 
Electro-transformation was carried out by electroporating the competent cells with the 
recombinant DNA using a Gene PulserTM (Bio-Rad) set with capacitance at 25)lF, and a 
pulse controlled resistance of2000. For cuvettes with O.lcm gap the voltage were set at 
1.8kV and for 0.2cm gap cuvettes, the voltage was set at 2.5kV. Generally, freshly 
prepared electro-competent cells were used. When frozen cells were used in the cloning 
experiments, the frozen cells were thawed on ice for 20min prior to transformation 
reaction. Sterile and cold cuvettes as well as the slide chamber were mandatory for 
electro-transformation reactions. Usually 50-100ng of DNA was mixed with the electro-
competent cells, transferred in pre-cooled sterile cuvettes, incubated for 5min before 
exposure to the electric pulse set with conditions mentioned above. Immediately after 
the charge release, the cells were retrieved from the cuvette with 1mL of SOC media 
(Appendix I). The transformed cells were elaborated for 1hr at 37°C, centrifuged for 
2min at 7,000rpm and harvested cells were spread on LB plates supplemented with 
appropriate antibiotics and incubated at 37°C for 24hr. 
3.2.6. Southern Hybridisation (Sambrook et al., 1989). 
3.2.6a. Probe labelling. 
A 1.5kb NotI fragment containing kanamycin gene from mini-Tn5KmlacZ2, was cloned 
in pBluescriptKS+ to construct pROBE (Table 3.1.). This was used to probe SaIl 
digested genomic DNA of the mutants to verify single transposon insertions. Random 
Primed DNA labelling kit from Boehringer Mannheim was used to radioactively label 
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50ng of the probe DNA, following the manufacturer's protocoL (aP32) dCTP was used 
as a labelled nucleotide, and the labelling reaction was incubated at 37°C for 30min. 
3.2.6b. Transfer method. 
The digested DNA was separated on a 0.9% agarose gel at 16 Volts for 12hr. The gel 
was stained briefly in freshly made TAE solution containing ethidium bromide 
(0.5~g/mL), visualised and photographed prior to destaining for an hour. The DNA was 
transferred from the gel on to a Hybond™ N+ membrane using a Phannacia LKB 
VacuGene XL vacuum blotting apparatus and following the protocol supplied in the 
instruction manual. This included partial depurination of the DNA by covering the gel 
with 0.25M HCl for 15min under 50mbar pressure, followed by replacing the HCl with 
4M NaOH for the denaturation and transfer of the DNA under similar pressure for one 
hour. Following transfer, the gel was restained to confirm complete transfer of DNA to 
the membrane and the membrane was washed briefly in 2 x SSC before probing. 
3.2.6c. Hybridisation and signal detection. 
The membrane was placed in a Hybaid glass hybridisation tube and pre-hybridised in 
the recommended pre-hybridisation buffer for 3hr at 65°C prior to addition of the 
labelled probe, in a rotary mini-hybridisation oven. Hybridisation was carried on for 
18hr at 65°e. Following hybridisation, the buffer was replaced with 2 x SSC and 
washed for 15min to remove unbound probe. The stringency washes were thereafter 
done at 65°C to ensure removal of non-specifically bound DNA probes. Stringency 
washes consisted of washing the membrane thrice in 2 x SSC and 0.1 % SDS for 5min 
each, followed by two washes for 10min each in 1 x SSC and 0.1 % SDS, and four 
washes in 0.1 % SSC and 0.1 % SDS, 5min each. The washed membranes were taken out 
of the rotary tube, wrapped in a Gladwrap and exposed to Amersham Hyperfilm-MP in 
an autoradiography cassette for 2hr at -80°e. The film was immersed in Agfa G-150 
developer for 5min, rinsed in flowing tap water and fixed in Agfa G-334 fixer for 
further 5min. The autoradiograph was then rinsed in water and air-dried. 
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3.2.7. DNA Sequencing. 
The chain terminating dideoxynucleotide triphosphate method of Sanger (1977) was 
used to sequence the DNA using infrared-labelled T3 and T7 primers. Initially all the 
clones were sequenced using a LI-COR4000L automated DNA sequencer in the School 
of Biological Sciences. The clones were later re-sequenced at the DNA sequencing 
facility of the University of Auckland using the same set of primers and using aLI-COR 
4000LD IR2 automated sequencer using two infrared dyes IRD700 and IRD800. The 
template DNAs were supplied to them at a concentration of O.2pmol/j..tL in sterile 
distilled water. The sequencing reactions and the gel conditions used for sequencing the 
clones in the School were as follows: 
3.2.7a. Sequencing reactions. 
The SequiTherm™ Long-Read™ Sequencing Kit LC from Epicentre Technologies was 
used for sequencing. The primers used were T3 and T7 labelled IRD41 dye. The 
reaction mixtures were made up following the manufacturer's protocol provided with 
the kit. Briefly, O.Spmol template DNA was added to 2.Sj..tL sequencing buffer, Ij..tL of 
DNA polymerase, 2pmol ofIR-labelled primer and the final volume of the mixture was 
made up to 17j..tL with sterile distilled water. 4j..tL aliquots from this bulk reaction mix 
was added to 4 separate O.SmL PCR tubes containing 2j..tL of 4 different Long-Read™ 
termination mixes (of one ddNTP and the remaining 3 dNTPs per mixture). This 
reaction mixture was overlayed with a drop of PCR mineral oil to prevent evaporation 
during the cycling reactions. The contents of the tube were collected at the bottom of 
the tube by a quick spin in a bench top centrifuge. The PCR reactions were done in a 
Hybaid Omnigene thermocycler for 30 cycles of 30sec at 9SoC, lSsec at SO°C and Imin 
at 70°C. At completion, the reactions were terminated by adding 3j..tL of stop solution 
containing formamide, EDTA and fuschin loading dye. The reaction mixes were 
immediately loaded on the sequencing gel and run overnight for 16hr, unless otherwise 
stated. Excess reaction mixes were stored at -20°C. Immediately before loading of the 
samples, the samples were denatured by heating for Smin at 9SoC. 
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3.2 .7b. Sequencing gels . 
Sequencing of double stranded DNA was done in a Li-COR automated sequencer 
available in the department, exploiting Sangers' dideoxy chain tennination method 
(Sanger et aI., 1977). A 4% Long Ranger Gel solutioD (Bio Whittaker Molecular 
Applications) was used to cast the gel using the casting mixture mentioned in Appendix 
11. Sixty six cm long gel casting plates were used with a 32 well comb. Polymerisation 
was carried out by incubation at RT for 2-3hr. Prior to loading the samples, the gels 
were pre run in I x TBE (Appendix ll). Data obtained from the electrophoresis of the 
samples were collected by using 2.31 Data Collection DEV7 software and the data were 
recorded using Version 2.30 Image Analysis Program of the LJ-COR4000L automated 
DNA sequencer. 
The sequences obtained were confinned by re-sequencing at the University of Auckland 
DNA sequencing facility. Sequences collected from both the sources were aligned using 
the software, DNA MAN Version 4.02 and is presented in Appendix Ill. 
3.2.7c. Analysis of sequence data. 
Sequence data obtained were first analysed to find overlapping sequences of the vector 
and the transposon ends using DNAMAN Version 4 .02 program from Lyonnon 
BioSoft. The sequences were processed to separate the overlapping sequences from the 
genomic DNA sequences. The processed sequences were thereafter submitted to BlastN 
and BlastX servers (\\ \\ \\ .ncbi .nll11 .nih.\!O\ , blast) and compared to the other referenced 
sequences in the database following methods stated by Altschul e/ al., (J 997) . 
3.2.8. Construction of genomic library of BG 164R (Fleischman et al. J 987). 
The genomic library was constructed according to the method outlined by Fleischman el 
al. 1987, except for the extraction of genomic DNA , which was done according to 
method stated by Pitcher e/ al. 1989 and described in section 3.2.4a. 
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3.2.8a. Preparation ofBG164R insert DNA. 
(i) Digestion of genomic DNA to obtain partially digested 20 kb fragments. 
Twenty sets of restriction digestions, each containing 25f.lg of genomic DNA of 
BG164R were digested with 0.005U enzyme/Jlg of DNA, for 7.5min to obtain 20-25kb 
partially digested DNA fragments. Aliquots from each digest were analysed on a 0.4% 
agarose gel, run for 14hr at 12 Volts with HindlII digested A-DNA as a molecular 
weight marker. Digested DNA samples were pooled and precipitated with 1I10th volume 
of 3M Na-Acetate and twice the volume of cold 100% ethanol, washed thrice with 70% 
ethanol, dried and re-dissolved in 20JlL ofTIO E j. 
(ii) Sucrose density gradient centrifugation for size fractionation of the genomic 
DNA. 
Partially digested genomic DNA fragments (20-25kb) were purified by sedimentation 
through a 10-40% (w/v) continuous sucrose density gradient, following the method 
stated by Sambrook et al. (1989) with a few modifications. 
(a) DNA was centrifuged in a SW27 rotor for 24hr at 26,000 rpm at 15°C. 
(b) Two hundred and fifty Jlg of DNA was loaded per 38ml gradient made in 40ml 
Beckman ultracentrifuge tubes. 
(c) One ml fractions were removed from the top of the gradient and 10JlL 
aliquots of every second fraction was separately analysed on a 0.4% agarose gel 
run at 12Volts for 14hr with HindlII digested ADNA as the molecular weight 
marker. 
(d) Following isolation of the 1mL fractions, which could be used in the library 
construction, each of them was separately diluted thrice with T IOE j. The pH was 
adjusted with 1110 volume of 3M Na-acetate pH-4.8, precipitated with twice the 
volume cold 100% ethanol, and resuspended in 20JlL ofTIOEj. 
(e) One JlL from each fraction was loaded and finally analysed on a O.4%agarose 
gel run at 12Volts for 14hr. Desired fractions were there after pooled into one 
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and the concentration of the insert DNA was estimated according to the method 
stated in section 3.2.4c. 
3.2.8b. Preparation ofpLAFR3 vector DNA. 
(i) Extraction and purification of vector DNA. 
pLAFR3 DNA was prepared by the standard plasmid DNA preparation method by 
alkaline lysis, as described in section 3.2.4b. from 2L culture of E. coli cells harbouring 
the cosmid. Extracted cosmid was purified by CsCb-ethidium bromide equilibrium 
centrifugation method described in Sambrook et al. (1998), with a few modifications in 
the methods of removal of ethidium bromide from the DNA isolated. 
(a) An equal volume of isopropanol, saturated with CsCb, was added to the band of 
DNA ethidium bromide CsCb solution taken out from the Beckman 
ultracentrifuge tube with a 16-gauge hypodermic needle and mixed by inversion. 
(b) The red, ethidium bromide containing, upper layer was discarded and the DNA 
solution was washed twice with isoproponol saturated CsCb, 
(c) After the second wash, the CsCb DNA solution was put in a micro-concentrator 
tube and spun at 5,000 rpm for 20min at 4°C. This was repeated 3 times to 
remove the CsCb. 
(f) The concentration of the DNA solution thus obtained was estimated according to 
the method stated in section 3.2.4c. 
(ii) Digestion and CIP treatment of the Vector DNA. 
Purified pLAFR3 DNA was digested with BamHI according to the conditions stated in 
section 3.2.4e., in this case to ensure the quality of DNA prepared and to ensure the 
complete linearisation of vector DNA. Linearised DNA was ethanol precipitated and 
resuspended in TlOE l . The vector was dephosphorylated by CIP treatment following the 
method stated in section 3.2.4h, and the concentration of DNA estimated according to 
the method stated in section 3.2.4c. 
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3.2.8c. Library construction. 
(i) Optimisation of the conditions for the digestion of genomic DNA. 
In a series of preliminary reactions, ideal conditions best suited to obtain 20-25kb 
partially digested fragments of Il-lg genomic DNA were established by varying the time 
of digestion and enzyme (Sau3AI) concentrations in the reaction. Aliquots from each 
digest set up with varying parameters were analysed on a 0.4% agarose gel run for 14 hr 
at 12 Volts with HindlII digested A-DNA as the standard molecular weight marker. 
From these reactions, optimum conditions of 7.5min digestion with 0.005U enzyme /I-lg 
of DNA was chosen. To set up digests using 251-lg of genomic DNA per reaction, all 
reagents were scaled up and reaction conditions duplicated. Prior to size fractionation of 
DNA by sucrose density gradient centrifugation, 20 sets of scaled up digestions were set 
up and each digest was analysed separately on 0.4% agarose gel to ensure presence of 
the desired fragment sizes of partial digests in the reaction mix. The ideally digested 
DNA samples were pooled together, precipitated, and purified by sucrose density 
gradient centrifugation. 
(ii) Preparation of Vector DNA. 
Initially, 11-lg of purified pLAFR3 DNA was digested with BamHI, to ensure the quality 
of the DNA prepared and to establish the digestion conditions. This was followed by 5 
sets of bulk digestion each containing 61-lg of DNA and replicating the conditions 
established. Complete linearisation of vector DNA was ensured by running an aliquot 
from each digest on a 0.9% agarose gel at 80 Volts for 2hr. Linearised DNA was 
precipitated with ethanol and resuspended in T lOE1 before being dephosphorylated by 
CIP treatment, following the method described in section 3.2.4h. The dephosphorylated 
vector DNA was extracted with phenol: chloroform to terminate the enzyme activity 
and remove contaminants of the reaction mixture, precipitated with ethanol and stored 
as the stock. 
Dephosphorylation of the 5' ends in the vector molecule was of paramount importance 
in the construction of a genomic library to avoid ligation of vector's anns leading to 
wrongly packed phage heads. Thus, before ligation of the vector with the insert DNA, 
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the efficiency of dephosphorylation was tested by comparing ligation reactions set up 
with 100ng of dephosphorylated vector and control non-dephosphorylated vector 
molecules independently. This was followed by transfonnation of electro-competent E. 
coli DH5a cells with 100ng DNA from the two above mentioned ligation mixtures. 
Results indicated a 98% efficiency of elP treatment of the vector DNA. The fmal 
concentration of dephosphorylated linearised vector DNA was estimated on a LKB 
Ultraspec Plus spectrophotometer and found to be 100ng/J.lL of the DNA solution. The 
insert and the vector DNA were ligated and packaged into phage heads using the 
Promega packaging kit and following the manufacturers protocol as described in section 
3.2.8. 
(iii) Ligation of vector to the insert DNA. 
Ligations were set up using a 3: 1 vector to insert DNA ratio (900ng of vector and 300ng 
of insert DNA) to ensure head on ligations of the vector and insert DNA instead of 
fonning ccc-recombinant DNA molecules. The head on ligation would facilitate 
packaging of DNA into the phage heads. The ligations were set up for 4 hrs at RT with 
3 units ofT4DNA ligase, run and analyzed on a 0.4% agarose gel. 
(iv) In vitro packaging of the Library into Phage heads. 
Ligated DNA was packaged in vitro into the phage heads by using Packagene® 
'Lambda DNA Packaging System' packaging extract bought from Promega, and using 
the manufacturer's protocol (Promega Technical Bulletin 005). Briefly, the 1.2~Lg 
ligated DNA was addcd to 50J.lL of the packaging extract and incubated at room 
temperature for 3hr. A negative control for the packaging reaction was carried out by 
packaging of 900J.lg of non-ligated vector DNA in 25J.lL of Packaging extract. A 
positive control to test the efficiency of packaging was carried out by packaging 488J.lg 
ofPackagene® control DNA (c1857 Sam7), provided in the kit. 
To detennine the efficiency of packaging, a pennissive host LE392 was made 
susceptible to phage infection. A serial dilution of the packaged positive control DNA 
(provided in the kit) was made. These were used to infect LE392 made susceptible to 
phage infection, in order to estimate the phage titre. 
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(v) Optimisation of conditions for transduction of DH5a recA- strain to construct 
the cosmid library. 
Dilutions of the packaging niix were used to transduce DH5a recA- cells. In a series of 
preliminary reactions 1:10 and 1:100 dilutions of packaging extract were used to 
transduce 1 OO)lL and 200)lL of susceptible DH5a cells. These reactions showed that the 
most efficient rate of transduction was obtained by transducing 100)lL of susceptible 
DH5a cells with 50)lL of the 1:10 dilution of packaging extract. Cosmid DNA was 
prepared from 10 trans ductants , digested with EcoRI and BamHI and run on a 0.9% 
agarose gel to check the nature and sizes of the insert. All 10 cosmids had different 
restriction pattern, and for each digest the total size of the fragments of insert DNA was 
approximately 20Kb. 
(vi) TransductionofDH5a recA- strain to obtain the cosmid library. 
DH5a recA- cells were made susceptible to phage infection by growing the cells in 
maltose supplemented LB broth for 20hr, followed by harvesting of the cells by 
centrifugation at 7,000rpm for 3min at RT and resuspending the pellet in half the 
volume of 10mM MgS04. 
To construct the genomic library, 100)lL of susceptible DH5a cells were mixed with 
50)lL of the 1: 10 dilution of packaging extract and incubated at RT for 30min.The 
mixtures were thereafter diluted and spread on LB plates supplemented with 
tetracycline to select for DH5a clones containing pLAFR3 derived cosmids. 
3.2.8d. Amplification and storage of the library. 
Six thousand colonies arising from 5 independent transduction experiments carried out 
with the standardized ratios and stored. The transduced cells were collected from the 
plates with 3mL of terrific broth (TB) (Appendix 1), washed with an additional 2mL of 
terrific broth, pooled together, volume of the final terrific broth was made up to 50mL 
and incubated for 3hr at 37°C. After the incubation, the cells were spun down, 
resuspended in 40ml of TB supplemented with 15% glycerol. 500)lL aliquots were 
stored in the -80°C freezer. 
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3.2.9. Colony Hybridisation. 
3.2.9a. Colony transfer. 
Three thousand and two hundred individual library clones were replica toothpicked on 
to 90mm LB plates supplemented with tetracycline. One of the plates from each replica 
was overlayed with a Hybond™ N+ membrane, so as to cover all the colonies 
toothpicked onto the plate and incubated at 37°C for 18hr, while the master plate was 
stored at 4°C. Following adequate incubation period of the replica plate lined with the 
membrane. The membrane was marked by making a hole through the membrane into 
the agar surface. This facilitated aligning of the autoradiogram with the plates later on. 
A pair of sterile forceps was used to remove the membrane, which was processed for 
the binding of DNA liberated from each lysed colony on the nitrocellulose membrane, 
as described in the following section. 
3.2.9b. Binding of DNA to the membrane. 
The membrane containing the colonies were places in a tray containing 3mm filter 
paper flooded with 10% SDS (Appendix II), with the side of the membrane containing 
the colonies facing up, and incubated for 3min to facilitate colony lysis. The membrane 
was removed from the solution and placed on paper towels to drain the excess SDS 
solution. Thereafter, the membrane was transferred to a filter paper flooded with 
denaturing solution (Appendix II) and incubated for Smin. The membrane was again air 
dried by placing on a paper towel. This was followed by treatment of the filter paper 
with a neutral ising solution (Appendix II) for Smin. The neutralising reaction was 
repeated, after which the membranes were allowed to dry in air for 10min. After 
complete drying, the membranes were pre-washed in 3 x SSC, 0.1 % SDS at 6SoC for 2-
3hr, followed by rinsing in 2 x SSC, to remove excess debris. 
3.2.9c. Probe labelling. 
The probes were labelled according to the protocol described in section 3.2.6a. To 
retrieve the cosmids containing intact copies of gsp genes of BG 164R, a probe was 
constructed by eluting the 1.S kb EcoRI/San fragment of genomic DNA from T3 end of 
the mutant clone, pSPRC12 (Fig.3.2). 
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3.2.9d. Hybridisation and Stringency washes. 
The membranes were placed in Hybaid hybridisation tubes and prehybridised in 
prehybridisation buffer (Appendix II), for 3hr at 6Soe prior to addition of labelled probe 
(approx. 200K cpmlmembrane), and further incubated for 16hr at 6Soe in a Hybaid mini 
oven. After 16hr hybridisation, the unbound DNA was removed by stringency washes. 
This consisted of 4 washes at RT for Smin each in 2XSSe and 0.1 % SDS, solution 
followed by a 4Smin wash in 0.1 % sse and 0.1 % SDS at 6Soe. The membranes were 
removed from the hybridisation tubes, wrapped in Gladwrap individually, and exposed 
to Amersham Hyperfilm-MP in an autoradiography cassette for 2hr at -80°C. The film 
was immersed in Agfa G-1S0 developer for Smin, rinsed in flowing tap water and fixed 
in Agfa G-334 fixer for further Smin. The autoradiograph was then rinsed in water and 
air-dried. 
3.2. ge. Isolating the DHSa colony clone containing the positively hybridised cosmid. 
The autoradiogram was lined up with the colonies on the master plate and the positively 
hybridised colony was identified on the master plate. The colony was isolated, and 
purified and DNA extracted was analysed. 
3.2.10. Complementation analysis. 
3.2. 
Triparental matings were used to transform the Burkholderia mutant strains with the 
complementing cosmid. The putative gsp cosmid was introduced into all mutants by 
triparental mating of the parents with a 'helper' strain, containing the plasmid 
pRK2013, which provided the conjugative and mobilising function in trans, to mobilise 
the pLAFR3-based mobilizable cosmid. Eighteen hour old cultures of the donor coli 
DHSa strains carrying the cosmid, helper E. coli HBl01 and recipients were washed 
twice with LB to remove the respective antibiotics, and 200J.,LL aliquots of all the 3 were 
mixed in equal ratios (1: 1: 1). The resulting mixture was concentrated by centrifugation 
and resuspended in 100J.,LL of fresh LR The suspension was spotted onto a sterile 0.22 
micron Millipore filter paper on a pre-warmed LB agar plate, and incubated for l6hr at 
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30°C.The bacteria were thereafter washed from the filter paper with 1mL of LB, 
harvested by centrifugation and resuspended in 400~L of LB. 200~L aliquots were 
spread on LB plates supplemented with antibiotics that would positively select the 
recipients with the cosmid, and incubated for 36-48hr at 30°C. Resultant 
transconjugants were selected from the plates, purified and checked for 
complementation. 
3.2.1 Ob.Complementation Assays. 
Transconjugants were assayed for and compared to the mutants and the wild type to 
check for the: 
(i) Capacity of forming cavities on mushrooms 
The different test bacterial strains growing on LB plates supplemented with appropriate 
antibiotics were tooth picked on mushroom slices. The assay was set up duplicating all 
conditions stated in section 2.2.5. 
(ii) Secretion of protease on the milk agar plates. 
Milk agar plates were used to test the protease activity of the bacteria and using the 
assay described in section 2.2.7f. 
(iii) Secretion of chitinase on chitin plates. 
Chitin plates were used to test the ability of the complemented mutants to secrete 
chitinase using the assay mentioned in section 2.2.7e. 
(iv) Morphological changes. 
Morphological changes in the mutants in the presence of cosmid were noted by 
observing the transconjugants under a TEM. The bacterial samples were stained 
according to the method stated in section 2.2.7a. Stained bacteria were observed under 
bright field in a Hitachi H-600 electron microscope in the Mechanical Engineering 
Department of the University of Canterbury. 
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3.2.11. Analysis of secreted proteins. 
3.2.11 a. Preparation of protein samples 
Bacterial cells were grown in mushroom extract medium (Appendix I) for 24hr, at the 
end of which bacterial cells were sedimented by centrifugation at 10,000rpm for 10min 
at 4°C. The supernatant was collected in a fresh sterile centrifugation tube, re-
centrifuged and the supernatant was frozen immediately in liquid nitrogen. The frozen 
supernatant was dried in Edwards High Vacuum Centrifugal Freeze Dryer 
(modeI30P.2. /822) available in the School of Biological Sciences. The samples were 
dried for 12hr with vacuum pressure set at 56 TORR, condenser temperature set at -
50°C and the chamber temperature set at 30°C. The freeze dried samples were 
resuspended in 1I10th volume of 1 x MS solution (Appendix I) and purified by acetone 
precipitation, whereby, double the volume of ice-cold acetone was added to the sample, 
mixed thoroughly, incubated in -80°C for 30min, and the protein samples collected by 
centrifugation at 12,000rpm for 10min at 4°C. The supernatant was discarded and the 
pellet was resuspended in a half volume of 1 x MS solution, which made the final 
concentration factor 1 :20. 
3.2.11b. Estimation of the protein samples 
Concentrations of protein in the solutions were measured using the Bio Rad Protein 
Assay Kit. This assay is based on Bradford's method to measure soluble proteins. 
Briefly, the assay consists of a colourimetric change in the dye, Coomassie® Brilliant 
Blue G-250, with varying concentrations of protein present in the solution. This dye has 
a shift in the absorbance maxima from 465nm to 595nm when protein residues bind to 
it, primarily aromatic and basic amino acids, such as arginine. Diluted protein samples 
(800).lL) were incubated with the dye reagent (200).lL) for 6min at room temperature 
and the absorbance of the coloured product was measured at 595nm in a Bio-Rad 
spectrophotometer. The concentration of the protein in the sample was measured by 
plotting the OD values against a standard curve drawn by plotting the OD595 values of a 
standard BSA sample of known concentrations. 
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3.2.11c. Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
(Sambrook et al. 1989) 
Estimated quantities of secreted proteins were made up to 25)..tL volumes with sterile 
distilled water, to it, 25j..tL of2 x Treatment Buffer (AppendixII) was added and the sample 
incubated for 90sec in boiling water to denature the proteins and reduce disulphide bonds in 
the protein solution. The samples were thereafter loaded on to a 4-20% mini gradient gel 
(commercially supplied by Gradipore) and electrophoresed for 1hr 30min at a constant 
voltage of 150 Volts in a Bio-rad mini PROTEINTM II gel apparatus. 
3.2.11d. Staining of the gels (Sambrook et al. 1989) 
Protein profiles were visualised after being stained by silver nitrate solution. The solutions 
(Appendix II) were freshly prepared immediately before use. The gels were washed in wash 
solution I for 30min on a shaking platform, rinsed for 15min in distilled water, incubated in 
solution II for 30min, rinsed in distilled water briefly for lOmin and then left washing in 
distilled water overnight at room temperature. The following day, the gels were stained for 
10min in freshly prepared silver nitrate solution, washed three times for 5min each in 
distilled water and then the bands were developed by soaking in a developing solution. As 
soon as the bands appeared, the reaction was stopped by transferring the gel into a fixer. 
The gels were left overnight in the fixing solution to remove the background stains. 
3.3. Results. 
3.3 .1. Cloning of transposon tagged genes in Cavity disease mutants. 
Regions of BG 164R chromosome flanking the transposon insertion sites were cloned in 
order to isolate the gene(s), interruptions that have rendered the mutant BG164R derivatives 
avirulent to Cavity disease formation. Sail-generated fragments of the chromosome were 
cloned using the vector pBluescript KS+ (Short et al., 1988), which simplified sequencing 
because the multiple cloning site of the vector is flanked by opposing T7 and T3 promoters. 
The transposon (Fig 3.1.) has no internal Sail recognition sites, so all fragments should have 
DNA flanking the insertion. The kanamycin resistance cassette present in the transposon, 
mini-Tn5KmlacZ2, was used to select the clones, which carried genomic DNA from 
BG 164R derivatives ranging in size from 8 to l1Kb (Table 3.2). 
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Figure 3.1: Schematic diagram of mini-Tn5/acZ2 (deLorenzo et al., 1990) [figure not to scale] 
Size of the D HSa. containing 
Mutant: Plasmid recombinant the clone 
construct: plasmids (kb) 
BG4-12 pSPRC12 1l.4 CMC4-12 
BG 12-88 pSPRC88 8.1 CMC12-88 
BG12-147 pSPRC147 8.2 CMC12-147 
BGl5-40 pSPRC40 8.3 CMC15-40 
BG15-87 pSPRC87 8.9 CMC15-87 
BG16-787 pSPRC787 8.3 CMC16-787 
Table 3.2: Size of the recombinant plasmids isolated from shotgun cloning of no-cavity forming 
mutants of BG164R. The DH5a containing clones were named as 'CMC' designating cavity 
mutant clone, with the numbers in the suffix arising from the numbers of the respective mutants 
3.3.2. Physical maps of the clones. 
Restriction maps of the clones were generated using the enzymes EcoRI, BamHI, HindIII 
and SalI. Restriction maps of the different plasmid clones were drawn using Mac Vector 
software and are presented in Fig 3.2. Plasmid clones, pSPRC147 and pSPRC88 and 
pSPRC40 and pSPRC787 have identical maps and insertion points and are therefore most 
likely to be duplicates (Table 3.3.) 
Plasmid 
Construct. 
Size of the 
construct (Kb). 
11.4 
8.3 
8.2 
8.9 
8.3 
8.1 
Size of enomie DNA cloned at 
T3 promoter end T7 promoter end 
1.5Kb 2.5Kb 
100b 700b 
500b 350b 
700b 800b 
100b 800b 
500b 350b 
Table 3.3: Length of genomic DNA cloned on either side of the transposon insertion points in 
the recombinant plasmid clones. 
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SaIl 11.410.0 
BamHII0.8 
EcoRllBamHI9.9, 
pSPRC 12 
IIAOO kb 
HindIlI 5.9 
HindllI 4.7 
Sail 8.9 0 .0 
pSPRC 87 
8.900 kb 
Sal I 8.25 10.0 
pSPRC 147 
8.250 kb 
BamH13.9 
3.6 
all 2.9 
3.4 
EcoRl/BamHI 7.4 
SaU 8.310.0 
T7 
pSPRC 40 
8.300 kb 
SalI 8.1 1 0.0 
EcoRUBamHI7.8 
HindIII 4.7 
EcoRl/BamHI7.6 
pSPRC 88 
8.100 kb 
Sal I 8.3 1 0.0 
pSRC 787 
8.300 kb 
99 
T3 
'all 2.9 
Figure 3.2.: Restriction maps of the plasmid clones arising from the no-cavity forming mutants 
of BG164R. 
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3.3.3. Number of trans po son insertio ns in each mutant. 
Southern hybridisalion confirmed that ach mutant had a si ngl e genomic insertion (Fig 
3.3). 'rhe size of the SaII genomic fragment containing the transposon was similar or 
identical among all th e mutants, s ugges ting that e(jch mutant was ti'om an insertion in 
the samc SulI fragment. 
B (' D f. F<; II I .1" L I 0 I' () 
Figure 3.3: Southern blot analyses to ensure presence of a single transposon in,sertion in each 
of the cavity minus mutant of BG164R The DNA gel in the left and the corresponding 
autorad iograph on the right. [A) pUT::mini-Tn5 (+ve control), [B! BG164R genomic DNA(-ve 
control) , [C) iJHindl1i marker, [D] BG4-12, [El pSPRC"12, [F] BG12-88, [G] pSPRC88, [H] BG12-
147, [I] BG14-722 , [J] pSPRC722, [K] BG15-40, [L] BG115-87, [M] pSPRC87, [N] BG16-787, [0] 
pSPRC787, [P] pSPRC40, [0] pSPRC147. 
T he insertiuns were not in identical phlces within this Sull genomic fragment. so each 
clone \vas sequenc ed to identify the poss ible opcn reading ii'ames that may have been 
interrupted , 
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3.3.4. Sequence analysis of the mutant clones. 
The sequence of the clones from the SalI genomic fragment are identical or highly 
similar at both the nucleotide and protein levels with the different 'gsp' genes of the 
'General f2ecretory 12athway' of two other species belonging to the genus Burkholderia, 
namely, B.cepacia strain KFI with accession number AB050004.1 and B. pseudomallei 
strain 1026b with accession number AFl10185 (Table 3.4). Detailed information about 
the statistical significance of the reported matches is presented in Table 3.5. 
From T3 end of the vector From T7 end ofthe vector. 
Length of Length of Similar Length of Length of Similar 
Mutant Plasmid cloned sequence to gene cloned sequence to gene 
number clone. DNA read out DNA read out 
fragment fragment 
BG4-12 pSPRC 1.5Kb 549bp gspE 2.5Kb 709bp 
12 
BG12-88 pSPRC 500bp 266bp gspK 3S0bp 99bp gspK I 
88 +Tn5 
BG12- pSPRC 500bp 402bp gspK 3S0bp S9bp gspK 
147 147 +TnS +TnS 
BG15-40 pSPRC 100bp 64bp gspE 700bp 429bp gspD 
40 +TnS 
BG15-87 pSPRC 700bp 2SSbp gspD 800bp 375bp gspD 
87 
BG16- pSPRC lOObp 64bp gspE 800bp 7S3bp gspD, gspE 
787 787 +TnS +TnS 
Table 3.4: Results of similarity searching with sequences from the six 'no-cavity' causing 
mutant clones. 
The cloned genomic DNA in pSPRC40 and pSPRC787 was identical (Tables 3.4 and 
3.5), but the DNA of clones pSPRC88 and pSPRC147 was not. In the case of the latter 
two strains, the mutations are in the same locus of the chromosome, gspK gene, 
although the exact position of transposon insertion site is separated by 40 nucleotides, 
as evidenced from the T7 end sequence reads presented in Table 3.5. 
Chapter III 102 
The transposon inserted within 40 nucleotides of each other and into the same gene, in 
the mutants from which the clones pSPRC88 and 147 were derived, but into the same 
gene in the mutants from which the clones pSPRC40 and 787 were derived. 
B. pselldomallei (1026b) B. cepacia (KF1) 
Plasmid Primer AFll0185 AB050004.1 
Clone reads Matches % Identity E-value % E-value 
Identity 
pSPRC12 T3 gspE 85 e-115 87 e-136 
T7 gspG, 89,93 4e-76,3e- 89,82 4e-76,le-
gspH 13 21 
pSPRC40 T3 gspE 89 3e-06 95 le-13 
T7 gspD 83 3e-50 92 7e-26 
pSPRC88 T3 gspK 98 2e-18 81 3e-ll 
T7 gspK NIM N/A 87 le-lO 
pSPRC87 T3 gspD 83 ge-36 88 3e-63 
T7 gspD 84 le-46 90 3e-65 
pSPRC787 T3 gspE 89 4e-06 95 2e-13 
T7 gspD, gspE 85,80 3e- 91,96 6e-
66,0.004 32,0.069 
pSPRC147 T3 gspK 98 3e-18 88 ge-07 
T7 gspK NIM N/A 86 le-08 
Table 3.5. Statistical significance of the matches with the two published sequences available in 
the database. N/M= no significant match found, N/A=Not available. 
Further evidence that the insertions were sufficient to explain the mutant phenotype was 
provided by complementing mutations with DNA from a genomic library, described in 
section 3.3.7. 
3.3.5. Construction ofBG164R genomic library. 
To ensure 99% probability of having a DNA sequence in the library, the minimum 
number of clones required to represent a genomic library consisting of 20kb genomic 
DNA fragments, was calculated on the basis of total genome size of B. cepacia and 
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B. pseudomallei genomes published by the Sanger institute. Although the calculations 
suggested the necessicity of 1610 clones, it was decided to store 6000 clones to 
represent the complete genomic library, constructed according to the methods detailed 
in section 3.2.8. 
3.3.6. Library probing and retrieving the wild type gsp gene containing 
cosmid(s). 
Probing 3,200 library clones (double the number of clones required to find at least 1 
copy of a single gene, as calculated), by colony hybridisation, initially led to the 
isolation of about 10 cosmid containing colonies. However, in repeat experiments, only 
one of the presumptive cosmids continually hybridised, thereby confirming its possible 
authenticity. The cosmid was named pCosGSP and stored for further analyses. The 
single cosmid isolated, pCosGSP, was found to have genomic insert of 23.4kb. The size 
of the GSP operon in the different species of Burkholderia varies from 9Kb to l4Kb 
(DeShazer et al., 1999; Kimoto & Nakazawa, 2000), making it plausible that the 
pCosGSP held all the GSP genes. 
3.3.7. Complementation of mutants with the cosmid. 
To investigate the length of the gsp operon present in the cosmid and also to confirm the 
authenticity of the cosmid, pCosGSP was introduced by tri parental mating initially into 
two independent GSP mutants, namely BG4-12 and BG12-88 that had the transposons 
inserted in two different gsp genes- gspF, and gspK, respectively. The two specific 
mutants were initially chosen because, these two genes in the gsp clusters of closely 
related members of Burkholderia were present at two opposite ends of the operon. 
Thus, complementation of these two mutations by the same cosmid would possibly 
mean the presence of the whole gsp gene cluster of BG l64R in the single isolated 
cosmid. 
Four independent conjugations were set up for each of the two mutants. Twelve putative 
transconjugants for each mutant type were purified and tested in the mushroom bioassay 
(Fig. 3.4). Cosmid DNA from two representative transconjugants was subsequently re-
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confinned to have the same restriction map as the original cosmid prior to setting up of 
the mushroom bioassays to test for complementation. 
Figure 3.4: Mushroom slice assay to check for complementation. [A] inoculated with BG164R, 
[B] blank control, [C] BG4-12, [D-F] BG4-12Cos, [G] BG12-88, [H-J] BG12-88Cos. 
Phenotypes of ability to degrade milk proteins (Figure 3.5), colloidal chitin (Figure 3.6) 
and the flagella number (Figure 3.7) in all the transconjugants were restored back to that 
observed in case of the wild type strains. However, the diameter of the zones of clearing 
for transconjugants on the milk agar plates was smaller compared to that of the wild 
type. This could be due to one of the two possibilities stated below: 
Fjgure 3.5A: Protease assay on milk agar plate to test for complementation. [Aj BG164R, [Bj 
BG4-12, [C] BG15-40, [Dj BG12-88, [E] BG4-12Cos, [F] BG15-40Cos, [Gj BG12-88Cos. 
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Figure 3.58: Protease assay on milk agar plate supplemented with tetracycline to test for 
complementation. [A] contro ll BG164R (pLAFR3). [B] BG4-12Cos. I[C] BG15-40Cos. [0] BG12-
88Cos. [E] control BG4-12(pLAFR3). 
(1) Partial complementation of secreted protease geJi1e(s), which is/are present either 
upstream or downstream of the GSP genes of Burkho/deria in the cosmid, and share a 
set of regulatory genes with the GSP operon. 
(2) The presence of more than one protease gene involved in casein degradation on thc 
milk agar plates, of which only one is being complemented by the cosmid. 
Fig 3.6: Chitinase assay to test for complementation. [A] Serratia entomophila A1M02 control, 
[B] BG164R, [C] P.cepacia B111, negative control [D] BG4-12, [E] 8G15-40, [IF] BG12-88, [G] 
BG4-12Cos, [H) BG15-40Cos, [I] BG12-88Cos. 
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Fig 3.7: Transmission electron microscopic observations to test for complementation. 
Observations of wild type, mutants and the complemented mutants. [Aj BG164R, [Bj BG4-12, 
[C] BG15-40, [OJ BG12-88, [E] BG4-12Cos, [Fj BG15-40Cos, [Gj BG12-88Cos. 
The reduced capacity to degrade colloidal chitin in mutants was restored back to the 
normal in the presence of the cosmid. Restoration of flagellar number was observed for 
all the transconjugants harbouring the GSP cosmid and can be morphologically 
compared to the wild type. About 75% of the bacteria in the observation frame 
exhibited the above-mentioned phenotype. The difference the in phenotype noticed in 
the remaining 25% could be attributed to the method of preparation of the TEM grid. 
3.3.8. Secretion profiles of the wild type and agsp mutant. 
Differences in the profiles of secreted proteins were expected to be visible in the culture 
supernatants, since the mutants isolated were all secretory mutants. To test this 
hypothesis, supernatant proteins were extracted from wild type and a representative 
GSP mutant (BG 15-40) and compared on SDS PAGE (Figure 3.8). All the protein 
samples were di luted to uniform concentration of 3!lg protein /I O!lL of sample extract 
Cf/(/p/I!/' fff 107 
diluted il) I x . ilS and the siz fra ctionated proteins were stained with silver nitrate 
solution, 
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Figure.3.8: Lane [A] Protein gel marker. Sizes in kO marked along the side. [B] blank row. [C] 
blank LB media extract. [0] extract of BG 164R supernatant growing in LB media. [iE] extract of 
BG15-40 growing in LB media. [F) blank Ilane . [G] blank MEM extract. [H) extract of BG164R 
supernatant growing in MEM. [I] extract of BG15-40 supernatant growing in MEM. [J] blank 
lane. [*] diagrammatic representation of the distinct bands that appear in lane H. 
Five distinct bands observed in lane (/-I) loaded with extracts from BCi 164R grown in 
mushroom extrnct media. All five bands were absent in the corresponding lane (I) 
loaded with extracts from the mutant bacteria grown in the same media. Interestingly, 
there arc some common bands observed in the extracts of wild type grown in LB media 
(lane D). All six extracts were spotted on milk aga r plates. Protease activity was evident 
in BG 164R culture supernatants extracted from both the media (Figure 3.9). This eould 
possibly indicate that proteases in the supernatants reprcsent the common bands 
observed in ease of both the media extracts. Notably the three common bands appearing 
in the lanes D and H do not have any counterpart in the lanes in which their respective 
mutant extracts from both the media are loaded (lanes E and I). Also, the upper four 
prominent bands appearing in the 13(; 164R ME media lane doc . appear to be presen t 
very bintly in the BG 164R LH extract lane, indicating minimal lewIs of express ion of 
the proteins represented by the three upper bands in the absence of mushroom specific 
compounds in the culture media. These differences in the banding patterns have been 
consistently observed in all the ] repeat gels run to ensure the ~Iuthenticity oj' the results. 
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Figure 3.9: [Left) Protein extract from LB media spotted on Milk Agar plate. [Right) Protein 
extract from MEM spotted on Milk Agar plate . [A) Quadrant containing extract from wild type 
BG164R supernatants. [B) Quadrant containing extract from media (control). [C) Quadrant 
containing extract from mutant BG15-40 supernatants . 
3.3.9. Screening of mutants on Milk agar plates. 
108 
In an attempt to find one or more structural gene(s) for protease which could serve as 
one of the possible pathogenic factors associated in the expression of Cavity disease, a 
second mutagenesis screen was carried out and the transconjugants were screened 
initially on milk agar plates . Protease deficient strains were tested on mushroom slices 
to check for the ability to form cavity. 
Of the 3,000 transconjugants screened on milk agar plates two mini-Tn5KmlacZ2 
mutants of BG 164R were selected as protease minus on 1 % milk agar plates . The two 
isolated mutants were tested on mushroom slices for the capacity of expressing Cavity 
disease. Interestingly, both the mutants lost the capacity of cavity formation on 
mushrooms. Since the main objective of this experiment was to identify protease 
gene(s), products of which could be linked to formation of cavity disease, shotgun 
cloning of the genomic region adjacent to the transposon insertion point into the 
sequencing vector pBluescript KS ' was carried out. The two clones isolated from the 
respective mutants, namely pBGProt-123 and pBGProt-125, had insertions on 6.6kb and 
8.3kb respectively . Sequence analyses of the regions adjacent to the site of insertion of 
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transposon revealed the presence of mutations in two different proteins of general 
secretory pathway, not isolated in the previous screen. The clone pBGProt-123 had a 
mutation in the gspL gene while the clone pBGProt-125 had a mutated gspF gene. 
3.4. Discussion. 
Identification of the genes of B. gladioli pv. agaricicola, BG164R involved in the 
expression of Cavity disease on button mushrooms was the primary objective of the 
chapter. Cloning followed by sequence analysis of the genomic DNA adjacent to the 
transposon tagged genes in the mutant clones suggested clustering of mutations in the 
gsp operon of BG164R. Complementation of three gsp mutants with the cosmid 
pCosGSP, restored the wild type phenotypes in the mutants, thereby establishing 
involvement of GSP in the expression of Cavity disease by BG 164R on mushrooms. 
Cloning of the mutants with no-cavity phenotype in case of BG 164R was restricted to 
SalI as this was the only enzyme, which did not have any site on the transposon. 
Sequence analysis of the mutated genes led to the identification of gspE, gspK, gspD, 
gspF and gspL genes in the gsp operon of BG164R. However, because SalI had too 
many sites along the operon, the size of the fragments of genomic DNA present on 
either side of the transposon was not sufficient to analyse the complete ORFs of the 
genes mutated. 
Screening of protease mutants on milk agar plates was attempted in an effort to identify 
the protease gene(s), production of which appeared to be important for the formation of 
Cavity disease. Sequence analysis of the two mutants isolated in the process also led to 
identification of genes of the GSP. Similar experiments conducted by DeShazer et ai. 
(1999) and Nakazawa et aZ. ( 1996) have been reported in which all the mutants isolated 
from milk agar plates were clustered in the GSP operon. An argument that crops up in 
this case is whether the number of transconjugants screened to isolate protease mutants 
was sufficient enough to isolate unique mutants. DeShazer et al. screened 15,000 
transconjugants and isolated 29 mutants all of which were clustered in the GSP operon. 
Nakazawa et al. screened 5000 transconjugants and isolated 14 mutants, of which, only 
one mutant had a mutation in the dsbB gene that is required for the proper folding of the 
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proteins that are secreted by the GSP. Thus, the inability to identify structural genes of 
the protein-degrading enzyme was not surprising. 
None of the mutants isolated had mutations in any other genes, products of which were 
directly responsible for the expression of disease symptoms in mushrooms. It is 
tempting to suggest that Cavity disease is a combined manifestation of more than one 
factors secreted through the Type II protein secretory system present in BG 164R. The 
secreted proteins are capable of causing disease symptoms only when present together 
on the substrate. Hence, to see a distinct no-cavity phenotype all the factors have to be 
absent, which is possible only when a common pathway involved in the secretion of 
them are blocked. When the products are produced individually the effects are either not 
detectable in the assay system used to screen for mutants, or they do not show any 
noticeable difference of the symptoms. Gill and Tsuneda (1997) in their study on the 
symptom development in the different types of mushrooms have also proposed a similar 
hypothesis. They suggested that chitinase and p-glucanases of B. gladioli pv. 
agaricicola, BG 164R, act together to cause Cavity disease, since activity of these two 
enzymes were detectable in in vitro plate assays. Differences in the secreted protein 
profiles were clearly visible when the wild type and mutants were grown in mushroom 
extract media and not in LB. However, the culture supernatants of mushroom extract 
did not show any activity on chitinase plates or on the mushroom tissues although it 
retained the capacity to degrade milk protein. The mutants, when complemented with 
the cosmid, regain the capacity to degrade casein on milk agar plates, degrades colloidal 
chitinase to a similar extent as that of the wild type and degrade mushroom tissue. This 
re-enforces the hypothesis that more than one factor is necessary for the successful 
expression of Cavity disease. 
Gill and Tsuneda (1997) proposed that the pathogen secretes/produces mushroom 
mycelia degrading components on induction, but, they did not have any concrete 
evidence for such a phenomenon being involved in the expression of Cavity disease in 
vivo. To assess the possibility of isolation of the active cavity causing compound(s) 
being produced only on induction, a bioassay was initially set up to check for the 
spontaneous production of any active compound(s) into the growth media. BG 164R was 
grown on M63 agar media, LB agar, PDA plates and MEM agar media for three days; 
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plugs of agar were taken from the plate and placed on mushroom slices. The assay was 
incubated at 25°C overnight. Plugs of agar containing fresh media from a plate on which 
BO 164R was not grown was taken as the control for each set of test media. A slight 
indent on the surface of the mushroom tissues could be observed with plugs of agar 
taken from the PDA plates and MEM agar media on which BG 164R cells were grown, 
although this was not as devastating as the control slices of mushrooms inoculated with 
live BG 164R cells. An interpretation for the observation of such a phenomenon could 
be a limitation in the amount of active compounds being present in the plug of agar, 
which was sufficient to cause the indent, but not enough to form the cavity. However, 
an interesting fact in this case was that no such indent was observed when agar plugs 
were taken from minimal agar or LB plates. The assay was repeated three times with the 
same results being noted in each case. The result either indicates the association of 
specificity of media with the production of active compounds, or indicates that the 
activity could be detected when bacteria were grown in a media with acidic pH. The 
former two media had a neutral pH around 7 while the latter two had a pH of 5.1, 
besides containing plant extracts. 
Gill and Tsuneda (1997) have also reported the observation of such indents on 
mushroom tissues inoculated with a cell free culture supernatant extracted from 
B0164R cells growing in nutrient broth. Notably, nutrient broth is not a plant extract 
with a pH of 7.4. Gill reports shrivelling of tissue at the site of inoculation in spite of 
not having any signs of degradation of hyphal cell walls, from electron microscopic 
observations with pieces of tissue taken from the zones of depression. Mushroom slices 
inoculated with mutants also show such shrivelling of mycelia. If Cavity disease could 
be associated with the production of more than one compound, formation of such 
indents could be attributed to the production of some, but not all of, the compounds 
needed for the manifestation of the disease. 
Mueller-Cajar (2001), working in a parallel project aimed to isolate the antifungal 
compound(s) produced by BG164R, reported antifungal activity from plugs of agar 
taken from PDA plates. He successfully extracted the active antifungal compound from 
PDA agar with acetone (Muller-Cajar, 2001). The acetone extract, which showed active 
antifungal property, was tested for its ability of cavity formation on mushroom slices. 
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No such activity was observed on mushroom slices. Indent fonnation on mushroom 
slices was also not observed in this case, and was rationalised as the compound being 
inactivated or denatured in the process of acetone extraction. Thus, although the active 
principle involved in the disease fonnation could not be extracted, the co-relation 
between general secretory pathway and Cavity disease fonnation has been established 
by the data presented in this chapter. 
The general secretory pathway or Type II protein secretion in bacteria fonns a tenninal 
branch of secretion of toxins and proteins across the outer membrane in Gram-negative 
bacteria (Pugsley et al., 1997b). The type II secretion system is generally associated 
with the secretion of more than one structurally diverse gene products and the only 
example where type II secretion machinery is associated with the production of one 
single exo-product is in Klebsiella oxytoca which secretes pullulanase (Pugsley et al., 
1997a). Incidentally, this iSfJlso the" sole example where the structural genes for 
pullulanase production are clustered with the genes involved in the secretion. In other 
systems, where more than one protein is secreted by the gsp system in bacteria 
(Wandersman, 1996), there still appears to be single secretion machinery responsible for 
the secretion of all the polypeptides. The mechanisms by which all these different 
proteins are identified by the same secretion apparatus is as yet unknown. 
The proteins fonning the secretion apparatus of general secretory pathway in members 
of the genus Burkholderia have been reported to be clustered in a single operon, and are 
responsible for the secretion of protease, lipase and phospholipase C (DeShazer et al., 
1999; Kimoto & Nakazawa, 2000). In the three gsp gene clusters studied in the different 
members of Burkholderia, the structural genes responsible for the production of the 
exo-enzymes have not been found to be associated with the genes forming the secretion 
apparatus and the bacteria has been studied as a human pathogen causing nosocomial 
infections in immuno-compromised patients. Burkholderia gladioli pv agaric ico la, 
BG 164R, is the first reported pathogen of mushrooms, and is involved in the fonnation 
of a massive tissue degradative disease in mushrooms. This is hence the first report on 
the association of the involvement of general secretory pathway of a pathogen to the 
expression of symptoms in case of a mushroom disease. 
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3.5. Concluding Remarks. 
Mutagenesis screenings of BG164R in association to Cavity disease lead to the 
identification of genes coding for GspE, GspK, GspD, GspF and the GspL counterparts 
of the type II secretion apparatus of B. gladioli pv.agaricicola. Further genetic analysis 
of pCosGSP to genetically define the borders of the gsp gene cluster present in cosmid 
pCosGSP forms the main theme of the study presented as chapter four. 
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Chapter IV 
Analysis ofpCosGSP .. 
4.1. Introduction. 
The construct pCosGSP is a cosmid that contains the putative gsp (General .s.ecretory 
.,r.athway) gene cluster of B. gladioli pv.agaricicola strain BG 164R, the causal organism 
of Cavity disease in mushrooms. The no-cavity mutants isolated in this study harbour 
mutations in different genes of the gsp operon of B. gladioli pv. agaricicola. The genes 
were identified by sequence analysis of clones containing genomic DNA adjacent to the 
transposon-tagged mutated genes. Subsequently, a genomic library of BG164R was 
constructed in the cosmid pLAFR3. Screening of this library led to the isolation of 
pCosGSP, which, as described in section 3.3.7, complements mutations in three 
separate genes along the gsp operon. This was observed by restoration of wild type 
phenotypes including cavity formation (on mushroom slices), flagella number and 
protease secretion in in vitro assays. 
The GSP operon of three different members belonging to the genus Burkholderia has 
been studied in association to pathogenesis (Mitsuko & Nakazawa, 1996; Nakazawa & 
Mitsuko, 1996; DeShazer et af., 1999). The complete GSP operon has been identified 
and mapped in B. pseudomallei (DeShazer et al., 1999), and, as mentioned in section 
3.3.4, has significant sequence similarities with the different proteins constituting the 
gsp operon of BG l64R. All the strains studied and reported previously were clinical 
isolates and an underlying feature connecting all these studies was the secretion of 
extracellular protease, some of which have been directly linked to the pathogenesis of 
the respective strain. 
DeShazer et af. (1999) in their study on the causative agent of melidiosis, B. 
pseudomallei 1026b, screened transposon mutants with an aim to identify the genes 
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involved in the secretion of protease, lipase and phospholipase C. The ultimate 
objective of the study was to correlate the effects of these exo products to pathogenesis. 
The 29 mutants selected initially did not secrete protease. In each case, they also 
appeared to be lipase and phospholipase C deficient. This phenotypic linkage indicated 
that the mutation was in a common secretory pathway. Sequencing of the mutated genes 
revealed that the mutations were in different genes of the general secretory pathway. 
The two boundaries of the gsp operon were identified by constructing mutants 
specifically in the orfC and the orjD genes present in the left and right ends of the gene 
cluster respectively, which did not have any effect on the secretion. A centrally located 
gene, gspC, transcribed in the opposite direction to the other genes in the operon, was 
also identified. The sequence of 20kb genomic DNA of Burkholderia pseudomallei 
1026b encompassing the gsp genes was published in the database. When the relative 
virulence of the wild type and a gspD mutant strain was compared in the Syrian hamster 
model, they did not fmd any major difference in the capacity of infection, thereby 
suggesting that the secreted protease, lipase and phospholipaseC played a minor role in 
the pathogenesis of the strain (DeShazer et at., 1999). 
Mitsuko and Nakazawa (Mitsuko & Nakazawa, 1996; Nakazawa & Mitsuko, 1996) in 
their analyses on the different clinical strains of B. cepacia screened transposon mutants 
of strain KFl to isolate protease mutants. Thirteen out of the 14 selected protease 
mutants did not secrete lipase. A protease reduced and lipase deficient phenotype 
(KF1008) mapped to a mutation in the gspF gene, while the mutation in the protease 
deficient and lipase-producing mutant (KFI007) was identified to be in the dsbB gene. 
Interestingly, the dsbB mutant was nonmotile, and afiagellate, and these phenotypes 
could be restored by complementation of the mutant with a plasmid containing the dsbB 
gene. The dsbB gene in E. coli is responsible for the formation of disulfide bonds in 
periplasmic proteins. On the basis of the results and correlation of the steps involved in 
the secretion of proteins by GSP in other studied models, dsbB-mediated efficient 
protein folding by B. cepacia KFI was proposed to be involved in protein secretion by 
GSP. However, the folding of prelipase is dependent on a molecular chaperone Lim, 
encoded by the gene limA. Hence, the dsbB mutant did not show any difference in the 
secretion of lipase. In a second publication by the same authors, anti KFI protease 
antibody was used to identify the size of the proteases secreted. This revealed the 
Chapter IV 116 
presence of two KF1 protease bands, of which the smaller band was similar to the 
purified protease of KFI. This led the authors to speculate that the protease precursor 
was 43 kDa which, when processed and secreted, was 37kDa in size. The above 
prediction was supported by the fact that the 43kDa band was also present in the dsbB 
mutant. The observation also emphasises the notion that dsbB is essential in the 
secretion of protease in B. cepacia KF1, which in turn is secreted by the general 
secretory pathway. 
Corbett et al. (2003) have correlated virulence to the production of a zmc 
metalloprotease, which also appeared to be secreted (Corbett et al., 2003). The 
metalloprotease had a presecretory protein and the mature proteins of similar sizes to 
that suggested by Mitsuko and Nakazawa (1996). Corbett et al. (2003) isolated the gene 
coding for the zinc metalloprotease (zmpA) from B.cepacia K56-2 and Pc715j. 
Mutations in the zmpA gene made the strains avirulent in rat infections. The primary 
amino acid sequence of the metalloprotease suggested the presence of a signal sequence 
thereby sec-dependent transport of the protease across the inner membrane of the strain 
and consequently GSP-dependent transport across the outer membrane was proposed. 
Thus, studies mentioned above have successfully correlated the proteins secreted by 
GSP to the pathogenicity in animal models. To the best of my knowledge, there has not 
been any such association described in the case of a mushroom disease. 
The main focus of this chapter is the analysis of the gsp cosmid, pCosGSP, in order to 
physically locate the genes of gsp operon on the cosmid and identify whether the gsp 
operon in this specific cosmid is associated with any other structural genes. In the last 
section of this chapter, results from a second mutagenesis screen are described, 
including cloning and identification of the mutated genes. This mutagenesis screening 
was undertaken as a repeat attempt to identify more gene(s) involved in the expression 
of Cavity disease. 
Chapter IV 117 
Material and Methods. 
4.2.1. Bacterial strains and plasm ids created or used. 
Strains Genotype or description References 
and plasmids 
Burkholderia gladioli pv.agaricicola. 
BG164R wildtype, cav+, Af+, Rif'R, Prot+ This study 
BG4-12 BG 164R gspF: :mini-Tn5KmlacZ2,Rif'R,KmR, 
cav-,Af+, Prot- This study 
BG12-88 BG 164R gspK: :mini-Tn5KmlacZ2,Rif'R,KmR, 
cav-,Af+, Prot- This study 
BG15-40 BG164RgspE::mini-Tn5KmlacZ2,Rif'R,KmR, 
cav-,Af+, Prot- This study 
BGII-I05 BG 164R gspE::mini-Tn5KmlacZ2,Rif'R,KmR, 
cav-,Af+, Prot- This study 
BGII-106 BGl64RgspK::mini-Tn5KmlacZ2,Rif'R,KmR, 
cav-, Af+, Prot- This study 
BGII-107 BGl64Rpks::mini-Tn5Km lacZ2,Rif'R,KmR, 
cav-, Af+, Prot- This study 
BG4-12Cos BG4-12 complemented with cosmid 
pCosGSP, Rif'R,KanR, Tef ,cav+ This study 
BG12-88Cos BG12-88 com!lemented with cosmid 
pCosGSP, Ri , KanR, TetR ,cav+ This study 
BG15-40Cos BG15AO complemented with cosmid 
pCosGSP, Rif'R,KanR, TetR ,cav+ This study 
BG4-12ME BG4-12 complemented with pGSP 
ME H-H16.7, Rif'R, GentR, KanR ,cav- This study 
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Eschericia coli 
DH5a 
HB101 
supE44 l'!.lacU169 (~80lacZL1M15) hsdR17 
thi-1 relA1 recA1 
supE44 hsdS20 (rB-mB-) recA13 ara-14 rspL20 
proA2lacY1 galK2 xyl-5 myl-1 
Pseudomonas fluorescence 
PRC121 Wild type mushroom isolate, Prot-
Plasmids and constructs 
pSPRC105 
pSPRC106 
pSPRC107 
pCosGSP 
pGSPME 
H-H16.7 
pGSPME 
H-H2 
pGSPME 
H-E1.7 
pGSPKS 
B-B2.2 
pGSPKS 
B-B7.2 
pGSPLA 
H-H2 
4Akb Sail fragment containing gspF: :mini -Tn5 
KmlacZ2 from B GIl -105 in pB luescript KS+, 
A R R P ,Kan. 
4.7kb Sail fragment containing gspK: : mini -Tn5 
KmlacZ2 from B GIl -106 in pB1uescript KS+, 
ApR,KanR. 
7kb Sail fragment containing pks: :mini -Tn5KmlacZ2 
from BGIl -107 in pB1uescript KS+, ApR, KanR. 
23 Akb Sau3Al partial fragment containing GSP 
gene cluster from BG164R into pLAFR3. 
16.7kb HindlIl subclone from pCosGSP 
in pME6001, GentR. 
2kb HindlIl sub clone from pCosGSP 
in pME6001, GentR 
1.7kb HindlIl -EcoRI subclone from 
pCosGSP, inpME6001, GentR. 
2.2kb BamHI subclone from pCosGSP 
in pBluescriptKS+, ApR. 
7.2kb BamHI subclone from pCosGSP 
in pBluescriptKS+, ApR. 
2kb HindlIl subclone from pGSP ME H-H2 
in pLAFR3, TetR 
Hanahan 
1983 
118 
Boyer 1969 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
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pROBE l.5kb NotI fragment containing the kanamycin 
gene from mini-Tn5KmlacZ2blunt end cloned 
into the EcoRV site ofpBluescriptKS-; ApR 
S.R.Giddens 
Vectors. 
pBluescript ColEl ori lacZalKS polylinker, T3/T7,ApR Stratagene 
(KS,M13+) 
pLAFR3 pRK290 derivative;RP4(IncP-l) ori, "-cos, Staskawicz 
pUC9 multi cloning site and lacZa,Tc\22kb) et al.1987 
pME6001 pBBRIMCS derivative; ColEl ori lacZal 
multiple cloning site polylinker, mob,rep; Stephan 
TcR (7.2kb) Heeb 
Table4.1. List of strains and constructs used in the experiments described in chapter 4. 
4.2.2. Media, reagents and antibiotics. 
All media and reagents used in this study were prepared as described in Appendices I 
and II. Concentrations of the antibiotics used to maintain the selective pressure on the 
strains or the strains containing plasmid or cosmid constructs are as described in 
Appendix I, unless otherwise stated. 
4.2.3. Bacteriological methods and mushroom bioassay system. 
The bacteriological methods and the cultural conditions used were as stated in section 
2.2.3. All mushroom bioassays were done following the method described in section 
2.2.5. 
4.2.4. DNA manipulation techniques. 
The DNA manipulation and cloning techniques, southern hybridisation, electro 
transformation and tripartite mating experiments were done following the techniques 
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described in section 3.2, unless otherwise stated. Mini-Tn5 transposon mutagenesis 
experiments were done according to the technique standardised and described in section 
2.2.6. 
4.2.5. Cosmid stability and mutant rescue assays. 
4.2.5a. In liquid media. 
Transconjugants were cultured without antibiotic, starting from 1; 100 dilution of a 
saturated culture growing overnight for 18hr as the initial inoculum. After every 24hr, 
for 3 days, 100llL aliquots were aseptically removed from the cultures, serially diluted 
to a factor of 106, and two sets of 100JlL aliquots from each were spread on LB plates 
and incubated for 24hr. A titre of viable colony forming units was calculated from the 
dilution series. A grid of 200 colonies from each plate (400 for each transconjugant) 
was made on a master LB+ rifampicin (Rif) plate. Tetracycline (Tet) and kanamycin 
(Km) resistance markers were checked by transferring the colonies to LB+Rif+Tet 
plates and LB+Rif+Km, respectively, to score for transconjugants that have lost the 
cosmid or the transposon. Colonies that were sensitive to both kanamycin and 
tetracycline were selected as putative wild type strains re created by an event of double 
crossover or allelic exchange. Such putative wild type strains were later verified by a 
Southern blot analysis to confirm the loss of the transposon. 
4.2.5b. On mushroom slices. 
Individual transconjugant colonies growing under appropriate antibiotic selection were 
tooth picked on to thick mushroom slices and the mushroom assays were set up 
according to the standardised conditions. After sixteen hours of incubation, a sterile 
loop was used to transfer bacteria from the mushroom slice to 100JlL of LB and 
vortexed to make a uniform suspension. This bacterial suspension was thereafter 
serially diluted by a factor of 104 and 100JlL of the dilution of cells were spread on a 
rifampicin supplemented plate, to avoid contamination by the bacteria coming from the 
mushroom pieces, and incubated at 30°C for 24hr. The total popUlation of mutants 
surviving on the mushroom pieces were scored and a representative population of it was 
replica tooth picked on all selection plates mentioned in section 4.2.5a. to check the true 
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population of transconjugants surviving and also to calculate the rate of recombination. 
The assay was repeated twice; in the first set-up, 400 colonies arising per transconjugant 
of each mutant were tested on the selection plates, while in the second set-up, 300 
colonies per transconjugant were tested. Results presented are average percentages 
arising from screening 700 colonies in each set of transconjugant. 
4.2.6. Verification of strains rescued by recombination. 
Initially, mushroom assays were set up to test the capacity of cavity formation by the 
putative rescued mutants from all the three mutants used in the experiment. The 
recreated strains were purified on selective plates, genomic DNA was prepared and a 
southern blot analysis was done according to the method stated in section 3.2.6.with a 
probe constructed from the 1.5kb NotI fragment of the kanamycin cassette from the 
transposon mini-Tn5KmlaeZ2 (PROBE) to confirm the results arising from mutant 
rescue assays. 
4.3. Results. 
4.3.1. Restriction analysis of pC os GSP-BG 
The exact sizes of the expected Sail fragments within the gsp gene cluster ofBG164R 
were theoretically calculated from the size of the mutant clones (Table 4.2.). The total 
size of the genomic DNA present in the cosrnid was calculated from the fragments 
arising from EeoR! and HindIII double digest of the cosrnid (Figure 4.1.), as these sites 
were present on either side of BamHI site in the MCS of pLAFR3 exploited to construct 
the library. 
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Size of genomic DNA don es l"pectcd band sizes on the gel 
Plasmid Total size of Fro m From Ball/HI 
construct the construct. T3 end T7 en d Sui I digests digests 
pSP RC 12 11 Akb I. Skb 2.S kh 4kh 2.2 kb +700bp 
pSPRC40 X.Jkb IOObp 700hp X()Obp l\A 
pS PRC 147 8.2kb SOObp 350bp 850bp NA 
pSr'Rl'X7 X.9 kb 700bp XOOibp 1.)kb NA 
Table 4.2: Size of expected DNA fragments arising from a gsp cosmid , isolated from the 
genomic Ilibrary. NA= No restri ction site present in the genomic DNA of the clones. 
Figure 4,1 :Restriction analysis of p CosGSP-BG. A= ,JHindlll marker DNA. Lanes B-K= 
pCosGSP digested with different enzymes. B=EcoRI , C=BamHI, D=Hindlll, E=Sa/l , 
F=Eco'RI+BamHI , G=EcoRI+Hindlll , H~Hindlll+BamHI, I=EcoRI+Sa/l, J=BamHI+Sa/l , 
K=Hindlll+Sall , Lanes L-P=pLAFR3 digested with different enzymes . L= Sail , M=Eco R/+Sa/l, 
N=BamHI+Sa/l , O=BamHI , P=Hindlll+Sa/l. Arrows pointing to bands of interest in lanes C & E. 
The predicted hands (indicated hy arrows in Fig 4. 1) were confirmed. Smaller arrO\vs 
rllinting upward in lane C indicates the expected internal BwnJ I hands that were 
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mapped in the clone pSPRC12. In lane E, the approximate sizes of the SalI fragments as 
calculated are also present and marked with bold arrows pointing downwards. When 
compared to lane J, where the cosmid is digested with both SalI and BamHI, the 4kb 
SalI band disappears, with the appearance of the 2.2kb and the 700bp intemal BamHI 
bands. Adding up the sizes of the six bands evident from the gel in lane G, the cosmid 
has an insert of 23.4kb of genomic DNA. 
The number of restriction sites in the 23.4kb genomic DNA could be detennined from 
the restriction profile, however, a physical map of the cosmid could not be constructed 
solely based on this data. Pugsley et al. (1997b) said that the relative order of the genes 
coding for the different components of the type II secretion machinery are generally the 
same along the chromosome of all the bacteria studied so far. If true, then a physical 
map of the gsp gene cluster in the BG164R can be provisionally drawn based on the 
published gsp gene clusters of Burkholderia spp (DeShazer et al., 1999; Kimoto & 
Nakazawa, 2000). 
4.3.2. Orientation gsp genes in BG164R. 
The relative order of the gsp genes in the strain B. cepacia strain KFI (Figure 4.2) 
(Kimoto & Nakazawa, 2000) was used as a guide to assemble the SalI fragments of 
BG164R cloned and sequenced from the mutants. Initially, with the infonnation 
available in the database (Kimoto & Nakazawa, 2000) a representation of the order in 
which the gsp genes were arranged along the chromosome of B. cepacia strain KFI was 
drawn. Comparing the relative order of the genes in KFI with the BamHI and some of 
the SalI fragments evidenced on the gel used for the restriction analyses of the cosmid, a 
partial map of pCosGSP (Figure 4.3) was constructed. 
The approximate location of the genes could be identified along the length of the 
cosmid (Figure 4.3.), but only BamHI and SalI sites could be exploited for mapping of 
the gsp gene cluster-containing region of the cosmid. Other restriction sites along the 
23.4kb cosmid could not be mapped because the location of the gsp genes could not be 
traced on them solely based on restriction digestion. The cosmid had sufficient genomic 
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DNA on either side of the gene cluster obtained, it was envisaged that entire gsp operon 
ofBG164R was present on the single eosmid isolated from the genomic library. 
Burkholderia cepacia strain KFI 
Uogsp" genes -----.. D E F C G H J K L 
A ::::::::1 i i j j I I 
B 
Figure 4.2: [AJ Burkholderia cepacia strain KF1, which has (84-90%) sequence similarities with 
BG164R GSP genes. [BJ Orange bars represent regions of similarities obtained from 
sequencing of genomic DNA adjacent to transposon insertion points in clones. (Scale 
0.86cm=1Kb) 
gspD gspE gspF ~spG,H gspK 
~ I · ~ t I I 1 It I I 
B S S S B B B S S S B 
pSPRC87 pSPRC40787 pSPRC12 pSPRC8B.1 47 
Figure 4.3: Partial physical map of pCosGSP. Blue bold arrows indicate the approximate 
location of the transposon insertion along the cosmid. B=BamHI, S=Sa/l. Map not to scale. The 
clone pSPRC 12 was sequenced from both sides. From one end it showed similarities with gspG 
and H proteins while from the other it showed similarity with gspE. Sub cloning and sequencing 
of the gspE end led to the identification of the insertion point of the transposon, gspF. 
4.3.3. Comparative cosmid stability and mutant rescue experiments. 
Complementation analyses described in section 3.3.7, were due to the trans 
complementation of the mutants in the presence of pCosGSP. To test the stability of the 
cosmids in the mutant backgrounds in the absence of antibiotic, the comparative 
stability assay on mushroom slices and in liquid cultures was designed. 
Cosmid replication or segregation instability and rate of recombination with the 
chromosome was calculated after culturing transconjugants in LB broth for 24hr and on 
mushroom slices without using antibiotics to select for bacteria with the cosmid (Table 
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4.3 and Figure 4.4.). The putative recombined strains that appeared by allelic 
recombination by growing in LB broth without antibiotics were tested for the ability to 
form cavity on mushroom slices (Figure 4.5). Loss of the transposon, mini-
Tn5KmlacZ2, from the mutant genomes in the rescued wild type strains were confirmed 
by Southern hybridisation of the genomic DNA of the rescued mutants with probe 
constructed from the transposon. Results of the Southern hybridisation of the three 
rescued mutants are presented in Figure 4.6. 
Transconjugant Cosmid loss (%) Recombinants (%) 
tested. In LB media On Mushrooms In LB media On Mushrooms 
BG4-12Cos 92.25 34.5 2.75 1.63 
BG15-40Cos 96.00 43.75 4.0 2.25 
BG12-88Cos 96.75· 42.89 3.0 0.85 
Table 4.3: Summary of the frequency of tetracycline susceptibility as an indirect measure of 
cosmid loss and kanamycin susceptibility as an indirect measure of recombination of cosmids in 
the mutant strains. 
The frequency of recombination at the kanamycin insertion sites in the mutants was 
very low. This result has also obviously been accentuated due to a high rate of cosmid 
loss in the liquid medium and the actual rate was in all probability slightly higher than 
that presented. Evidently, the cosmid is more stable in the absence of antibiotics on the 
mushroom slices than in LB medium. This result could be a reflection of the 
transconjugants going through a different number of generations in the two backgrounds 
tested. Although, as presented in chapter II, when the rate of growth of mutants in LB is 
compared, it is evident that the mutants reach a stationary phase after 10hr growth in LB 
and steady state in the CFU/mL are observed beyond 10hr. Presence of the 
transconjugants on the mushroom slices in the assay for longer period could have 
compensated for this difference in the generation times. However, since the possibility 
was not addressed in the course of this specific assay it cannot be ruled out. 
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Figure 4.4: Comparative loss of cosmids from the transconjugants in LB and on mushroom 
slices 
Figure 4.5: Mushroom assay to test the cavity formation by rescued mutants. Row 1 :Mutants 
rescued from BG4-12Cos, Row 2: Mutants rescued from BG15-40Cos, Row 3: Mutants rescued 
from BG12-88Cos. 
In the mushroom assay (Figure 4.5), the transconjugants (BG4-12Cos, BG 15-40Cos and 
BG 12-88Cos) show clear cavities in contrast to the mutants (BG4-12, BG 15-40 and 
BG 12-88); however, there are clear distinctions between the cavities formed by the 
transconjugants and those mutants repaired by recombination (in the rows 1,2,3,4 in 
Figure 4 .5) . This observation re-emphasises the fact that transconjugants lose a 
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population of the cosmids, when grown in absence of any antibiotic selection, When the 
wild tyre strains are recreated from the mutants, they cause cavities identical to the 
controls, 
1 2 3 4 5 6 7 8 9 10 'i 11 2 1 2 3 4 5 6 7 8 9 '10 11 
Figure 4,6: [A] DNA gel, [B] Respective film of the southern probed with kanamycin cassette 
from the transposon . [Lane1] Probe (positive control), [Lane 2] BG164R genomic DNA(control) . 
[Lane 3] IJHindlll, [Lane 4] pSPRC40, [Lane 5] BG15-40 genomic DNA. [Lane 6] Rescued 
mutant from BG15-40. [Lane 7] pSPRC12, [Lane 8] BG4-12 genomic DNA, [Lane 9] Rescued 
mutant from BG4-12, [Lane 10] pSPRC88, [Lane 11] genomic DNA of BG12-88, [Lane 12] 
Rescued mutant of BG12-88. 
Southern hybridisations (Figure 4,6.) confirmed loss of transposons from tbe strains, 
which became kanamycin and tetracycline sensitive in the course of cosmid stability 
experiments, Since these strains fonned cavities of comparable sizes to that of the wild 
type strains, it can be predicted that events of allelic recombination of the mutants 
occurred with the cosmid DNA and has resulted in the recreation of wild type strains, 
4,3.4. Mapping of pCosGSP by Southern Hybridisation. 
Southern hybridisation was used to identify the relative order in which the different 
fragments of DNA identitied from the mutants were arranged along the 23.4kb DNA 
present in the cosmid pC:osGSP. Two probes constructed frolll different mutant clones 
were used to confinn the cosmid map (Figure 4.7.). A summary of the DNA bands that 
hybridiscd with the probes is represented in Table 4.4. 
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Bands in kb, that hybridise with the 
Enzymes used in respective probe. 
the digestion. 
JrspFprobe f,!spKprobe 
EcoRl 14.5 14.5 
BamHI 2.3 and 7.2 6.5 
HindIII 16.7 16.7 
SalI 4.0 850bp 
EcoRl+BamID 2.3 and 7.2 4.5 
EcoRl+HindIII 12.0 12.0 
EcoRl+SalI 4.0 850bp 
BamHI+SalI 2.3 850bp 
Table 4.4: Results of Southern hybridisation of the cosmid DNA with two different probes. 
The results confinn the partial map of cosmid pCosGSP (Figure 4.3). The 1.5kb SalI-
EcoRl fragment from the T3 end of the plasmid clone, pSPRC12, served as the gspF 
probe. This fragment has a single internal BamHI site. As evident from the 
autoradiogram, the probe hybridised to two bands in the BamHI digested cosmid DNA 
(Figure 4.7.), a 2.3kb band and the 7.2kb band, which according to the physical map of 
the cosmid are present contiguously. The SalI clone, pSPRC12, has three internal 
BamHI sites in the 4kb genomic DNA on either side of the transposon. The T3 end, 
which was used to construct the probe, has a single BamHI site and the T7 end has two 
sites. The three BamHI sites should theoretically release a 2.3kb and a 700bp band from 
the 4kb SaIl fragment, both of which are obvious in the restriction digest and presented 
in the map. The gspK probe, hybridises with a 6.5kb BamHI fragment (Figure 4.8.), as 
predicted from the restriction map data. In the SaIL digested lanes, the gspK probe 
hybridised with the 850bp (Figure 4.8.) fragment while the gspF probe hybridised with 
the 4kb band (Figure 4.7.). 
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'Figure 4.7: pCosGSP digests probed with gspF probe. Lanes 1-9) Cosmid digested with 
different enzymes. [1) EcoRI, [2) BamHI , [3) HindlH, [4) Sail , [5) EcoRI+BamHI , [6) 
EcoRI+Hindlll , [7) EcoRI+Sa/l , [8) BamHI+Sall, [9] 'IJHindll1 marker, [10) Negative control , 
pLAFR3/Hindlll+Sa/i 
234 5 6 7 8 9101112 1 2 3 4 5 6 7 8 9 101112 
Figure 4.8: pCosGSP digests probed with gspK probe [1] Positive control pSPRC12/Hindlll-
Sail , [2] Negative control , pLAFR3/Hindlll+Sall , [3] A/Hindi I I marker, 1[4-11] Cosmid digests with 
enzymes as follows . [4) EcoRI, [5) BamHI , [6] Hindlll , [7] Sail, [8] EcoRI+BamHI , [9) EcoRI+ 
Hindllll , [10] EcoRI+Sall , [11] BamHI+Sall, [12] Genomic DNA of BG164R di'gested with BamHI. 
Chapter IV 130 
The size of the genomic fragment inserted in the cosmid as calculated earlier from 
EcoRI-HindIII digest was 23.4kb. From the results presented, it was evident that both 
the probes hybridised to similar bands in the HindIII, EcoRI single digests, and EcoRI + 
HindIII double digests. A second objective of the experiment was to locate a fragment 
of DNA that would possibly have all the genes of the gsp operon and enable us to 
determine the boundary of the gsp gene cluster. Sub-cloning followed by 
complementation analysis of the 16.7kb HindIII and the 12kb EcoRI-HindIII fragments 
was attempted fIrst. 
4.3.5. Sub-cloning and analysis of the "gsp JJ gene cluster ofBG 164R. 
IdentifIcation of the minimum unit of the cosmid capable of complementing the clones 
was attempted by sub-cloning of the cosmid. The pBBR1MCS based broad host range 
Pseudomonas cloning vector, pME6001, with gentamycin resistance marker (Antoine & 
Locht, 1992; Kovach et al., 1994; Maurhofer et al., 1998), was used to sub-clone the 
genomic DNA inserted in the cosmid pCosGSP in an attempt to isolate smaller 
fragments of the cosmid capable of complementing the mutants. Shotgun cloning of the 
HindIII fragments yielded both the 16.7kb (pGSP ME H-H 16.7) fragment and the 2kb 
(pGSP ME H-H 2) fragment. However, in case of EcoRI-HindIII cloning, only the 12kb 
(pGSP ME E-H 12) and the 1.7kb (pGSP ME E-H 1.7) fragments could be cloned out 
of the six fragments generated by the digestion of the cosmid DNA in 4 independent 
attempts. Complementation of the mutants with pGSP ME H-H 16.7, were initially 
tested before any further sub cloning attempts. 
Tripartite matings with pRK2013 as the helper plasmid was fIrst used to transfer pGSP 
ME H-H 16.7 sub-clone into the gspE, gspK and gspF mutants. Transconjugants 
isolated from matings with all the three different mutants were isolated and tested for 
complementation of the cavity phenotypes with mushroom bioassays. None of the 
mutants were complemented with the biggest cosmid sub-clone. This indicates that the 
minimum complementation unit is larger than the largest clone, although, the Southern 
hybridisations with probes constructed from two different gsp genes showed positive 
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hybridisation of the same fragment. Considering the fact that the size of the insert DNA 
in the cosmid pCosGSP is 23.4kb, there was about 6.7kb of DNA missing in the Hindill 
clone. Of the 6.7kb missing DNA, 2kb was sub-cloned as pGSP ME H-H 2, however 
4 .7kb DNA was attached to the cosmid vector with Hindill digestion. These missing 
portions could simply be a missing promoter on one end of the sub-clone, or could be 
some other genes in the GSP operon, which were necessary for the efficient functioning 
of the GSP system. Alternately , there could also be some other gene(s), downstream or 
upstream the gsp operon in Burkholderia, which were silenced by polar effects in the 
mutants and could not be complemented by the sub-clone because of the absence of the 
corresponding region in the sub-clone. These could include products secreted by GSP or 
involved in the efficient processing of the products being secreted by GSP machinery 
and thus were essential for the formation of cavity disease . If some other genes present 
upstream or downstream the region sub-cloned from the cosmid was necessary for 
complete complementation, then introduction of another clone containing such regions 
would result in restoration of wild type phenotypes. Such an attempt was undertaken 
and will be discussed in section 4 .3.7. 
4.3.6. End sequence analysis of the cosmid sub-clones. 
To analyse possible reasons for the failure of the complementation studies with the 
pGSP ME H-H 16.7 sub clone and also to orient the sub-clones and the mutant clones in 
comparison to the published complete gsp operon of Burkholderia pseudomallei strain 
J 026b (Fig:4.9) (DeShazer et al. , 1999) ends of the cosmid sub-clones were sequenced 
to identify the genes at the boundaries of each sub-clone. 
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Figure 4.9: gsp gene cluster of Burkholderia pseudomal/ei 1026b redrawn from De Shazer et 
al. 1999 (De Shazer et aI., 1999). Figure not to scale. 8= BamHI, E=EcoRI, 8g=Bg/ll. 
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Name of 
the clone 
T3 sequence similarity 
Gene I % Identity E-Value 
pGSP ME Last 20bp 
100% 0.98 
H-H 16.7 orfD 
NA NA 
dbhB 92% e-107 
H-E 
132 
T7 sequence similarity 
Gene % Identity E-Value 
orfB 85% 2e-26 
dbhB 92% e-125 
orfA 84% 4e-12 ~~s X --------~--------~------_+--------+_------_4--------~ pGSP KS 
BoB 2.2 
pGSP KS 
B-B 7.2 
gspC,F 
orfB 
85%,89% 
82% 
4e-12 
7e-55 
1e-21 
gspE,F 83%,86% 
gspE 85% 
2e-42, 
4e-35 
e-143 
Table 4.5: Sequence similarity of pCosGSP sub clones with B. pseudomal/ei strain 1026b gsp 
genes. 
Interestingly, the two HindIII sub clones were identical to genes of B. pseudomallei 
strain l026b, from one end (Table 4.5). In case ofpGSP ME H-H 16.7, a short stretch 
of20bp (at the end ofT3 sequence read out off the vector) revealed identity to the orjD 
of B. pseudomallei 1026b while the rest of the sequence did not show similarity to 
genes adjacent to the orjD genes present in B. pseudomallei, namely, orjF and orjE 
(Figure 4.9). The two sub-clones based on the end sequences being read off from the 
vectors were aligned along the physical map of the complete gsp operon of B. 
pseudomallei. The sub-clones appear to be two adjacent fragments, as presented in 
figure 4.7. The 1.7kb EcoRI-HindIII clone fonned a part of the 2kb HindIII sub clone, 
with the HindIII end of both the clones showing significant sequence similarity with the 
dbhB gene responsible for coding of a DNA binding protein. The EcoRI end sequence 
of the Eco-Hind sub-clone was similar to another DNA binding protein, OrfA, present 
adjacent to the gsp operon in case of B. pseudomallei. 
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Figure 4.10: Alignments of the cosmid sub clones with the gsp operon of B.pseudomal/ei strain 
1026b. Blue arrows indicate the alignment of the genes in B. pseudpma/lei, Pink lines indicate 
the sub clones isolated from the cosmid pCosGSP, while blue lines indicate genomic DNA 
present in the mutant clones. [1] pGSP ME H-H 16.7, [2] pGSP ME H-H2,[3] pGSP ME H-E 1.7, 
[4] pGSP KS B-B 2.2, [5] pGSP KS B-B 7.2, [6] pSPRC87, [7] pSPRC40 and 787, [8] pSPRC12 
and [9] pSPRC88 and 147. Each orange arrow corresponds to the middle of a 600-800bp 
sequenced DNA fragment from the end. (Figure not to scale) 
Sequence of the two BamHI sub-clones was also found to be very similar to the gsp 
genes of B. cepacia KF 1 strain. According to predictions, the 2.2kb BamHI sub-clone 
read into GspC and GspF proteins from the T3 end. Sequence similarities with the 
published sequences of B. pseudomallei is presented in Table 4.4, while it revealed 80% 
and 88% similarity with .aspC and gspF gene of B. cepacia, with an E-value of 2e-07 
and 3e-5J respectively. From the T7 end, the sequences showed 82% identity (Expected 
value=4e-47) with the gspC gene and 85% identity (Expected value=ge-07) with the 
gspF genes of B. cepacia. 
Both pGSP ME H-H 16.7 and pGSP KS B-B 7.2, had similarities to the orlB genes of B. 
pseudomallei strain 1026b, the former from the T7 end, while the latter was from the T3 
end of the clone. When the sequence of these two genes are aligned they reveal a 99% 
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similarity (Appendix Ill), with the BamHI site being at 16bp downstream from the 
HindIII site present adjacent to the orjB gene. 
4.3.7. Cosmid-plasmid complementation of the mutants 
A cosmid-plasmid complementation study was attempted to fmd out whether the two 
HindIII cosmid sub-clones, when present together in the mutant, had the ability to 
complement the no-cavity forming phenotype of the mutant. The 2kb HindIII fragment 
from pGSP ME H-H 2 was re-cloned into the compatible plasmid pLAFR3 to create the 
cosmid pGSP LA H-H 2. pLAFR3 belongs to a different replication incompatibility 
group than pME6001 so both are theoretically stable in the same celL Triparental 
matings with the helper plasmid pRK2013 was used to transfer the new cosmid clone 
pGSP LA H-H 2, into BG4-l2ME. Transconjugants were tested on mushroom slices for 
complementation. None of the transconjugants isolated could complement the mutants 
in the mushroom slice bioassays. 
No complementation of the mutant in the presence of two contiguous fragments 
containing sub-clones of the cosmid indicated that either the presence of some essential 
genes downstream the gsp gene cluster in the cosmid, or separation of essential DNA 
sequences a promoter site) required for the activation of the mutated gsp gene in 
the gsp gene cluster containing sub-clone, pGSP ME H-H16.7. Another possibility is 
the instability of the pME600l clone in the mutant background. Such questions need to 
be addressed in future projects. 
4.3.8. Does pCosGSP contain genes of cavity causing principle(s)? 
The cosmid pCosGSP was introduced into a Pseudomonas fluorescence mushroom 
isolate (PRC121) to test whether the cosmid, apart from having the secretory genes, also 
had the structural genes responsible for the production of enzymes/compounds 
responsible for causing Cavity disease. Pullulanase secretion by Klebsiella oxytosa and 
cellulase and pectinase secretion by E. chlysanthemi has previously been reconstituted 
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in E. coli. Cosmid pCosGSP containing a DH5a clone isolated from the library was 
tested on mushrooms for the ability to cause any disease like symptoms, but no such 
reaction was observed on the mushroom tissues. This was more likely due to the fact 
that E. coli cells did not appear to grow on the mushroom slices. Thus, to eliminate the 
problem of growth of a different strain harbouring the cosmid, pCosGSP was 
transferred into one of the strains isolated from the button mushrooms, PRC121 
(discussed in section 5.4.1.). PRC121 transconjugants with the cosmid did not make 
cavities on the mushroom slices. 
Generally, the gsp genes of one species do not complement gsp mutants of a second 
species. Also, there is a specificity of the identification of products secreted by the gsp 
apparatus of each bacterial species. However, there are occasional reports of exoprotein 
secretion by gsp of heterologous hosts, like the secretion of Aeromonas hydropila 
aerolysin by a marine Vibrio strain (Wong et al., 1990) and P. aeruginosa elastase by P. 
alcaligenes (de Groot et al., 2001). PRC121 or, P. fluorescence was a readily available 
strain that could be tested in this specific case, as ability of the test strain to grow on 
mushroom slices would also form a major factor in this situation. Transconjugants 
isolated by triparental matings were used to set up mushroom bioassays and none of the 
transconjugants showed any sign of cavity disease. 
Inability of the mushrooms to react to any other bacteria harbouring the cosmid 
pCosGSP could have either been due to the absence of the products responsible for the· 
exhibition of the specific phenotype, alternatively, it could also mean inability of 
substrate recognition by the GSP in Pseudomonas fluorescence. Without knowing what 
product(s) were supposed to be secreted by the GSP ofBG164R, co-relating the ability 
of products to be secreted by the GSP of other related strains or the reconstitution of the 
BG164R GSP in heterogenous strains was difficult. 
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4.3.9. Second mutagenesis screen for isolation of further no-cavity forming 
mutants. 
A second mutagenesis screen was undertaken in an attempt to isolate more no-cavity 
forming mutants of BG164R, essentially because all mutants isolated up to this point 
were in the GSP operon. 
4.3.9a. Mutagenesis screens and phenotypic characterisation of mutants. 
A new group of random insertional mutants were created by mini-Tn5KmlacZ2 and 
screened using the standard bioassay system for the loss of the capacity of forming 
cavities on mushroom pieces. Of the 5000 transconjugants tested, 3 prototrophic 
mutants were selected for exhibiting the no-cavity phenotype. The lacZ fusion status of 
the transposon in the gene of interest was checked in all the three mutants by plating on 
an LB plate supplemented with 5-bromo-4-chloro-3-indoyl-~-galactopyranosidase (x-
gal). All 3 mutants produced the characteristic blue colour, thereby revealing the 
formation of active lacZ translational fusion in the mutated genes. 
BGII-l05 had a single flagellum and BGII-l06 had two flagella observed by TEM. 
However, in case ofBGII-l07 there appeared to be three or more flagella present across 
several fields of observation, with some rare ones with two flagella. The mutants BGII-
105 and BGII-l06 had defects in protease secretion while BGII-l07 did not have any 
such defects. The main purpose of this second round of mutagenesis screening was 
aimed to find out if any other gene apart from the gsp gene cluster could be attributed to 
cavity formation on mushrooms by BG164R using the specific mutagenesis tool and the 
bioassay system. So, the mutations isolated were cloned into the sequencing vector 
pBluescript KS+ using SalI. Properties of the mutants isolated and the clones created 
are described in Table 4.6. 
I 
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Name ofthe 'lacZ Name ofthe Name of the Total size of Amount of 
mutant fusion respective respective insert DNA genomic DNA 
isolated status clone in DH5a. : plasmid in the clone present 
BOIl-105 Blue CMCII-I05 pSPRCI05 4.4kb 200bp 
BOIl-l 06 Blue CMCIl-I06 pSPRCI06 4.7kb 500bp 
I 
BOIl-I07 Blue CMCIl-107 pSPRCI07 7kb 2.8Kb • 
Table 4.6: Properties of the mutants and the respective clones isolated in the second lot of 
mutagenesis screening of no-cavity phenotype. 
Evidently, two of the clones were quite small, unlike any other clone isolated in the first 
round of mutagenesis screening experiment and the size of all three clones were quite 
different to the mutants cloned so far. 
4.3.9b. Sequence analyses of the mutant clones and complementation studies. 
The sequences were used to search the available database. Two out of three clones had 
mutations in the OSP genes, one of which was different to the gsp genes identified so 
far. Interestingly the third mutation was in a gene which had significant sequence 
similarity with the polyketide synthetase (Pks) gene of Myxococcus xanthus involved in 
the synthesis of the polyketide antibiotic, TA (Simunovic et al. , 2003). Details of the 
similarity search with the sequences are presented in Table 4.7. 
Construct 1'3 primer 1'7 primer Possible Gene 
number I Length read i Identity to Length read Identity to Mutated 
out gene out gene 
pSPRCI05 17bp+Tn5 No sim 154+Tn5 E gspE 
pSPRCI06 396bp+Tn5 K 97+Tn5 K gspK 
pSPRCI07 840bp pks 800 pks Polyketide 
synthetase 
Table 4.7: Results of similarity searches with the gene sequences. 
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Similarity searches revealed that the gspE mutation in pSPRCI05, was in a 171bp Sall 
fragment, which has not been isolated before. The 17bp genomic DNA sequenced from 
the T3 end of the vector did not match with any published sequence, either because of 
the very small amount of information present in it, or because the mutation was at an 
extreme end of the published gspE sequence. Sequence from the T7 end of the clone 
was 89% similar to B. cepacia gspE gene, with an E value of le-39, and 87% similar to 
the gspE of B. pseudomallei with an E value of 4e-33. The 154bp sequence did not 
match with any of the partial gspE sequences from the clones pSPRC40, pSPRC787, 
pGSP KS B-B 7.2 andpGSP KS B-B 2.2. 
There is 96.63% similarity in the sequences from the T7 end of the clones pSPRC88, 
pSPRC147 and pSPRC106 and 86.7% similarity from the T3 end. Although sequences 
up to the transposon insertion point was not achieved in the clone pSPRC147 from the 
T3 end, based on the data collected from the T7 end, it appears that the clones pSPRC88 
and pSPRCI06 are similar, indicating that the mutants BG12-88 and BGII-I06 are the 
same. 
BOll -107 has a unique mutation in the gene that shows significant sequence similarities 
both at the DNA and protein levels to the polyketide synthetase gene of Myxococcus 
xan th us. The exact location of the mutant could not be traced in case of the clone as 
sequencing reactions were done with primers based on T3 and T7 promoters present in 
the vector. From both the ends, over 800bp sequences were obtained which did not 
overlap with the end of the transposon. The sequences from the T3 end of the BGII -107 
clone showed 83%, 84% and 90% similarity over three stretches of approximately 
100bp DNA with E values of 2e-06, le-07 and 0.024 to the Myxococcus xanthus 
polyketide synthetase gene (Appendix III). Analyses of the translated amino acid 
sequence from the 800p DNA sequence 1ll the Blast X server 
,~_:":"-'-'_':'==~,~~:'c=-'-'-:'c~=~/ revealed a similarity valying from 45% to 74% with type 
I polyketide synthase protein of Bacillus subtilis. From the T7 end a small stretch of 
34bp shows 94% DNA sequence identity with the Myxococcus xanthus polyketide 
synthetase gene. 
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All the three new mutants were complemented by the cosmid pCosGSP. This indicated 
the probable presence of the polyketide synthetase gene somewhere along the 23AKb 
genomic insert in the cosmid. Based on results of the Southern hybridisations and 
sequencing data from the mutant clones, the cosmid sub-clones and the new mutants 
clones, a restriction map of the cosmid was reconstructed (FigA.ll), which revealed 
approximately 5kb genomic DNA downstream the gsp gene cluster of BG 164R and is 
possibly the location of the polyketide synthetase gene in the cosmid. 
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Figure 4.11: Restriction map of pCosGSP genes. The blue arrows indicate the partial sequence 
of the genes obtained from sequencing of the mutant clones and the cosmid sub-clones. The 
directions indicate readouts from the T3 and T7 primers, and not the direction of transcription of 
the respective genes. E= EcoRI, B=8amHI, H= Hindlll, S=Sa/l. 
4.4. Discussion. 
In this project, screening of 15,000 random mutants yielded 9 prototrophic no-cavity 
causing mutants. Of these, 8 mutants have the transposon inserted in the different genes 
of gsp operon of BG 164R. The only mutant that had a mutation in a different gene was 
the polyketide synthetase mutant, BGII-I07. Complementation of mutants with 
pCosGSP indicates the presence of the gsp as well as the polyketide synthetase genes 
along the cosmid. While the exact physical location of the gsp genes along the cosmid 
have been established, speculation regarding location of the polyketide synthetase gene 
needs further genetic verification. It is likely that GSP in B. gladioli (BG 164R) secretes 
a product, synthesised by the polyketide synthetase gene of the Cavity disease pathogen. 
The I 6.7kb HindU] sub clone consisted of all the genes of the gsp operon, as identified 
by the Southern bolt analysis, however, it did not complement the mutations. De Shazer 
et al. (1999) from their experiments suggested that the 5' and 3' termini of the gsp gene 
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cluster were the orfC and the orjD genes in their strain (B. pseudomallei t026b). It does 
not appear to be the case in BG164R gsp genes. End-sequence analysis of the clone 
suggests that the 16.7kb HindUI sub-clone has both the terminal genes present in the 
case of B. pseudomallei 1026b. The result indicates the absence of a promoter or 
operator gene required for the activation of gsp gene cluster in the sub-clone, as a result 
of which the genes are not transcribed. Alternatively, this could indicate silencing of 
gene products downstream of the gsp operon, in the case of mutants due to polar effects 
exhibited by mini-Tn5KmlacZ2. 
Sequence analysis of the cosmid sub-clones and mutant clones used to align the genes 
reveals the presence of a gap between the gspM and the orjD genes identified by the end 
sequencing of pGSP ME H-HI6.7. According to the order of the genes in B. 
pseudomallei 1026b, gspM is followed by gspN gene. The presence of gspN gene in the 
gsp operon of BG164R needs to be verified by sequencing of the intermediate region. 
Notably, orjD appears to be the last gene in the cluster in case of the BG 164R gsp 
operon, in contrast to that of orjE and orjF genes present beyond orjD in the case of the 
B. pseudomallei 1026b gsp operon (Fig 4.9). The boundary of the BG164R gsp operon 
could not be determined by the sub-cloning and complementation analysis. 
In the absence of knowledge about the actual products that were responsible for cavity 
formation, and the fact that the cosmid, pCosGSP, did not exhibit any disease symptoms 
on mushroom slices when tested from E. coli background, restricted the possibility of 
screening the mutated cosmids for cavity formation in the E.coli background. Thus, 
screening for 'no-cavity' phenotype of the mutated cosmids would be dependent on the 
ability to create a huge number of mutant Burkholderia strains by recombination with 
randomly mutated cosmids. However, an alternative strategy could be adopted in this 
case, which would involve saturation mutagenesis of the cosmid, introduction of the 
mutated cosmid into the existing mutants, and identification of mutant cosmids, that 
would not complement the cavity formation. This, although was not the best possible 
alternative, would have given us some indication about the regions of the cosmid 
necessary for disease formation. A problem associated with this saturation mutagenesis 
approach was the fact that BG 164R is resistant to a wide range of common antibiotics. 
A mini-Tn to transposon derivative with a gentamycin resistance gene cassette in a 
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suicide vector (pBSL177), pBSL 182 ( Alexeyev et al. 1995; Alexeyev & Shokolenko, 
1995) was used in mutagenesis experiments, but transposition could not effectively 
induced. The alternative strategy of sub cloning of fragments from the cosmid, to 
isolate smaller complementing fragment appeared to be a quicker approach to delimit 
the boundaries of gsp gene on the cosmid, as southern hybridisations indicated a high 
probability of the presence of the gsp gene in the 16.7kb HindIII fragment. 
The polyketide synthetase gene of Myxococcus xanthus, codes for a unique polypeptide 
with combined enzymatic activities of non-ribosomal peptide synthetase and type I 
polyketide synthase (Paitin et ai., 1998). Thus, when analysed at the translated query 
levels, significant similarity was observed with the Bacillus subtilis type I polyketide 
synthase. The Myxococcus xanthus polypeptide assembles amino acids by peptide bond 
formation in energy dependent manner by virtue of the non-ribosomal peptide 
synthetase enzyme activity, which covalently adds acetate or propionate units as by the 
type I polyketide synthase function (Simunovic et al., 2003). The final outcome of the 
complex enzyme in Myxococcus xanthus is the synthesis of a macrocyclic polyketide 
antibiotic, T A, which has an unsaturated a~-methaoxy group and is formed from 
methionine, glycine and acetate precursor molecules. The antibiotic is known to be an 
inhibitor of cell wall synthesis by interfering with the lipid-disaccharide-pentapeptides 
aggregation (Paitin et al., 1998). 
Polyketides form a versatile group of natural products, essentially secondary 
metabolites, produced by bacteria, fungi and plants. The activity range of the different 
compounds varies from being anticancer agents to antibiotics, from 
immunosuppressants to mycotoxins. The question that arose was whether the mutant 
had the capacity to inhibit fungal hyphae, a well-exhibited character of B. gladioli pv. 
agaricicoia, BG 164R. Fungal assays revealed no change in the characteristic of the 
mutant (Figure 4.12), although the mutant has lost the capacity of forming cavity on 
mushroom tissues. 
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Figure 4.12: Inhibition of Gaeumanomyces graminis mycelia by the polyketide synthetase 
mutant, BGII-107 
142 
The isolation of 8 GSP mutants in the course of mutagenesis certainly indicates the 
involvement of extracellular enzymes in the fonnation of cavity disease in mushrooms. 
GSP has been associated with the secretion of toxins in many species, including toxin A 
secretion in Pseudomonas (Mc Yay & Hamood, 1995), aerolysin in Aeromonas (Wong 
et aI., 1990; Howard & Meiklejohn, 1995) and the cholera toxin in Vibrio (Sandkvist et 
aI., 1997). However, in all these cases, the toxins are basically proteins in nature, and 
specifically recognised by the respective gsp secretin. The general secretory pathway, is 
a system dedicated to the secretion of proteins and hence, the possibility of a gene 
product being synthesised by an enzyme that has mixed function of non-ribosomal 
peptide synthetase and type I polyketide synthase cannot be ignored. 
Since the polyketide synthetase mutant is complemented by the cosmid, it is predicted 
that the genes are situated downstream from the gsp gene cluster in this species. The 
prediction needs further verification; however, the questions that remain unanswered are 
what is the chemical nature of the product being produced by the polyketide synthase 
gene linked to cavity disease of mushrooms? On consideration of the possible roles 
played by the polyketide synthetase genes in formation of cavity disease, two probable 
mechanisms can be proposed: (i) as a signalling molecule involved in quorum sensing 
(ii) in the production of surface bound components of the bacterial cells, which playa 
role in the bacterial pathogenesis. It has been demonstrated by DeShazer et al. (200 I) 
that the webR gene with putative type I polyketide synthase functions plays a role in the 
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biosynthesis, export and translocation of polysaccharides necessary for the fonnation of 
capsules (DeShazer et al., 2001). Mutation in the wehR gene, which has polyketide 
synthase function, reduces Burkholderia mallei pathogenicity in the fonnation of 
glanders disease in Syrine hamster and mice models. Could such a phenomenon also be 
working in the fonnation of cavity disease on mushrooms? 
4.5. Concluding Remarks. 
An efficient random mutagenesis system and a genomic library to study genes of 
BGl64R have been established in the course of this study. Isolation and identification 
of more mutations would certainly lead to the identification of the products involved in 
the expression of Cavity disease. Alternatively, secretory mutants isolated in the course 
of this study could be exploited in a reverse genetics approach to identify the secreted 
gene products involved in the expression of disease symptoms. 
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Chapter V 
Initiation of Cavity disease on mushrooms .. 
5.1. Introduction. 
The tenn 'disease' is derived from old French, which literally means 'a departure from 
nonnal or easy living' (Brogden & Guthmiller, 2003). Over the years, the defmition has 
undergone many changes and current usage implies the 'manifestation of damage to 
host' that results from host-microbe interactions. Expression of disease symptoms in a 
host is the final outcome of. a series of sequential steps, starting from the initial 
establishment of the pathogen, followed by the colonisation of the host tissue and 
ultimately leading to the expression of disease. 
In order to successfully establish themselves as pathogens, microorganisms not only 
overcome the defence mechanisms of the host but also compete with other 
microorganisms in the immediate environment, the rhizosphere or phyllosphere of the 
host tissue. Mushroom sporocarps harbour a population of non-pathogenic commensals 
(Moquet et al., 1996). Expression of some disease processes in mushrooms has been 
reported to involve secondary infection in the presence of a primary pathogen (Inglis et 
aI., 1996a; Moquet et al., 1996). In the commercial cultivation of mushrooms, the fruit 
bodies grow from mycelia that are seeded on compost beds that have been reported to 
consist of microbial populations in them (Godfrey, 2003). The induction of sporocarp 
fonnation from mycelia needs a signal from Pseudomonas putida to remove the "self 
inhibitory compounds" produced by the growing mushroom mycelia into its 
environment below the threshold level (Rainey, 1989). P. putida also fonns a dominant 
population of the compost bed used in the commercial cultivation of mushrooms 
(Rainey, 1989). Sporocarps of mushroom thus provide microenvironments to the 
pathogen, analogous to the phyllosphere and rhizosphere organisms in case of plants. 
Studies on the effect of bacteria present in the microenvironment of mushroom 
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sporocarps in Cavity disease initiation by BG 164R fonns one of the main bases of this 
chapter. 
Besides being the Cavity disease pathogen, the strain BGI64R, has been associated with 
the inhibition of filamentous phytopathogens as Fusarium oxysporum and Trichophyton 
sp. (Young, 1992). The chapter also describes experiments designed to further explore 
the host range of the pathogen, in an effort to biologically characterise the strain. 
5.2. Material and Methods. 
5.2.1. Bacterial strains used. 
Strains Genotype or description 
and plasmids 
Burkholderia gladioli pv.agaricicola. 
BG164R wildtype, cav+, Af+, Rit-, Prot+ 
Pseudomonas aureofaciens 
PA147-2 wildtype, Af+, Bfm+, Rit-, CmR,(10/-ig/mL) 
Ewingella americana 
PRC120 non-pathogenic, wild type mushroom isolate, Prot+ 
Pseudomonas jluorescens 
PRCl21 non-pathogenic, wild type mushroom isolate, Prot-
PRC122 non-pathogenic, wild type mushroom isolate, Prot-
Table 5.1: List of strains used in the experiments described in Chapter 5. 
References 
This study 
Carruthers et 
al. 1994 
This study 
This study 
This study 
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5.2.2. Media, reagents and antibiotics. 
All media and reagents used in this study were prepared as described in Appendices I 
and II. Concentrations of the antibiotics used to maintain the selective pressure on the 
strains are as mentioned in Appendix I, unless otherwise stated. 
5.2.3. Bacteriological methods and antifungal assays. 
The bacteriological methods and cultural conditions used for BG164R and PA147-2 
were as stated in section 2.2.3. The strains of Ewingella americana and Pseudomonas 
jluorescens, isolated from mushroom sporocarps were grown under aerobic conditions, 
in a 30°C incubator. Individual single colonies of the E. americana and P. jluorescens 
strains appeared within 20hr of incubation. The antifungal assays were set up according 
to the method stated in section 2.2.7h. 
Initially, antifungal assays were set up in different media to identify a media best suited 
to exhibit the antifungal characteristics of BG 164R. Potato dextrose agar (PDA), Tris 
Buffered potato dextrose agar (TB-PDA) maintained at pH 7.6 and com meal agar 
(CMA) were tested for the purpose. The growth of BG 164R was monitored over a 
period of four days in each media and compared to another antifungal pseudomonad, P. 
aureofaciens, strain PA147-2. 
5.2.4. Experiments designed to determine the inoculum SIze required to 
initiate Cavity disease. 
To test the influence of inocula on the initiation of Cavity disease, stationary phase 
cultures grown overnight for 18hr and arising from well-isolated single bacterial 
colonies were serially diluted to a factor of 108, and SJlL drops from all dilutions were 
spotted in triplicate onto mushroom slices and onto LB plates to enumerate the 
inoculum size. Inoculated slices were incubated up to 120h and disease progression was 
monitored at regular intervals. Data collected from four repeats of the assay were used 
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to detennine the minimum number of cells necessary for disease initiation within 16hr 
under standardised mushroom assay conditions described in section 2.2.5. 
5.2.5. Assay to monitor the growth ofBGl64R on mushroom tissues. 
To select the best process for the extraction of live bacterial cells from mushroom 
tissues, methods like sonication and vortexing of samples, with varying intensity and 
time to retrieve fixed number of cells were tried. Based on these preliminary 
experiments it was established that vortexing of the mushroom pieces with 100J.lL of 1 x 
M63 minimal salt solution was the most efficient method for the extraction oflive cells. 
To measure the growth of BG164R over time on mushroom tissue, sporocarp tissues 
were cut into lcm x lcm x 2 mm slices and inoculated with drops of suspension 
cultures containing estimated number of bacteria. At regular intervals of time, bacteria 
were extracted from the mushroom slices by continuous vortexing the tissue samples in 
100J.lL of minimal salts (M63), in an Eppendorf tube for 1 min. The suspensions were 
serially diluted and plated on LB plates supplemented with Rifampicin to enumerate 
BG164R and select against the growth of the other (rir') microflora present in the 
mushroom pieces. 
5.2.6. Mushroom bioassays to test the effect of mixed popUlations on the 
capacity of disease formation by BG l64R. 
Eighteen hour old saturated cultures of BG164R, PRC120, PRC121, PRC122, and a 
control strain, Pseudomonas aureofaciens PA147-2 (that does not show any disease on 
mushrooms), were diluted to an optical density of 0.5 at 600nm wavelength. Hundred 
J.lL aliquots of diluted samples from the three mushroom isolates were separately mixed 
with BGl64R and PA147-2. Mixed samples were centrifuged, resuspended in a final 
volume of 100J.lL of 1 x MS and used as the stock inoculum. Five microliter aliquots 
were spotted on to mushroom slices in duplicate, incubated at 30°C and disease 
progression recorded at regular intervals over a 3-day period. The ratio of BG 164R and 
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mushroom isolates used as inoculum was estimated from viable plate counts on LB 
plates and LB plates supplemented with rifampicin, confirming roughly 1: 1 ratio in the 
case of all the mixed samples and an inoculum size of approximately 107 cells per 
bacterial type in the mixtures. 
5.2.7. Mushroom bioassays to determine the inhibition of BG164R by 
PRC120. 
Mushroom slices were inoculated with a mixed population consisting of BG 164R and 
PRCI20, bacteria retrieved from the slices by vortexing at Ohr and 6hr were 
enumerated. In a control set-up, mushroom slices were inoculated with BG 164R only 
and the concentration of cells estimated after both Ohr and 6hr. The total number of cells 
present in the mixed population was counted by plating the mixture on LB plates, while 
the number of BG164R cells in the mixed population was selected by plating the 
mixture on rifampicin plates. 
5.2.8. Extraction of endogenous bacteria from mushroom tissues. 
Caps of button mushrooms were washed twice with sterile distilled water and internal 
pileus tissue were aseptically collected under sterile conditions in a laminar airflow 
chamber. From four different sporocarps, 0.3g of internal tissue samples were 
macerated with a sterile glass rod in 100)lL of minimal salts (MS) and the macerate 
spread on an LB plate and incubated at 30°C for 20hr to facilitate growth of bacterial 
colonies. Preliminary identification, based on colony morphology, revealed the presence 
of three distinct colony types, which were enumerated and re-purified by streaking on 
fresh LB plates. These three strains were thereafter distinguished by Gram's stain, 
oxidase test and designated as PRCI20, PRC121 and PRCI22. 
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5.2.9. In vitro plate assays to test whether the antifungal compound(s) are 
produced by BG 164R on induction by growing fungal mycelia. 
Plugs of agar were taken from (i) the zone of inhibition of fungal mycelia on a PDA 
plate previously used for the antifungal assay, (ii) around the zone of growth of 
BG 164R colonies on a PDA plate, which did not have any fungus growing on it (iii) 
around the fungal mycelia growing on a PDA plate without any bacteria growing on it, 
and served as the test blocks. In the actual experiment, agar plugs were taken out from 
around a young culture of Gaeumanomyces graminis growing on a PDA plate were 
replaced with the three plugs of agar listed above. The fungal plate with plugs of 
replaced agar was incubated at 25°C and the effect on the growth of the fungal mycelia 
observed over two days. 
5.2.10. In vitro plate tests to determine the capacity of inhibition of a lawn 
of test bacteria by an antagonist. 
Fifty ilL aliquots of 18hr old cultures of test strain were added to liquid water agar 
(Appendix I) held at 40°C and overlayed onto pre-wanned MA plates. The overlay was 
allowed to set at RT under sterile conditions and fixed volumes of the putative inhibitor 
strain(s) were spotted onto the overlay plates. Test plates were incubated at 30°C 
incubator and the zone of clearing of the bacterial lawn was accepted as a measure of 
the capacity of inhibition. 
5.3. Results. 
5.3.1. Size of inoculum plays a significant role in the initiation of Cavity disease. 
The effect of inocula on the initiation of Cavity disease was tested to detennine whether 
Cavity disease initiation was a cell density-dependent process. A minimum 
concentration of approximately 2.4x105 cells of BG164R was required for disease 
symptoms to be observed within 32hr. Increasing the inoculum size advanced onset of 
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the disease. However, if the inoculum size was reduced to 20-24 cells, no disease 
symptoms were observed even after 120hr of incubation (Table 5.2.). 
Dilution Estimated Symptom observation (Hours after inoculation) 
factor Inoculum 16 32 48 64 80 96 112 120 
size 
R=t 10° 24XI06 * ** **+ x x x X 10 2 24XIo4 - * ** **+ x x X 
10 4 24X102 - - - H H H A 
10 6 24 - - - - - - - A 
10 8 - - - - - - - - A 
Table 5.2: Cavity formation as a function of inoculum size. Legends: [*] cavity formation, ["''II] 
massive tissue degradation, [**+] Complete tissue degradation of mushrooms, [-] No reaction 
observed, [H] Hypersensitive reaction in 30% of the mushroom slices, [A] mushroom slice starts 
degenerating assay terminated, [X] tissue disappearance due to excess degradation by the 
pathogen. 
Often only a few potentially pathogenic bacteria can colonise a host and multiply to 
reach the threshold concentration required to cause a disease (Atkey et al., 1992). In the 
case of BGI64R, 20-24 cells were unable to cause observable symptoms of disease 
even after 120hr incubation. A possible hypersensitive reaction was observed after 80hr 
incubation on the slices inoculated with 24X102. These reactions were distinctly evident 
on the surface of the mushroom tissues but did not have any similarities to BG 164R 
infection of mushroom. The observation was unchanged even after extended periods of 
incubation (ti11120hr). The tissue samples could not be incubated beyond 120hr because 
the test slices started degenerating. Generally, tissue degradation was such that it would 
obscure disease symptoms after 5days so whether inocula of roughly 2,400 cells could 
cause disease on further incubations could not be concluded. Interestingly, the tissue 
slices inoculated with approximately 24 cells did not show any signs of even 
hypersensitive reactions after 120hr of incubation. 
5.3.2. Effect of the size of inocula on the growth rate of BG 164R on mushroom tissues. 
The growth rate of BG164R on mushroom tissue was monitored over time. Sporocarp 
slices were inoculated with approximately 9x102 and 4x104 CFU/mL. The BG164R titre 
was enumerated at regular intervals by extracting the bacteria from the tissues. 
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The population of bacteria increased over a period of 36hr (Figure 5.1.). No differences 
were observed in the in vivo growth rate on tissue slices compared to in vitro growth in 
liquid broth. By 30hr, all populations incubating on mushroom tissues converged onto 
the same concentration. No disease symptoms developed in the first 12hr of incubation 
on mushroom tissues from either starting concentrations of the pathogen. Signs of initial 
tissue degradation appeared after 36hr starting from the inoculum of 4x I 04 CFU/mL, 
and the cavity was observed in both inocula when the bacterial population reached a cell 
density of 4x 1 09 CFU/mL, thereby re-establishing a density-dependent disease initiation 
by the pathogen. 
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Figure 5.1: Differential growth of BG164R on different substrates and on mushroom tissues 
from different starting inocula. 
There were two problems associated with this assay system. A significant loss of 10-
20% bacteria inoculated was realised during extraction from tissue samples. To 
compensate for the loss, the minimum initial inocula had to be quite high (9x 1 0\ An 
inoculum of 20 cells was run in parallel, but the titre decreased over time. Significant 
observations from the above experiment were - (i) Initial loss of bacteria in the interim 
period of inoculation and extraction from samples in case of Ohr readings. (ii) When 20 
cells were used as inocula there was surprisingly inconsistent number of cells being 
retrieved from the mushroom ti ssues with increasing time. Inhibition of the BG 164R by 
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non-pathogenic bacteria, which forms the natural micro flora in mushroom tissues, was 
hypothesised to be the reason for such observations. 
5.3.3. Isolation of endogenous bacteria from mushroom tissue. 
Bacteria in button mushrooms were isolated and categorised prior to investigating the 
involvement of such endogenous mushroom bacteria in the initiation of Cavity disease. 
Three distinct colony types were observed in a preliminary identification of the bacteria 
present in the mushrooms (being supplied by a fixed farm in Christchurch). Quite 
naturally, the concentration of the three types of bacteria varied when extracted from a 
fixed weight of tissue samples arising from different sporocarps (Fig: 5.2). They were 
designated as PRC120, PRCl21 and PRC122. Distinguishing features of these three 
isolates are presented in Table 5.3. 
Character PRC120 PRC121 PRC12Z 
Colony Morphology Brown with a small Small, round, white White, round, 
papilla and transparent opaque 
Gram's Stain Negative Negative Negative 
Fluorescence Negative Negative Positive 
Oxidase Test 
(OX reagent in Negative Positive Positive 
API20NE) 
Antibiotic Sensitivity Amp lOo,Nal 15, Kan50, Strep 50, Kan50, Strep 50, 
Kan50, Strep 50, Tet 15Gent 30, Tet 15Gent 30, 
Tet 15Gent 30, Chl 30 Rif 50 ChI 30 Rif 50 
ChI 30 Rif 50 
Antibiotic Resistance Amp lOo,Na1 15 Amp lOo,Nal 15 
Table 5.3: Distinguishing features of three mushroom isolates 
The possible interactions of these bacteria with BG164R in the initiation of Cavity 
disease, was investigated in a number of ways. Firstly, sterilisation of mushroom 
sporocarps was attempted, with the intention of observing effects of BG 164R 
monoculture on it. Sporocarps were exposed to UV and Gamma irradiations but neither 
treatment proved to be effective. Sterilisation of mushroom tissues by soaking in 
rifampicin solution was also attempted and a marked reduction in the ability of BG 164R 
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to cause disease on mushroom pieces was noticed. But, due to problems associated with 
the re-appearance of endogenous strains of bacteria from mushroom over time from the 
rifampicin treated mushroom samples, the assay could not be entirely relied upon. 
Thereafter, experiments were designed using mixed populations of the indigenous 
bacteria and BG) 64R. 
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Fig 5.2: Relative abundance of endogenous bacteria present in mushroom sporocarps. 
5.3.4. Endogenous mushroom bacteria affect the initiation of Cavity disease . 
No disease symptoms appeared on mushroom slices challenged with mixed inocula 
containing BG 164R and PRC 120 in 1: 1 ratio (approx 107 cells for each type) . Mixed 
inocula containing one or more of the other bacterial isolates together with PRC 120 and 
BG 164R showed a marked reduction in disease intensity. Even after 3 days of 
incubation there was no sign of disease symptoms caused by BG 164R in the presence of 
PRCI20. This indicated that PRCI20 inhibited the virulence of BGI64R, which 
normally caused symptoms at a titre of 2.4x107 cells within 16hr (Table 5.2). The 
indication was confirmed by re-isolation of the total population of bacteria from 
mushroom tissues inoculated with mixed bacterial populations of PRC 120 and 
BG 164R. A marked reduction of the BG 164R population after 6hr of co-incubation 
with PRC120 was observed on the mushroom slices (Figure. 5.3.) , while the BG164R 
monoculture increased over time. However, since we have not been able to challenge 
sterile mushroom pieces with the mixed inocula, it is difficult to rule out the possibility 
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of other mushroom isolates, namely PRC 121 and PRC 122 also having a synergistic 
effect in the expression of Cavity disease . 
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Figure 5.3: Effect on population of BG164R on co-inoculation of with PRC120 on mushroom 
slices. 
5.3.5. Interaction between PRC 120 and BG 164R. 
The inhibition of BG J 64R by PRC 120 was further confirmed using an in vitro assay. In 
an overlay test (section 5.2.10), a lawn ofBG164R on minimal agar plate was inhibited 
by PRC 120 (Figure 5.4), thereby confirming the in vivo observation on mushroom 
slices reported in section 5.3.4. 
Figure 5.4: Inhibition of BG164R lawn by PRC120. [AJ Control colony, which does not inhibit 
the lawn, [BJ PRC120 creating a zone of inhibition on the lawn of BG164R. 
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5.3.6. Identification of the antagonist and other endogenous bacteria extracted from 
sporocarps of white button mushrooms. 
PRCI20, was identified as Ewingella americana, by its 16s rDNA sequencing. The 
other two isolates, namely PRCl21 and PRCI22, were identified as strains of 
Pseudomonas fluorescens. These results were further confirmed by Biolog tests done at 
the National Plant Pest Reference Laboratory, Ministry of Agricultural and Forestry, 
New Zealand. PRC120 was the first report of a New Zealand isolate of E. americana 
from mushrooms, and has been deposited in the New Zealand Culture Collection 
(accession number ofNZRM 4225). E. americana has been reported to be the causative 
agent of internal stipe necrosis in mushroom (Inglis et al., 1996a). Interestingly, 
PRC120 isolated from button mushrooms in New Zealand does not cause any necrotic 
symptoms on mushroom stipes or sporocarps and forms a natural population of 
microbial flora of the mushroom sporocarps. 
5.3.7. Interaction ofBG 164R with other phytopathogenic filamentous fungi. 
To identify whether the antifungal activity of the Cavity disease pathogen was restricted 
only to Fusarium oxysporum and Trichophyton sp. reported by Young (1992), a number 
of filamentous phytopathogens were tested by the antifungal assays on PDA plates 
because they best supported the antifungal activities of BGI64R BGl64R inhibited 
Fusarium oxysporum (wilt disease in plants), Fusarium so/ani (sudden death disease in 
soy bean), Gaeumanomyces graminis (Take-all disease in wheat, oat and barley), 
Phytophthora megasperma (root and stem rot of Alfalfa) and, Rhizoctonia solani 
(damping off and sheath blight of tobacco plants) (Figure 5.4.). The best and most 
drastic inhibition was observed in the case of Gaeumanomyces graminis and has been· 
used in all the assays to test the capacity of inhibition of filamentous fungi in all the 
genetic experiments described earlier. 
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Figure 5.5: Comparative suppression of Phytopathogenic fungi by BG164R. 
Mushroom mycelia were thereafter challenged with BG 164R. However the assay had to 
be done on Compost Malt Agar (Appendix 1), as it best supports the growth of 
mushroom mycelia. As expected, BG 164R clearly inhibited Agaricus mycelia too. 
5.3.8. The antifungal compound(s) is constitutively produced by BG 164R. 
To test whether the production of antifungal compound(s) by BG 164R was induced by 
the growing fungal mycelia (section 5.2.9), Gaeumanomyces graminis was challenged 
with antifungal compounds in the absence of live BG 164R cells (Figure 5.6.). Plugs of 
agar from around BG 164R, in"espective of whether it had the fungus growing around it, 
were able to inhibit the growth of Gaeumanomyces graminis. 
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Figure 5.6: Left: Control plate showing inhibition of 3 day old Gaeumanomyces graminis by 
BG164R.Right: Inhibition of BG164R with plugs of agar taken from three different plates. [A] 
Plug from plate with only BG164R growing on it. [B] Plug taken from zone of inhibition of fungus 
from the 3 day old assay plate. [C] Plug of agar taken from plate with only fungi growing on it. 
5.3.9. Does BG 164R inhibit common yeasts? 
Capacity of BG 164R to inhibit common yeasts such as Candida albicans, known for its 
ability to cause Candidiasis , and Saccharomyces cerevisiae, commonly known as 
Baker's yeast was tested by overlay tests (section 5.2.9) on PDA plates. 
Figure 5.7: Inhibition of Saccharomyces cerevisiae lawn by BG164R, and its products . [A] 
control PDA plugs, [B] colonies of BG164R ,[C] Plugs of PDA containing secretory products of 
BG164R. 
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S. cerevisiae inhibition was assayed (Figure 5.6.) by live bacteria as well as plugs of 
agar containing secretory products of BG 164R. In contrast, C. albicans failed to inhibit 
BG164R lawn. 
5.4. Discussion. 
The density-dependent induction of disease by BG 164R is a novel observation. In 
addition, the list of fungal phytopathogens that could be biologically controlled by of 
BG164R, has been extended beyond that reported by Young et al. in 1992. It has also 
been proved that the antifungal compound(s) involved in the inhibition of 
Gaeumanomyces graminis mycelia are constitutively produced by BG164R. The strain 
is also active against S. cerevisiae. 
It was initially predicted that if the inhibition of fungal mycelia was an effect of 
localised degradation of the growing mycelia tip by BG 164R, Cavity disease formation 
in mushrooms could also be affected by the same group of compounds. It was 
demonstrated, in section 2.3.14, that Cavity minus mutants can still inhibit fungal 
mycelia, especially the mushroom mycelia. It has also been demonstrated that 
antifungal-reduced mutants still cause the cavity on mushroom slices. This suggests that 
Cavity formation and inhibition of filamentous fungi are controlled by different groups 
of compounds. 
Isolation of a natural antagonist of BG164R from mushroom sporocarps supports the 
concept of the presence of 'Polymicrobial interactions' in the cap tissues in mushroom 
sporocarps. Polymicrobial interactions (Brogden & Guthmiller, 2003), as opposed to the 
conventional idea of a single pathogen causing a disease in a host, is an evolving 
concept (Casadevall & Pirofski, 1999, 2000). Mushroom diseases studied so far have 
only been attributed to single pathogens (discussed in the introductory chapter), 
although the presence of a range of non pathogenic bacteria in mushroom sporocarps is 
well known. Secondary infections by P. fluorescens have been noted in the case of 
internal stipe necrosis (ISN) caused by E. americana (Inglis et al., 1996a) and brown 
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blotch disease of mushrooms caused by P. tolaasii (Moquet et al., 1996), but this has 
not been claimed as the outcome of polymicrobial interactions. Although a similar 
interaction among pathogenic and non pathogenic forms of P. syringae on the 
phyllosphere in the formation of bacterial blight in soybean (May et al., 1997) has been 
reported, in general, there is a paucity of reports on the effects of polybacterial 
interactions in the formation of plant disease. Frequently reported examples of 
interactions in the formation of plant diseases are polyviral synergisms (Vance, 1991; 
Anjos et al., 1992; McKern et al., 1992; Pruss et al., 1997). 
Diseases in plants due to mixed viral infections are very common. Individual 
components of such infections act either synergistically or antagonistically in the 
expression of disease symptoms. A common example is the increased concentration of 
non-poty viral genomes and symptom expression in the case of mixed viral infections 
with poty viruses, as demonstrated by Pruss et al. (1997) and Anjos et al. (1992). 
Bacterial diseases of plants, in contrast, generally support the classical concept of 
disease formation by a single pathogen. It is likely, however, that some plant diseases 
are the results of interactions between a wide variety of bacteria dwelling in, or 
spreading through, the rhizosphere or phyllosphere. Therefore, when dealing with 
disease processes that are being expressed in a host, which has a microbial population of 
its own as in the case of mushrooms, it is difficult to distinguish between diseases 
caused by a single pathogen and those requiring interactions with other microorganisms 
in the immediate environment. 
Well known mushroom diseases such as brown blotch caused by P. tolaasii (Moquet et 
al., 1996), and ISN caused by americana (Inglis et ai., 1996b), also require very high 
inocula (108 cells) for the initiation of respective diseases, under test conditions. Inglis 
et al. (1996) mentioned a variation in the intensity of disease symptoms by E. 
americana and reported an interaction between P. fluorescens and E. americana in the 
formation of ISN of mushrooms. They also suggested a contributory role played by P. 
fluorescens in the expression of disease symptoms. Moquet et al. (1996) in their study 
of blotch disease observed a variation in the susceptibility of P. tolaasii to different 
species of mushrooms tested and reported a variation in the intensity of disease 
expression amongst the different species of mushrooms tested. These variations were 
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perhaps a reflection of polymicrobial interactions between pathogenic and the non-
pathogenic strains present in the sporocarps of different mushroom species. Initiation of 
Cavity disease expression involves an antagonism played by PRCI20, a natural 
mushroom isolate. If natural antagonists like PRCl20 were not present in nature, 
perhaps Cavity disease would be a very prevalent disease in mushroom industry. 
In the first publication on Cavity disease by Gill and Cole (1992) a variation in 
development of disease symptoms from mild to severe tissue necrosis was reported. 
However, no plausible explanation for such a phenomenon was put forward by them. 
Gill and Cole's observation has been confmned in the course of assays presented in this 
work and evidence is provided that the differential expression of disease symptoms 
could be explained in terms of the relative ablll1dance of PRC120 in an individual 
sporocarp sample or be due to the production of an antibiotic by PRC120 that targets 
BG 164R. This has been confirmed by in vitro and in vivo inhibition assays. 
Brogden and Guthmiller (2003), in a recent review on polymicrobial diseases, suggested 
that future research should be directed towards elucidating mechanisms of microbial 
interaction and disease pathogenicity in order to understand the molecular mechanisms 
of disease formation (Brogden & Guthmiller, 2003). Based on the observations 
presented in case of Cavity disease initiation it is tempting to suggest that mushrooms 
could be used as a model to study 'Polymicrobial interactions' and previous studies on 
mushroom diseases should be re-visited in order to explore the possible roles played by 
the indigenous mushroom bacteria in the expression of those diseases. 
BG164R has to overcome the initial inhibition by PRC120 prior to achieving successful 
establishment as a pathogen of mushrooms and, as a result, the inoculum has to be fairly 
high for expressing disease symptoms. Disease progression in nature starts from very 
few pathogenic cells acting as the inocula. The pathogen thereby goes through the 
stages of establishment and colonisation of the host tissue. Disease symptoms are 
displayed only after successful completion of the initial stages. This is, however, not 
observed in the case ofBG164R infections starting from 20-24 cells. As demonstrated, 
high inoculum of BG 164 R is the absolute requirement for initiation of Cavity disease in 
mushrooms, which is in contrast to the data presented by Atkey et al. (1992), with the 
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type strain RR3 of B. gladioli pv agaricicola. They showed the initiation of soft rot 
disease expression within 72hr with a low inoculum of 3-4 cells. Moreover, with an 
inoculum of 1000 BGl64R cells, mushroom samples exhibit disease symptoms after 
36h incubation. With an inoculum as high as 106 cells, BG 164R consistently produced 
Cavity disease symptoms within a significantly short time of 16hr, indicating that 
primary inoculum size plays a vital role in disease initiation. In the case of natural 
infections, initiation of Cavity disease would also be dependent on the presence of a 
high inoculum. Thus, chance factors involved in the presence of high inocula of 
pathogenic bacteria in nature and the presence of antagonists, like PRC120, are possible 
explanations for the sporadic occurrence of Cavity disease in the mushroom industry. 
Cell density-dependent gene regulation or 'quorum sensing', identified initially as 'co-
operative behavioural patterns' and exemplified by feeding and sporulation in 
inyxobacteria and actinomycetes, swarming motility of Vibrio parahaemolyticus and 
Proteus mirabilis (Fuqua et aI., 1994) has often been associated with the regulation of 
virulence genes (Lewenza et al., 1999; Anand & Griffiths, 2003; Jude et al., 2003). 
These systems regulate the production of virulence factors like protease, lipase and 
siderophore in the different species, thereby playing an indirect role in the pathogenesis 
of the bacteria. Besides the regulation of virulence factors, a number of other functions 
such as conjugation mediated by the tumour-inducing Ti plasmid of Agrobacterium, 
bio-Iuminescence of Vibrio fischeri, swarming motility in Serratia liquefaciens and 
antibiotic production in Erwinia carotovora, have been reported to be under the 
regulation of quorum sensing signals (Fuqua & Greenberg, 1998). In P. chlororaphis 
(PCL1391), an important biocontrol strain of tomato foot and root rot disease caused by 
Fusarium oxysporum, the production of the antifungal compound, phenazine-1-
carboxamide, has been demonstrated to be under the regulation of quorum sensing 
signals (Chin-A-Woeng et al., 2001). 
Pseudomonas aeruginosa has two quorum sensing systems, popularly known as the las 
(Pearson et al., 1995) and the rhl (Ochsner & Reiser, 1995) are present. The former is 
involved in the productions of signalling molecules known as N-(3-oxododecanoyl)-L-
homoserine lactone (HSL) and has been associated with the activation of a wide range 
of virulence genes and production of pyoveridine siderophores. The rhl system has N-
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butyryl-L-HSL as the signalling molecule and is involved in the activation of 
rhamnolipid synthesis genes and lasB genes, besides production of some secondary 
metabolites like pyocyanin, cyanide and chitinase (Whiteley et ai., 1999). Chapon-
Harve et al. (1997) have demonstrated that the type II secretion system of Pseudomonas 
aeruginosa, the xcp pathway, is involved in the production of virulence factors, and is 
under the control of both the las and the rhi quorum sensing systems (Chapon-Herve et 
al., 1997). Perhaps in case of Cavity disease too, the gsp system, which has been 
demonstrated to be involved in symptom production, is under the control of the quorum 
sensing signals. 
The quorum sensing systems identified in the different members of Burkholderia, are 
LuxR homologues and are known as cepl-cepR system in case of B. cepacia (Lewenza, 
1999) and bvil-bviR system in case of B. vietnamiensis (Conway & Greenberg, 2002). 
These systems have been demonstrated to regulate the production of virulence factors 
like protease, lipase and siderophore production of the strain. Interestingly, McKenny et 
al. (1995) reported an inter-specific communication between B. cepacia 10661 and P. 
aeruginoasa PAGI in the production of virulence factors of B. cepacia. They offered 
evidence of an increased amount of protease, lipase and siderophores in a rnidlog phase 
culture of B. cepacia in the presence of concentrated extracts from culture supernatants 
of P. aeruginosa (McKenny et ai., 1995). In the absence of data on the effect of 
BG164R on sterile mushroom tissue, the possible role of the other endogenous 
mushroom bacteria in the generation of such inducing signals can also not be 
eliminated. As presented in section 5.3.3 and figure 5.2, there is a consistently high 
population of P. fluorescence strains in mushroom pieces, and their role, if any, in the 
expression of disease is unknown. Perhaps, Cavity disease is also an effect of 
interspecies signalling between BG164R and P. fluorescence. Assays with refined 
conditions to sterilise mushroom tissues in future should lead to the identification of any 
involvement of interactions between the non-pathogenic endogenous mushroom 
bacteria and BG164R in the induction of Cavity disease. 
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Chapter VI 
Conclusions. 
6.1. Introduction. 
Burkholderia gladioli pv. agaricicola BGI64R, is a micro organism with the potential 
to cause severe disease on economically important crops such as the edible mushroom, 
A. bisporus. The objective of this research was to identify the molecular mechanism(s) 
by which BG164R expresses Cavity disease symptoms on button mushrooms. One of 
the key findings of this research is that the typeII secretion pathway is required for 
virulence ofBG164R in the expression of a mushroom disease. The consistent isolation 
of GSP mutants, with a 'no-cavity' phenotype, in more than one mutagenesis screening 
strongly suggests that toxin(s)/protein(s) secreted by the type II secretion pathway lead 
to the expression of disease symptoms. Gill and Tsuneda's proposal (1997), that Cavity 
disease is a combined effect of chitinase, glucanase and toxins, is enhanced with the 
additional finding that a putative polyketide synthetase gene product may be involved in 
pathogenesis. Cavity disease requires a fairly high inoculum of the pathogen at the 
initiation of colonisation of the host, which provides a competitive advantage to the 
pathogen over the antagonistic microflora present in the mushroom. Such high density 
of inocula is not very frequently encountered by the button mushrooms in commercial 
farms, where all conditions for cultivation are controlled. Thus, the sporadic occurrence 
of the disease can be explained by the variable outcome of the (initial) competition 
between endogenous mushroom bacteria and the pathogen in the initial colonisation of 
the mushroom. 
The main objective of this chapter will be to summarise the key findings, to outline 
models describing the steps involved in the formation of Cavity disease on mushrooms 
by BG164R and to discuss future directions of work on this project, including key tests 
of the models. 
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6.2. Summary of Results. 
The project was initiated with two broad objectives with respect to Cavity disease 
formation. First, to identify the Burkholderia gladioli genes involved in degradation of 
the mushroom tissue. Second, to describe the stages through which the pathogen 
successfully establishes itself on the host and causes the symptoms of Cavity disease. 
The present section discusses the project achievements in relation to these objectives (as 
described in section 1.5). 
Identification of BG164R genes involved ill the expreSSIOn of Cavity 
disease. 
An efficient bioassay was required to screen for mutants that could no longer cause 
disease. The mushroom bioassay system developed in the course of this study has been 
used to successfully isolate avirulent (no-cavity) mutants. The majority of BG164R 
mutants isolated on the basis of this bioassay have mutations in the different genes 
required for formation of the GSP apparatus of B. gladioli pv. agaricicola. This 
suggests that the Cavity disease process is dependent on the secretion of tissue 
degrading enzyme(s) via this type II secretion system. It is also likely that Cavity 
disease is a multifactorial process and therefore avirulent mutants are likely to be 
isolated only when a common system involved in the secretion of all these factors is 
blocked. Therefore, the bioassay system used may not have allowed detection of 
mutants with reduced cavity forming phenotypes resulting from absence of a single 
factor involved in the disease process. 
The assay also had other limitations: Firstly, mushroom tissues are neither sterile, nor 
colonised by identical populations of endogenous bacteria, which may result in variable 
disease outcomes. Secondly, transferring test bacteria with toothpicks created variability 
in the inoculum size, which might have masked isolation of mutants with reduced 
capacity to form cavities in the course of mutagenesis screenings. These factors need to 
be considered in any future attempts to isolate mutations in genes required for Cavity 
disease. 
Chapter VI 165 
Development of the bioassay was followed by the identification of the genetic markers 
present naturally in BG164 and establishment of an efficient mutagenesis system. 
BG164 was found to be rifampicin-sensitive. For practical reasons, a spontaneous 
rifampicin resistant mutant, BG164R, was isolated. BG164R was judged to be as 
virulent as its parent strain BG 164. The genes involved in the virulence of BG 164R 
were interrupted using a mini-Tn5KmlacZ2 mutagenesis system designed to generate 
random insertion mutants, which were phenotypically screened for expression of 
disease symptoms on mushrooms. Genes interrupted were identified by sequencing of 
genomic DNA adjacent to the transposon insertion sites. Prior to screening for no-cavity 
phenotypes, random integration of the transposon into the genome of BG164R was 
tested by the isolation of auxotrophic mutants, which resulted in 1.5% auxotrophs 
suggesting the randomness of transposition. The efficiency of the transposon to 
randomly insert into genes of B.gladioli is confirmed by the fact that the mutants 
isolated had mutations in different GSP genes involved in the formation of type II 
secretin, and that an antifungal-reduced mutant was also isolated using this mini-
Tn5KmlacZ2 mutagenesis system. Screening of 10,000 mutants for 'no-cavity 
phenotype' led to the isolation of 8 prototrophic GSP mutants. A second round of 
mutagenesis, in an attempt to isolate mutations outside the GSP region identified a 
putative polyketide synthetase gene as a candidate. 
The GSP has been shown to be required for Cavity disease, suggesting that proteins 
and/or toxins secreted by the GSP are responsible for cavity symptoms. The mutations 
identified were in gspE~ gspK, gspD, gspF, and the gspL genes of the type II secretion 
apparatus of B. gladioli pv. agaricicola, which prevent secretion ofthe virulence factors 
required for forming cavities on mushrooms. In the course of this project, analysis of 
the DNA sequences of sub-clones from the cosmid able to complement GSP mutants 
led to the identification of four more homologues of GSP genes, partial DNA sequences 
of which have been presented as Appendix III. 
A unique mutation in a gene that has significant sequence similarity to the polyketide 
synthetase (Pks) gene of Myxococcus xanthus was also isolated. An interesting feature 
of this mutant is that the mutation is complemented by the gsp operon-containing 
cosmid. The mutant, unlike the gsp mutants, secretes protease(s) in spite of not being 
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able to cause cavities on mushrooms. As discussed in Chapter IV, this putative 
polyketide synthetase gene may have a dual function. Polyketide synthetases, in 
general, participate in non-ribosomal peptide synthesis and act as modular type I 
polyketide synthases. Polyketides have a diverse range of functions, toxins being an 
example. It was demonstrated that the pks mutant still retains the capacity to inhibit 
fungal mycelia; thereby suggesting that the compound assembled by an enzyme 
produced by translation of the gene is not involved in the inhibition of fungal mycelia. 
Since non-ribosomal peptide synthesis is one of the functions of polyketide synthetases, 
it is also possible that the enzyme assembles a unique peptide product that is secreted by 
the GSP of BG 164R. 
Colonisation of mushrooms and expression of disease by BG 164 R. 
The final aim was to understand the host-pathogen relationships involved in the 
expression of Cavity disease. The strains comprising the endogenous microbial 
population present in the sporocarp of the mushroom have been identified. One of these 
endogenous strains, constantly present in the mushrooms, has been shown to be a 
natural antagonist of BG164R. The strain, PRC120, was isolated from mushrooms in 
New Zealand, for the first time. Other strains of this bacterium, identified as EwingeUa 
americana, have been reported to be the causative agent of internal stipe necrosis of 
mushrooms. However, the PRC120 isolate does not show any signs of causing necrosis 
on mushroom. In vitro plate assays (lawn tests) confirmed results obtained from in vivo 
assays on mushroom slices in which mixed populations ofBG164R and PRC120 clearly 
indicated inhibition ofBG164. This may explain why the disease occurs sporadically, as 
natural inocula of the pathogen, BG 164, may often be too low to overcome this 
inhibition and would therefore fail to colonise the mushroom tissues. 
Once the pathogen establishes itself on the host, it multiplies over a time and cause 
disease only when a certain quorum of cells is reached, as demonstrated in chapter V. 
Thus, expression of Cavity disease also appears to be dependent on a certain density of 
pathogenic cells on the mushroom tissues. Quorum sensing could lead to the expression 
of Cavity disease by: 
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a) Density-dependent induction of the gsp gene cluster resulting in the secretion of 
products, which cause Cavity disease. 
b) Induction of virulence genes, products of which are directly involved in the 
rapid degradation of the mushroom tissue. 
Tagging candidate genes with reporter genes like lux or lac systems and monitoring the 
expression of the reporter at lower concentrations of bacteria in the presence of culture 
extracts from spent cultures could be used to test these hypotheses. 
6.3. Models for Cavity disease formation by BG164R. 
The findings presented can be discussed in the context of three different models of 
Cavity disease process. In all models the mushroom sporocarps must be inoculated with 
a population of B. gladioli pv. agaricicola (BG164R) greater than 102 cells in order to 
overcome inhibition by the local flora, such as PRC120. This is the first step common to 
all three models after which each model is based on three distinct pathways leading to 
Cavity formation. It is worth noting that these possibilities are not mutually exclusive. 
Common Steps involved in the initiation of disease. 
}> Inoculation of mushroom sporocarps with a population of pathogenic 
BG164 cells capable of out-competing endogenous PRC120 populations. 
}> Competition of BG164 with PRC120 and the establishment of the 
BG 164 population on the mushroom sporocarps as the dominant 
population. 
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Model I: Quorum sensing-dependent formation of type II secretin. 
);> At a threshold concentration of cells, gsp genes are induced and 
BG 164 produces a functional type II secretin. 
);> Induction of tissue degrading enzymes by a polyketide derivative 
acting as an auto inducer. 
);> Formation of cavity/degradation of mushrooms. 
Model II: Secretion of the polyketide derivative and tissue degrading enzymes by 
GSP of Burkholderia gladioli. 
);> Tissue-degrading enzyme(s) are induced by a quorum sensing 
mechanism when BG164R cells reach a certain threshold 
concentration. 
);> Induction and secretion of both the tissue degrading enzymes and 
polyketide derived toxin(s) by GSP ofBG164R. 
);> Degradation of mushroom sporocarps by a combined action of all 
compounds. 
);> Formation of cavity/degradation of mushrooms. 
Model III: Quorum sensing-dependent activation of the polyketide synthetase 
gene. 
);> Polyketide synthetase gene induced by a quorum sensing mechanism 
when BG 164R cells reach a certain threshold concentration. 
);> The polyketide synthetase enzyme assembles a toxin, which ruptures 
the hyphal cell walls of the mushroom sporocarps leading to the 
exudation of cytoplasmic contents from ruptured fungal mycelia. 
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>- Induction of the genes responsible for translation of the tissue 
degrading enzymes of BG164R by compound(s) present in exudates 
liberated by the damaged mushroom mycelia. 
>- The GSP of BG 164R secretes one or all the mushroom degrading 
enzymes. 
>- Formation of cavity/degradation of mushrooms. 
6.4. Testing the models. 
Firstly, a bioassay less susceptible to variation would be an advantage for all aspects of 
the investigation of Cavity disease. One possibility would be to aseptically culture 
mushrooms for use in the bioassay. Once the bioassay conditions have been re-
standardised, further mutagenesis could be carried out in an attempt to identify 
additional genes involved in Cavity disease. 
Another important issue to be addressed is the isolation and identification of products 
that are secreted by the GSP of BG 164R and their role in the formation of Cavity 
disease process. The secretory mutants isolated during the course of this study are likely 
to be of use in the identification of the active components that take part in the 
degradation of the mushroom tissues. 
Testing Model I: 
The first point to resolve is the chemical nature of quorum sensing signals to which 
BG 164R responds in the formation of Cavity disease. If homoserine lactones, the 
common auto inducers in Gram-negative bacteria are involved, they can be detected by 
HPLC analysis of culture supernatants from spent cultures. Growing fresh BGl64R 
cells in presence of extracts from spent cultures could induce the production of active 
compounds at a much earlier stage of growth. Thus, isolation of active tissue degrading 
compounds from supernatants of young, actively growing cultures ofBGl64R grown in 
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presence of quorum signalling molecules extracted from spent cultures would indicate 
whether quorum sensing is involved in the disease process. 
To identify whether quorum sensing activates gsp genes specifically, the expression of a 
a reporter gene-tagged gsp mutant at various phases of growth in the presence and 
absence of extracts from spent culture supernatants and quorum signalling molecules 
could be monitored. Several mini-Tn5KmlacZ-generated gsp mutants isolated show 
active translational fusions to the promoter-less lacZ, which could be exploited in such 
assays. 
Testing Model II: 
A confirmed observation is the indirect involvement of a product produced by the 
putative polyketide synthetase in the expression of cavity disease, as mutants lose the 
capacity to form cavities on mushrooms. It is postulated that the secretion of the 
product( s) assembled by an enzyme produced by the putative polyketide synthetase 
gene is dependent on the GSP of Burkholderia gladioli. 
An interesting characteristic of Cavity disease, first reported here, is the ability of 
pCosGSP to complement the putative polyketide synthetase mutant, BGII-107. It is 
predicted that the 5kb DNA downstream of the gsp region in the cosmid harbours genes 
able to complement the mutation in BGII-I07. A strain of BG164R with mutations in 
both the gsp operon and in the putative polyketide synthetase gene would allow testing 
of this hypothesis. Also required would be a cosmid sub-clone of the 5kb DNA region 
containing the putative polyketide synthetase gene. Effects of such a double mutant 
strain on the mushroom slice in the presence of a sub clone of the cosmid polyketide 
synthase gene would help us to confirm the association of GSP in the secretion of 
product assembled by the enzyme produced by the putative polyketide synthetase gene. 
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Testing Model III: 
The lacZ reporter gene in the polyketide synthetase mutant, BOIl-I07, also forms an 
active translational fusion. The lacZ reporter gene can be used in assays as detailed 
above to test the quorum sensing-dependent activation of this gene. 
On the basis of DNA sequence similarity, it has been concluded that the mutation in 
BOlI-107 is in a putative polyketide synthetase gene. Firstly, the full sequence ofthe 
genomic DNA flanking the transposon insertion needs to be determined in order to 
locate the exact position in which the transposon has inserted. This would establish the 
authenticity of the mutation being in the putative polyketide synthetase gene. 
Sequencing using primers designed to read out from the ends of the transposon into the 
chromosomal DNA or, alternatively, primers based on the known DNA sequence could, 
be used to identify the transposon insertion point. 
To test the stepwise action of the toxin and the degradative enzymes, the individual 
active components need to be identified and, at least partially, purified. Effects of 
challenging sterile mushroom mycelia with the individual components and with various 
combinations of components to an actively growing culture of wild type BO 164R, 
should enable determination of specific auto inducers required for the activation of 
genes. 
6.5. Concluding remarks. 
Answers to the questions raised in this chapter should allow adoption of an appropriate 
model for the Cavity disease process. This project has provided major insights into the 
process of the rapid mushroom tissue degradation by BO 164R. In addition the basic 
biology and genetics of B0164R have been characterised, and methods for genetic 
manipulation of Burkholderia gladioli pv. agaricicola (B0164R) have been established 
in the course ofthis project. 
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MEDIA, ANTIBIOTICS AND SUPPLEMENTS 
(A) MEDIA: 
All media were made up in dH20 and autoclaved at 121°C for 20 minutes at 120kPa 
1. Luria Bertani media (LB). (Miller 1972) 
1 % w/v Bactotryptone 
0.5% w/v Yeast extract 
0.5% NaCI 
pH 7.0 
2. LBAgar 
LB media with 1.5% w/v agar 
3. M63 Minimal media. (Miller 1972) 
lOX M63 salt stock solution( autoclaved separately) 
1MKH2P04 
0.15M (NH4)S04 
0.018mM FeS04.7H20 
pH 7.0 with KOH pellets. 
M63 media. 
1XM63 media made by 1:10 dilution of 10XM63 stock salts in sterile dH20, 
followed by addition of sterilised 100 times concentrated stock solutions and made 
up to a final concentration of: 
0.02% MgS04 
0.0005% Thiamine 
0.2% Glucose 
4. M63 Minimal Agar. 
1XM63 media supplemented with 1.5% w/v agar 
5. Nutrient Agar. 
0.8% w/v Nutrient broth powder (GIBCO BRL) 
1.5% w/v agar. 
Appendtxl 
6. Kings 'B' Media. (King et al. 1954) 
2% w/v Bactotryptone 
65mM K2HP04 anhydrous 
60mM MgS04.7H20 
1.5% v/v Glycerol 
7. SOC Media (for electroporation). (Sambrook et al. 1989) 
2% w/v Bactotryptone 
0.5% w/v Yeast Extract 
10mMNaCI 
2.5mMKCl 
10mMMgCh 
20mM Glucose 
8. Potato Dextrose Agar. 
PDA Oxoid as per manufacturer's instruction 
3.9g/L of dH20 
9. Motility Agar. 
0.1% w/v Bactotryptone 
0.05% w/v Yeast Extract 
0.5% w/v NaCI 
0.3% w/v Agar 
10. Milk Agar (protease plates). 
Solution A: 1 % skimmed milk solution 
Solution B: 0.8% Nutrient Broth Powder 
1.5% Agar 
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The solutions were separately sterilised, cooled to about 55°C and mixed in a 
proportion so as to make a final concentration of 0.1 % skimmed milk solution in 
0.8% Nutrient broth agar. 
11. Water Agar. 
1.5% w/v agar in distilled water. 
12. Chitin Agar. 
1 % Chitin extract mixed in equal volumes with 2X Nutrient Agar. 
10mL overlayed onto pre-made Nutrient agar plates. 
Appendix 1 
Preparation of 1 % Chitin extract. 
(a) Sg Chitin dissolved in 200mls of 8S% Phosphoric acid for 72hr at 4°C. 
(b) Dissolved chitin was washed three times in water by adding 2.SL water, 
followed by stirring and precipitating chitin each time. 
(c) The pH of the dissolved chitin was adjusted to 6.8 with NaOH; 
(d) Washed three times with water. 
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(e) After the final wash, chitin was precipitated by centrifugation and resuspended 
I water to make a final solution of 1 %. 
(f) Autoc1aved and stored at 4°C. 
13. Compost Malt extract agar. 
0.7S% Malt extract (Oxoid) 
1.5% Agar 
100mL Sterile Compost Infusate. 
pH adjusted to 7.4 with leN) NaOH. 
Autoclaved . 
Preparation of Sterile Compost Infusate. 
(a) 5% w/v oven dried commercially prepared mushroom compost left to infuse in 
water for 1hr. 
(b) Temperature was raised to lOO°C for 5min to remove microbial matrix and 
stirred vigorously. 
(c) The mixture was left aside for further 2hr, cooled and filtered through four 
layers of muslin cloth. 
(d) Autoclaved twice. 
14. Mushroom juice extract media. 
10% w/v Fresh mushroom sporocarp tissue from young mushrooms macerated in 
sterile distilled, decanted through nappy liner and autoclaved immediately. 
IS. Mushroom juice extract Agar media. 
Mushroom juice extract media supplemented with I.S% w/v agar. 
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(B) ANTIBIOTICS AND SUPPLEMENTS: 
The following concentration of antibiotics and supplements were added to bacterial 
cultures on Agar plates or broths, unless otherwise stated, either to maintain selective 
pressure or to identifY strains and constructs. 
Ampicillin 
Chloramphenicol 
Gentamicin 
Kanamycin 
Nalidixic acid 
Streptomycin 
Tetracycline 
Rifampicin 
5-bromo-4-chloro-3-indoyl-~ 
-D-galactopyranoside 
(Ap) 
(Cm) 
(Gm) 
(Km) 
(Nal) 
(Strep) 
(Tet) 
(Rif) 
(Xgal) 
100f-tg/mL in glass dH20 
15f-tg/mL in 100% Ethanol 
30f-tg/mL in glass dH20 
50f-tg/mL in glass dH20 
30f-tg/mL in 0.05M KOH solution 
50f-tg/mL in glass dH20 
15f-tg/mL in 100% Methanol 
50f-tg/mL in Dimethylsulfoxide 
25f-tg/mL in Dimethylfonnarnide 
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Appendix!! 
BUFFERS AND REAGENTS 
I. GENERAL BUFFERS AND SOLUTIONS 
TloEl (TE) 
10Mm Tris- HCI 
hnMEDTA 
In dH20, pH adjusted to 8.0 
TAE 
50mM Tris base 
1 tnMEDTA 
0.11 % v/v Glacial acetic acid 
In dH20, pH adjusted to 8.0 
DNA loading buffer for agarose gei electrophoresis 
30% glycerol 
0.25% Bromophenol blue 
0.25% Xylene cyanol FF 
l0f.l.mrl RNAase 
SPECIFIC BUFFERS AND SOLUTIONS 
Alkaline Lysis Preparation of PlasmidiCosmid DNA 
Solution I (Stored at 4°C) 
1 % w Iv glucose 
25tnM Tris- HCI, pH 8.0 
10MmEDTA 
Solution II (prepared fresh) 
l%SDS 
0.2NNaOH 
Solution III (stored at 4°C) 
3M Potassium acetate 
8. 7% v/v Glacial acetic acid 
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Genomic Preparation of DNA 
GES solution 
5M Guanidium thiocyanate 
100mM EDTA, pH 8.0 
20% v/v dH20 
Heat at 65°C until dissolved. 
Add 0.5% N-Iaurylsarcosine (from 10% solution). 
Make up to volume with dH20 and filter through 0.45f-lm filter 
Silver Staining Solutions for Protein Gel Electrophoresis 
Wash Solution I 
50% Methanol 
10% Acetic Acid 
40% dH20 
Wash solution II 
10% Gluteraldehyde 
90%dH20 
Staining Solution 
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Reagents added according to the order presented with continuous stirring. If at 
any stage the colour of the solution went brown the solution was titrated back 
by adding NH40H drop wise until clear. 
0.3% NaOH 
Concentrated NH40H 
O.2g/mL stock of AgN03 in H20 
100% Ethanol 
Developing Solution 
1% Ethanol 
0.25% Citric Acid solution (1%) 
0.025% Fonnaldehyde (38%) 
98.725% dH20 
Fixing Solution 
5% Acetic Acid solution 
95% dH20 
15.3mL 
1.03mL 
3mL 
55mL 
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Lysis buffer for Protein sample 
2%SDS 
1M Tris (pH 6.8) 
4% ~-mercaptoethanol 
0.05% Bromophenol Blue 
10% Glycerol 
Solutions for Southern and Colony Hybridization 
Depurination solution (DNA blotting) 
0.25NHCI 
Denaturation solution (DNA blotting) (Freshly prepared) 
O.4NNaOH 
20 x SSC (stored at 4°C) 
3M NaCI 
0.3M Na3Citrate 
In dH20, pH adjusted to 7.0 
Denaturating Solution (Colony Hybridisation)(Freshly prepared) 
0.8gNaOH 
28mLdH20 
12mL NaCI soh~tion (5M) 
Neutralisation Solution (Colony Hybridisation)(Freshly prepared) 
40ml Tris-HCI (1M) 
24mL NaCI solution (5M) 
16mL dH20 
Solution to remove excess debris in Colony hybridisation 
3XSSC 
0.1% SDS 
Pre-Hybridization buffer 
9mL SSC 
1.5mL Denhardt's solution 
1.5mL SDS (10%) 
o .15mg Blocking reagent 
18mL dH20 
196 
Appendix II 
Hybridization buffer 
Pre-hybridisation buffer with 200Kcpm (per 30mL buffer) labelled probe 
Low stringency wash buffer 
0.1% SDS 
2xSSe 
Medium stringency wash buffer 
Ix sse 
OJ%SDS 
High stringency wash buffer 
0.1% SDS 
OJxSSe 
Sequencing 
lOx THE 
890mM Tris base 
890Mm Boric acid 
20Mm Na2EDTA.2H20 
Sequencing Gels 
31.Sg Urea 
36ml dH20 
6ml SO% Long Ranger Gel solution 
9mllOx TBE 
SOO~llO% APS (made fresh) 
SOIlI TEMED 
197 
Appendix III 198 
Appendix III 
PRIMERS USED AND DNA SEQUENCES 
A. Primers used. 
T7 promoter 5' GTAATACGACTCACTATAGGGC 3' 
T3 promoter 5' AAT TAACCC TCACTAAAGGG 3' 
B. Sequences flanking transposon insertion points. 
1) pSPRC12, T7 end. 
CGGCTCGGTGCCGAACACGATGCGATGCACTTCGGTGTCGGAGCCGGGATAGTCGATGG 
TCGCGCCGGTCACGCCGCCGTCCCAGTTGCGCGGCCGGAACAGGTCGTCGCGCASGCGC 
CAGCGTCCTCGCCGCGCACGTCGAAGCGGAACGCGTTGTCGGTGGGCTGCCAGGCGATC 
GGCCGCGCGCGCACCTGCSTCGTCGCCGGCGCTCTCGAGCAGCAGCGCCACTCGCTGGG 
CTTCCTCGCGCAGGTCGGTGCGATTGCGATGCATGGTCAGCGTGGCCGCCGACACGAGG 
ATCCCCGCGATCACGAGCACGACGAGCATCTCGAGCAACGTGAAGCCACGCATCCGCCG 
GGGSAAACGCAGCGAGGTCGTGCCGGTGGTTCGCATGTCAAACGAAACTGACCAAGAGG 
GAAGGGACGGGCGGTGCGATCCGATGCGCCGGGCTTACTGCCAGGAACCGATGTCGGCG 
TCGTTGTTCTCGCCGCCTTCCTTGGCGTCGGCGCGTAGCTGAACACGTCGATCTCGCCG 
TGCACGCCCGGGTTCAGGTACTTGTACGGGTTGCCCCAGGGATCGTTGGGCAGGCGCTC 
GAGGTAGCCGCCGTCCTTCCAGTTGTTCGGCACCGGATCGGTGGTGGGCTTGGCGATCA 
CGATTGCAGGCCCTGCTCCTGGGTCGGATAGCGGCCGTTGTCGAGGCGGTAGAGCTTGA 
2) pSPRC12, T3 end. 
GGCACGCTGCGACCGTGGTGCGGCCCAAGAAGGCCTGCACGGCGCGCTGATCTCGCGGA 
TCAAGATCATGGCGCACGACATCGCCGAGAAACGCCTGCCGCAGATGGCCGGATCACGC 
TGCGGCGGCGCCGGTGGACGTGCGGGTCTCGACGCTGCCCACCGGCCACGCGAGCGCGC 
GGTGCTGCGTCTGCTGGAAAAGGATGCGCGCCTGAACCTCGAGGCGCTCGGCATGGGCC 
GACACGCTGGTGCAGTTTGACAAGCTGATCGGCCGCCCGCACGGCATCGTGTGGTCACC 
GGCCCGACCGCTCGGAAGACCACCACGCTCTACGCGGCGATGTCGCGCTGGAGACGGCC 
ACCACCAACATCATGACGGTCGAGGATCCGATCGAATACTACCTGTCCGGCATCGGCCA 
GACGCAGGTGAACGAGCGGATCGGCATGAGCTTCGCGCGCGCTGTCTCGATCCTGCGCC 
AGGTCCGGACGTTTCATATCGGCGAAATCCGCGATCTGGAAACCGCGCAGATCGCCGTG 
CAGCTCGCT 
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3) pSPRC40, T7 end. 
CGTGCTGTGCGACAACGGCGAGATCATCGTGCTCGGCGGCCTGATGCAGGACAACTACC 
AGGTCAGCAACAACAAGGTGCGCTGCTCGSGACATCCCGTGGATCGGCCAGTTGTTCCG 
TTCGGAAGGCAAGCAGCGCCAAGACCAACCTGATGGTGTTCCTGCGCCCGGTGATCCTC 
AGCGACCAGGCCACYACCCAGGCCGTCACCGCGAACCGCTACGACTACATCAGGGCGTG 
CAGGGCGCGTACAAGTCCGACAACAACCTGATCGCGACAAGGACGACCCGGTGGCGCCG 
CGATGCCGCTYGGGCCGACAGGGCGGGCGCGGCCGCGAACCTGTTCGACCTGACGCGCA 
TGACGCACCCCGGTTATCGGCCCTCTCGCAGCGCACCGACCAACGTGCCGGCTCCCGCG 
GTGGCCAC 
4) pSPRC40, T3 end. 
CTCGCCTTCCACCTCGCCGACCACCTGCGCCGCGCTGCCGTCCTGGCGCATAGGGTGTT 
GATGCTGACTCTTATACACAAGTGCGGCCGCCGCGTTTAATGACCAGCACAGTCGTGAT 
GGCAAGGTCAGAATAGCGCTTAGGTCTGCTCGTGAAGAAGTGTTGCTGACTCATACCAG 
GCCTGAATGCCCCATCATCCAGCCAGAAAGTGAGGGAGCCACGGTTGATGAGAGCTTTG 
TTGTAGGTGGACCAGTTGGTGATTTTAACTTTTGCTTTGCCACGGAACGGTCTGCGTTG 
TCGGGAAGATGCGTGATCTGATCCTTCAACTCAGCAAAAGTTCGATTTATTCAACAAAG 
CCGCCGTCCCGTCAAGTCAGCGTAATGTCTCCAGTGTTACAACCAATTACCAATTCTGA 
TTAGAAAAACTCATCGAGCATAAA 
5) pSPRC88, T7 end. 
TCCTGCTCGACGTCAACGGCGTGACGCCGAGATCGTCGAGAAGCTGCGGCCCTTCGTGA 
CGGTGCTGCCGTCCACCACGCCGGTCAACCTCAATACTGTCTCTTGATCAGATCTGGCC 
GCCTACGAATTCCCGGGGATCCCGTCGTTTTACAACGTCGTGCTGGGAAAACCCTGGCG 
TTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCCAGCTGGCTAATAGCGAAGAG 
GCCCGCACCGATCGCCCTTCCCAACAGTTGCGCACGCTGAATGGCGAATGGCGCTTTGC 
CTGGTCCGGCACCAGAAGCGGTGGATAGCTGGCTGGAGTGCGATCTTCCTGAGGCCGAT 
ACTGTCGTCGTCCCCTCAAACTGGCAGATGCACGGTTACGATGCGCCCATCTACACCAA 
CGTGACCTATCCCATTACGGTCAATCCGCCGTTTGTTCCCACGGAGAATCCGACGGGTT 
GTTACTCGCTCACATTTAATGTTGATGAAAGCTGGCTACAGGAAGGCCAGACGCGAATT 
ATTTTTGATGGCGTTAACTCGGCGTTTCATCTGTGGTGCAACGGGCGCTGGGTCGGTTA 
CGGCCAGGACAGTCGTTTGCCGTCTGAATTTGACCTGAGCGCATTTTTACGCGCCGGAG 
AAAACCGCCTCGGGATGGTGCTGCGCTGGAGTGACGGCAGTTATCTGGAAGATCAGGAT 
ATGTGGCGGATGAGCGGCATTTTCCGTGACGTCTCGTTGCTGCATAAACCGACTACACA 
AATCAGCGATTTCCATGTTGCCACTCGCTTTAATGATGATTTCAGCCGCGCTGTACTGG 
AGGCTGAAGTTCAGATGTGCGGCGAGT 
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6) pSPRC88, T3 end. 
GAGCGCGAACGACACGCATTGCACTCGGCCAGCCGGCGGTTCGCGCGGGCAAAACAACA 
ATCAACGTGCTCAAGAGCTCCTCTCCCGGATGGCGTTGTTATAGCTGATCGGAACCCGG 
ACCACGCGCGTGTGTGCGTGTTGGGGTCACGATACACGAGCGAGGTGCGGTCGATTTCC 
GCGCGCCCGTGCTCAATATGACCGTGAACGATGAAATAACTGGACGTCACGTCGATCTG 
GGTCGGGTCCAGCAGCGTGTTCGGCACSCGGTGGCCTGCAGCGCGACTGCATCGCCGAC 
GTTGCGGAAGAACACGTTCTCGCGTCGCCACCAGCGTCTGCGCGGAGGACACCGAGAGC 
CCCGGCAGCAGCGCGCGATCACCTCGGCGCGCGGTATTGAGGCTGACTCTTATACACAA 
GTGCGGCCGCCGCGTTTAATGACCAGCACAGTCGTGATGGCAAGGTCAGAATAGCGCTG 
AGGTCTGCCTCGTGAAGAAGGTGTTGCTGACTCATACCAGGCCTGATGCCCCATCATCC 
AGCCAGAAAGTGAGGGAGCCACGGTTGATGAGAGCTTTGTTGTAGGTGGACCAGTTGGT 
GATTTTGAACTTTTGCTTTGCCACGGAACGGTCTGCGTTGTCGGGAAGATGCGTGATCT 
GATCCTTCAACTCAGCAAAAGTTCGATTTATTCAACAAAGCCGCCGTCCCGTCAAGTCA 
GCGTAATGCTCTGCAGTGTTACAACCAATTAACCAATTCTGATTAGAAAAACTCATCGA 
GCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTT 
7) pSPRC87, end. 
ACCACCGAGGAATCCTCGTGTGAGATCTGCAGCTTCAGGATGCCGCCCTCGGTGATCTG 
CGGCTTGACGTGCAGGGTCAGGCCGACGTCTTGGCGGTCGAAGGTATTGAAGGCGTTGC 
TGTTGCTGCCGCTGGTCAGGTTGGCATACGAACCGGTCGCGATCGGCACGTTCTGGCCC 
ACCACGATCTTCGCTTCCTCGTTGTCGAGCGTGACCAGGTTAGGCGTGGACAGCACGTT 
CGCGTCGGTGGTGCCCGAGAAGGCCTGCAGCAGGGCGCCCAGGCCAGTGATGCCGAACA 
TGTTCTTGAGCCAGCCGATGTTCAGGCCCGGCGTCAGCGCCCTTTGGCATAAGCGTGCG 
CGTTTGGTGGAATAAAAGGGA 
8) pSPRC87, T3 end. 
ACCACCGAGGAATCCTCGGTAGATCTGCAGCTTCAGGATGCCGCCCTCGGTGATCTGCG 
GCTTGACGTGCAGGGTCAGGCCGACGTCTTGGCGGTCGAAGGTATTGAAGGCGTTGCTG 
TTGCTGCCGCTGGTCWGGTTTTCATACGAACCGGTCGCGATCGGCACGTTCTGGCCCAC 
CACGATCTTCGCTTCCTCGTTGTCGAGCGTGACCAGGTTAGGCGTGGACAGCACGTTCG 
CGTCGGTNGTGCCCGAGAA 
9) pSPRC787, T7 end. 
CGTGCTGTGCGACAACGGCGAGATCATCGTGCTCGGCGGCCTGATGCAGGACAACTACC 
AGGTCAGCAACAACAAGGTGCCGCTGCTCGGCGACATCCCGTGGATCGGCCAGTTGTTC 
CGTTCGGAAGGCAAGCAGCGCGCCAAGACCAACCTGATGGTGTTCCTGCGCCCGGTGAT 
CCTCAGCGACCAGGCCACCACCCAGGCCGTCACCGCGAACCGCTACGACTACATCCAGG 
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GCGTGCAGGGCGCGTACAAGTCCGACAACAACCTGATCCGCGACAAGGACGACCGGTGG 
CGCCGCGATGCCGCTCGGGCCGAGCCAGGGCGGGCGCGGCCGCGAACCTGTTCGACCTG 
ACGCGCATGACGCACCCCCGGTTATCCGCCGCGCCGCAGCGCACCGACCAACGTGCCGG 
CTCCCGCGGTGGCCACGCGACGGTGAACCCCGCGCCGATGCCCGCGCCCGCCGTCACCA 
CGAGGTGCCGACGCCTGGCCTGACCAGCCAGCCCGGAGCGCACGTGAACGAGCCCGTGC 
GCGATGCAGCGACCAGCGAGGGGCCGTCGGATCGCTGCTCGCCTGCTGCCCTACGGCTT 
CGCAAGGCCGGCCAGATCCTGGTCGCGCAAGGACGGCGAGGCGATCGAGGTCTGGATCA 
GCGATCGCAACCGACGCCGCGCTGGCCGAGGTGGCACGCAACTTCGGCGCGTTGANCGC 
CGGCTGCGCCGACGAGCTCGCGCAGGCCATCAACAC 
lO)pSPRC787, T3 end. 
CTCGCCTTCCACCTCGCCGACCACCTGCGCCGCGCTGCCGTCCTGGCGCATAGGGGTGT 
TGATGCTGACTCTTATACACAAGTGCGGCCGCCGCGTTTAATGACCAGCACAGTCGTGA 
TGGCAAGGTCAGAATAGCGCTGAGGTCTGCCTCGTGAAGAAGGTGTTGCTGACTCATAC 
CAGGCCTGATCGCCCCATCATCCAGCCAGAAAGTGAGGGAGCCACGGTTGATGAGAGCT 
TTGTTGTAGGTGGACCAGTTGGTGATTTTGAACTTTTCTTTGCCACGGAATCTGCGTTG 
TCGGGAAGATGCGTGATCTGATCCTTCAACTCAGCAAAAGTTCGATTTATTCAACAAAG 
CCGCCGTCCCGTCAAGTCAGCGTAATGCTCTGCCAGTGTTACAACCAATTAACCAATTC 
TGATTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTAT 
CAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAG 
TTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAAT 
ACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAG 
TGACGACTGAATCCGGTGAGAATGGCAAAAGCTTATGCATTTCTTTCCAGACTTGTTCA 
ACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCAT 
TCGTGATTGCGCCTG 
11)pSPRC147, T7 end. 
TCCTGCTCGACGTCAACGGCGTGACGCCCGAGATCGTCGAGAAGCTGCGGCCCTTCGGT 
GACGGTGCTGCCGTCCACCACGCCGGTCAACCTCAATACCTGTCTCTTGATCAGATCTG 
GCCGCCTAGGCGGAATTCCCGGGGAGTCCCGTCGTTTTACAACGTCGTGACTAGGAAAT 
CCCTGGYGTTACCCAACTTAA 
12) pSPRC147, T3 end. 
AGCGCGAACGACAGGCGCATTGCACTCGSCAGCGRCGGCSTTCGCGCGGGGCAAAACAA 
CAATCAACGTGCTCAAGAGCTCCTCTCCCGGATGGCGTTGTTATAGCTGATCGGAATCC 
CGGGGACCACGCGCGTGTGTGCGTGTGGGGTCACGATACACGAGCGAGGTGCGGTCGAT 
TTCCGCGCGCCCGTGCTCAATATGACCGTGAACGATGAAATAACTGGACGTCACGTCGA 
TCTGGGTCGGGTCCAGCAGCGTGTTCGGCATCGCCGACGTTGCGGAAGAACACGTTCTC 
GCGTCGGCCACCAGCGTCTCGGAGGACACCGAGAGCCCCGCAGCAGCGCGGCGATCACC 
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TCGGCGCGCGCNGTATTTACTGACTCTTATACACAATCGTCTNTCGTTTAATGACACAC 
ATTGTTATGGCAATCAGATATTTTGAGTCTCTCCTCAAGAACTCTTTTGACTCATACCA 
GTCTATCCCCATCATCCATCCAGAAATATAACCACTTGATGATACTTTTTTATGACCAT 
TCGTATTTTAACTTTTTGTTTTACGGAACGTCTTTTCGGGAAGACTGATCTATTTCAAC 
TTAAAAAATTCATTTATTTAACAAAGGCGCCC 
13) pSPRCI05, T7 end. 
CTGTCGCGGCTGATGCAGGACATCCCGGAAGTCGAGGACCTGCTGGAATCGGAGGACGA 
CGCGCCGATCATCCGCATGATCAACGCCCTGCTCACCCAGGCCGCGCGCGAAGGCTTCC 
GACATCCACATCGAGCCCTTCGAGAACGCCTCGGTCTGTCTCTTGATCAGATCTGGCCG 
CCTACGAATTCCCGGGGATCCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCG 
TTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCCAGCTGGTAATAGCGAAGAGG 
CCCGCACCGATCGCCCTTCCCAACAGTTGCGCGCTGAATGGCGAATGGCGCTTTGCCTG 
GTTTCCGGCACCAGAAGCGGTGAGCTGGCTGGAGTGCGATCTTCCTGAGGCCGATACTG 
TCGTCGTCCCCTCAAACTGGCAGATGCACGGTTACGATGCGCCCATCTACACCAACGTG 
ACCTATCCCATTACGGTCAATCCGCCGTTTGTTCCCACGGAGAATCCGACGGGTTGTTA 
CTCGCTCACATTTAATGTTGATGAAAGCTGGCTACAGGAAGGCCAGACGCGAATTATTT 
TTGATGGCGTTAACTCGGCGTTTCATCTGTGGTGCAACGGGCGCTGGGTCGGTTACGGC 
CAGGACAGTCGTTTGCCGTCTGAATTTGACCTGAGCGCATTTTTACGCGCCGGAGAAAA 
CCGCCTCGGATGGTGCTGCGCTGGAGTGACGGCAGTTATCTGGAAGATCAGGATATGTG 
GCGGATGAGCGGCATTTTCCGTGACGTCTCGTTGCTGCATAAACCGACTACACAATCAG 
CGATTTCCATGTTGCCACTCGCTTTAATGATGATTTCAGCCGCGCTGTACTGGAGCTGA 
AGTTCAGATGTGCGGCGAGTTGCGTGACTACCTACGGTA 
14) pSPRC105, T3 end. 
GCGTCAGCCACCGAGGCGCTGACTCTTATACACAAGTGCGGCCGCCGCGTTTAATGACC 
AGCACAGTCGTGATGGCAAGGTCAGAATAGCGCTGAGGTCTGCCTCGTGAAGAAGGTGT 
TGCTGACTCATACCAGGCCTGATCGCCCCATCATCCAGCCAGAAAGTGAGGGAGCCACG 
GTTGATGAGAGCTTTGTTGTAGGTGGACCAGTTGGTGATTTTGAACTTTTGCTTTGCCA 
CGGAACGGTCTGCGTTGTCGGGAAGATGCGTGATCTGATCCTTCAACTCAGCAAAAGTT 
CGATTTATTCAACAAAGCCGCCGTCCCGTCAAGTCACGTAATGCTCTGCCAGTGTTACA 
ACCAATTAACCAATTCTGATTAGAAAAACTCaTCGAGCATCAAATGAAACTGCAATTTA 
TTCATATCAGGATTATCAATACCATATTTTTGAMAAGCCGTTTCTGTAATGAAGGAGAA 
AACTCACCGAGGCAGTTCCATAGGATGGCAAGCATCCTGGTATCGGTCTGCGCATTCCG 
ACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAGGTTATCAAGT 
GAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGCTTATGCATTTC 
TTTCCAGACTTGTTCAACAGGCCAGCCATTAGCTCGTCATCAAAATCACTCGCATCAAA 
CAAACCGTTATTCATTCGTGATTGCG 
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15)pSPRC106, T7 end. 
TCTCTGCTCGACGTCAACGGCGTGACGCCGAGATCGTCGAGAAGCTGCGGCCCTTCGTG 
ACGGTGCTGCCGTCCACCACGCCGGTCAACCTCAATACCTGTCTCTTGATCAGATCTGG 
CCGCCTACGAATTCCCGGGGATCCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTG 
GCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCCAGCTGTAATACGAAGAG 
CCCGCACCGATGCCCTTcCCAACAGTTGCGCAGCTGAATGGCGAATGGGCTTTSCCTGG 
TTTCCGGCACCAGAAGCGGTGGTAGCTGGCTGGAGTGCGATCTTCCTGAGGCCGATACT 
GTCGTCGTCCCCTCAAACTGGCAGATGCACGGTTACGATGCGCCCATCTACACCAACGT 
GACCTATCCCATTACGGTCAATCCGCCGTTTGTTCCCACGGAGAATCCGACGGGTTGTT 
ACTCGCTCACATTTAATGTTGATGAAAGCTGGCTACAGGAAGGCCAGACGCGAATTATT 
TTTGATGGCGTTAACTCGGCGTTTCATCTGTGGTGCAACGGGCGCTGGGTCGGTTACGG 
CCAGGACAGTCGTTTGCCGTCTGAATTTGACCTGAGCGCATTTTTACGCGCCGGAGAAA 
ACCGCCTC 
16) pSPRC106, T3 end. 
GAGCGCGACACAGTCGCATTGCACTCGCAGCCAGCGGCSGTTCGCTGCGGCAAAACAAC 
AATCAACGTGCTCAAGAGCTCCTCTCCCGGATGGCGTTGTTATAGCTGATCGGAACCCG 
GACCACGCGCGTGTGTGCGTGTGGGGTCACGATACACGAGCGAGGTGCGGTCGATTTCC 
GCGCGCCCGTGCTCAATATGACCGTGAACGATGAAATAACTGGACGTCACGTCGATCTG 
GGTCGGGTCCAGCAGCGTGTTCGGCACSCGGTGCTGCAGCGCGACTCATCGCCGACGTT 
GCGGAAGAACACGTTCTCGCGTCGCCCACCAGCGTCTGCGCGAGGACACCGAGAGCCCC 
GGCAGCAGCGCGCGATCACCTCGGCGCGCGTATTGAGGCTGACTCTTATACACAAGTGC 
GGCCGCCGCGTTTAATGACCAGCACAGTCGTGATGGCAAGGTCAGAATAGCGCTGAGGT 
CTGCCTCGTGAAGAAGGTGTTGCTGACTCATACCAWGCTGAWTHTCCCCATCATCCAGC 
CAGAAAGTGAGGGAGCCACGGTTGATGAGAGCTTTGTTGTAGGTGGACCAGTTGGTGAT 
TTTAACTTTTCTTTGCCACGGAAC 
17)pSPRC107, T7 end. 
GGGGCGCTTGGCGCGCAGCTCTCGSCGCSGGCGCGTGGCAGACGGGCGATCGGCCATCG 
TCTCGCGATGSTCTCGACCAGATAAGCCGTGAGCGCCGCCAGCGTCGGATGCTCGAAGA 
ACACCGTCGGCATCAGATCCAGTTCGTAGGTGCGATTCAATTCGGTGGCCAGTTCAGTC 
AGCGAGATCGAGTCGAAGCCATAACCGGCCAGCTCCTCGTCGAGATCGATGTCCTCGGG 
CTTCACCTTGATCAAGGCAGATACGCGGCTCAAGAGCGCCGCTCCGACCACGCGCGACA 
GATCAACCCCGGCACCGGCGCTGCTGCGGCGGCACGACGGCTTCGGTCGTGTCTTCGTC 
GGCCTGGTCCCCGGCCGTGcAACAGCGCGAcAGCTTCTCGCGTCGCCCGCCGCCACCAG 
CACCTGCGCCGCATCGCCCGTCACCGCCTGCGCGAACGCCGCCAGTGCCGCCTCGTTCT 
CCAGCGGCACCAGCCCGCCGTGACGCATCAGCTCGACGCTCGCCGCGTCCGGACGCATC 
GCCCCCTGCGCCCACAACGGCCAGTTCACCGACACGCTGCGCCCGCTCGCCTCGCCACG 
CGCCACACGCTCGGSSGAGTATCACATAGTGATCCATGAACGCGTTCGCCGCCGCATAG 
TCCGCCTGACCCGGATTGCCTCCATAACCCGCCAGCGACGAGAACGTCACGAACAACTC 
Appendix III 204 
CAGCGGCACATCGCGCGTACCCGATCCAGGTTCACGACACCCGCCACCTTCGGTGCCAG 
CACCGTCCAGTTCCGCCACGCTCTTGTT 
18) pSPRC107, T3 end. 
GAGTTTCGATCCGCTGTTCTTCGGCATCTCGCGCGTGGTGATGGATCCGCAACAGCCTC 
CTGATGACTTATGTCTGGAAGGCGCTGGAAGATGCCGGTTATGCGTCGGAGTCGATCTC 
GGGCAGCCGCACGCGCTGTTCGTCGGCACCGGGCTGAGCGGTTATCAGAACCTGTTCTC 
GGCCGAGGCGCGGGCGGGCGAGGGCTACAGCGCGACTTCGGTGGTGCCGTCGGTCGGGC 
CGAACCGGATGAGCTACTTCCTGAACCTGCATGGGCCGAGCGAGCCGATCGAGACGGCC 
TGCTCCAGCTCGCTGTGGCGATCAACCGCGGCATCGCAGTGCTGCGCGATGGGACCTGC 
GAGATGGCGATCGTCGGCGGCATCAACACCATCGTCACGCCCGACGCGCATGTGAGCTT 
CAGCAAGGCGGCATGCTCAGCGAGGACGGCCGCTGCAAGACCTTCTCGGCGGAACGAAC 
GGCTACGTGCGCGTGAGGGCGTGGGGATGCTGGTGCTGAAGCGTCTGAGCGACGCGCAG 
GCGCCGGCGATGCGATCTATGCCGTGATTCGCGGCGGTTCGGAAAACCACGGCGGCCGG 
GCGAGTTCGCTGACGGCACCCAACCCGCAGCACAAGCGGCCCTGCTGATGGACGCGTAT 
CGCCGCTCGGGCTCGATCCGCGCACGCTCAGCTATATCGAAGCGCACGGCACGGGTACC 
.AAGCTCGGCGATCCGGTGGAGATCACCGCCTGAAGAGTGCGTTTGCAAACCTCGGCGTC 
GAGTCGGGCGACACGTTCTGCGGGCTCGGTTCGGTCAAGAGCAACATCGGCCACCTGGA 
GCTGGCCGCGG 
19) pProt- 123, T7 end. 
CCGGTCGCGTGCCCGACGGCCGGCGTGCTGGCGGTGATCGATCGCGAGTGGTTCCGCTT 
CGCCATCGAGGCCTTCACCACGCCGGCCATCGCGCGATCGCGGACCGAAGCGCTGCCTG 
CCGCAGCCGGCCGSGCCACGCTCGCGCCCGCCGCCGAGGCCTGGCCGGCGAGAGCGGGG 
CCTCAGCGACGCTCGTGATCTCGCCCGAGGACACGCCGGAAGTGAGCGATGGCGAGGCG 
CGCGCACCGATCGTCGCCGCCATCATGGSCGCATCGAATCGATGCCGGTGGACGAGGCG 
CTGTCGATCGCGACCGGCGCGTGGAACTGGCGATCGCCGCGGCGCTCGGCGAGGGCCTC 
ACCGCGCGCCGCCTCCGACGCTGGCCGCGCTGACCG 
20) pProt- 123, T3 end. 
CTGACGTCTTCCTTCAGCGCGGTGGTGCGCTCGGCCACCTGCACCTTGAACTGCTTGCG 
CACGTCGTCCACCCATTGCGTCCAGGCCGGGAAGCGGCGTTCTTGAGCTGGATCTGCAC 
GCCGTTGCCGACCACCTGCACCTGCGCGGCCGCAAGCCGTGATCGGACAGCGAGCTGGT 
CAGCGCGTCGCGCGATGCCGGTGGGCGCCACGCTGCGCGGGCGGCCAGCGAGCGCCTCG 
TTGGCCTGCTCGGTCATCTGCGCGAGTGCAGGCGCATGCCGGCAGCGCGGTGGCGATCT 
TCTCGCTGTTCTCGGCGGCCGGCGACCACAGCACCGAATACAGCACCACCGCCACCAGC 
AGGGCGCCGCCAGCCCAGCAGCAGCTTCTCGCGCGAATTCGTCGTCCCAGAACTGGGTG 
AGGGTTTCGGTCAGTTCCGCCTTCATGATCCGCTCCGGATGGTCCATTTGCCCGTGCTG 
CTGTCGATCTCGCCCGACAGCCGTTACGCGCCAGG 
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21) pProt-125, end. 
CGGCTCGGTGCCGAACACGATGCGATGCACTTCGGTGTCGGAGCCGGGATAGTCGATGG 
TCGCGCCGGTCACGCCGCCGTCCCAGTTGCGCGGCCGGAACAGGTCGTCGCGCGGCGCC 
ACGTCCTCGCCGCGCACGTCGAAGCGGAACGCGTTGTCGGTGGGCTGCCAGGCGATCGG 
CCGCGCGCGCACCTGCSTCGTCGCCGGCGCTCTCGAGCAGCAGCGCCACTCGCTGGGCT 
TCCTCGCGCAGGTCGGTGCGSATTGCGATGCATGGTCAGCGTGGCCGCCGACACGAGGA 
TCCCCGCGATCACGAGCACGACGAGCATCTCGAGCAACGTGAAGCCACGCATCCGCCGG 
GGcGAAACGCAGCGAGGTCGTGCCGGTGGTTCGCATGTCAAACGAAACTGACCAAGAGG 
GAAGGGACGGGCGGTGCGATCCGATGCGCCGGGCTTACTGCCAGGAACCGATGTCGGCG 
TCGTTGTTCTCGCCGCCTTCCTTGGCGTCGGCGCGTAGCTGAACACGTCGATCTCGCCG 
TGCACGCCCGGGTTCAGGTACTTGTACGGGTTGCCCCAGGGATCGTTGGGCAGGCGCTC 
GAGGTAGCCGCCGTCCTTCCAGTTGTTCGGCACCGGATCGGTGGTGGGCTTGGCGATCA 
GCGATTGCAGGCCCTGCTCCTGGGTCGGATAGCGGCCGTTGTCGAGGCGGTAGAGCTTG 
AGCGCCTGCATGATGGTGCCGATATCCTGCTTGGCGGCCACGCCGTGCCTCGTCCGGGC 
GGCTCATGATCTTCGGCACGATCAGCGCGGCCAGGATGCGAGGATCGCGATCACGACCA 
TGATTTCGATCAGCGTGAACCGCGTTGGSACGGCTGGCGGCAGCGCGATTGATCCACGT 
TTGCATGAGTGAAACCTCTCTTTCAAAAACAGTAGTCAACATTGAATGGCGCCGCGGCA 
CGTCGCCGCCAGAAGCCGCATTGTAA 
22) pProt- 125, T3 end. 
CCGTGGTGCGGCCCAAGAAGGCCTGCACGGCGCGCTGATCTCGCGGATCAAGATCATGG 
CGCACGACATCGCCGAGAAACGCCTGCCGCAGATGGCCGGATCACGCTGCGCGCGGCGC 
CGGTGGACGTGCGGGTCTCGACGCTGCCCACCGGCCACGCGAGCGCGCGGTGCTGCGTC 
TGCTGGAAAAGGATGCGCGCCTGAACCTCGAGGCGCTCGGCATGGGCSCGACACGCTGG 
TGCAGTTTGACAAGCTGATCGGCCGCCCGCACGGCATCGGTGGTCACCGGCCCGACCGC 
TCGGAAGACCACCACGCTCTACGCGGCGATGTCGCGCTGGAGACGGCCACCACCAACAT 
CATGACGGTCGAGGATCCGATCGAATACGACCTGTCCGGCATCGCCAGACGCAGGTGAA 
CGAGCGGATCGGCATGAGCTTCGCGCGCGCTGCGTCGATCCTGCGCCAGGATCCGGACG 
TGATCATGATCGGCGAAATCCGCGATCTGGAAACCGCGCAGATCGCCGTGCAGCTCGCT 
GACGGGCCACCTGGTGCTGGCCACCCTGCACACCAACGACGCCGCCTCGSCGTCACGCG 
CCTGACCGACATGGGCGTGGAGCTACCTGCTGGCTTCCTCGCTGCTCGGCGTTGGCGCA 
CGGCTGGTGCATCCTGGCCCGCATTGCAAGGAACCGCGCGAGGAGGAAGGCCGCGTGAT 
CTATCACCCGGTGG 
23) pGSP ME H-H 16.7, T7 end. 
GACCATCGACCGAGGCGGGCCTCAAAGGGYTTTCAGTGGCGATGGACGATTTCCTCGTC 
GTCGTGATCGTCGTGCTCGTCGAGGTCCCAGGACGGAAACGGATCGGGCAGCGCGCGCC 
AGGCTTCCACGCCGGCCGCGTATTCGGCATCGTCGAGCAGGCAGGCGTCGAATTTCGCG 
CGCCATTGCSGTCCAGGCCGATGCCGATCAGCACCAGTTCCTGGCGGCGGTCGCATGCT 
GTCGTCGTCGGGCGCGCCATGCCAATCGGCGGCGATCTCCTCGAGCAGCGCCGGATCGT 
CGTCGGGCCATTCGGCGCGGTCCTGCcGGCCCACCAGAGCCCGGCCGGCCCGTSASGAC 
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GCCGCCCGCCTGCGAGASGAGCCGCCGATATCGTTGCGCGTGGCCAGCCAGAAGAAGCC 
CTTGCTGCGCACACGCCCTGCCATTCGTCGTGCAGCAGGGTCCAGAAACGTTGCGGATG 
AAACGGTCGGCGCGCGCGATAGACGAAGTTGCCGATGCCGAACTCGCCGGCCGCGTGCG 
TGTGCCCGCAATCCTCGCCGCAATCTTCCCCGTGTTCGTGATCGTGCCGATGCTCGAGC 
GAGGCAGCCAGCCCGGCGCGTTGGCGGCGCCTCGAAATCGAACAGGCCGGTGTCGATCA 
CCTCGCGCA 
24)pGSP ME H-H 16.7, T3 end. 
GCTGATGGTGGCGATGCTGGTTCTGCCGGGCCTACGCTGGCGGCACTCGGTTTCGCCTG 
GATCGACCAGCGGCGCCACCAAGGATGCCGCCGCCACCTCCGATGAGCCGTCCTCGTGG 
CGGCTCGCGCTACGTCTGCACCCGCCGCATTGCACGCATTGAGGCTGCCGGCCGCGACC 
GCCGAGCTTCCCTCATCATCCTCATCCGCTTCAGGCGTCCATTCGTGATGCCGAATCTT 
CCCGCCTGCTTCCAGGCCGGCTCATCGTCCAGTGAAAGCCCTCCACCAACTGCTCCTGG 
CGCTCGTCTTGACGATCCTGATCTACCTCGGCCTGGCGAATTCGCGCTGGACGACTGGT 
TCCAGGGCGGCGCGGCTGCTTCGAACGCTGTTCGATGCCATGGCAAGGCTCGGTATCCA 
.CGGGGAAGGCGGCATCCTGATCGGCGCCATGCTGGTCGCCAGCCTTGCGATTGCGGCGA 
TGCTGGTTCGGCTCGCCAGCTTTCGGCGCCGTAATCGCCGGTAACCAGCCACCCCGCGC 
CGGTAACACATCGGCTCGCGCCACGTCTTAACCTTACGGCTGATCCGATCGTGTTTCCC 
GCGTTCGTCAGTTACCATTTCGGCCA 
25) pGSPME 2, T7 end. 
GGTCAATCGGGGAAAAGCGTCCCAAACACGTCATTCCAGCGCCCGCGAGCTTCCTCGGG 
ACGAAAAAAACCCGCCGCGTCCGTTCACAAACGCTGGACTCACCTTGTTCACTGCATCC 
TTGAATGCCTTGCCAGCCGTGAACTTGACGGTCTTGGCTGCCGGAATCTTGATGGTTTC 
GCCCGTCTTCGGTTGCGGCCGGTACGTGCTGCACGCTTACCCGAGCCGAAGCTGCCGAA 
GCCGATCAACTGAACCGCGTCGCCTTTCGACACGGCCTTCTTGATCACCTCGAGGAGCG 
TGTCCAGCGTTTCGCCGGTTTGAGCCTTGCTGGCGCCCGTCTGTGCGGCGACGGCGTCG 
ATCAGTTCCTGTTTGTTCATTAAGGTTCCTTTCTCAGGTTAAGTTGACACGAACAGCGC 
GGACGCGATTATACGTGCGCAGGCCGTAGCATCGCAGTTCGCGGCGACGRCCAGGCCAT 
CCGGACCGCGCCGNCCTGGTACCCGCGGTGAGCCCTGAGGCGCTTCCGCAGTACGGCGC 
TTGCTATGATAGCGCAAAACCCAATAACGACAAGGGTTTCAAAGATTTTCATCCGGATT 
TTGCCGGATCTTCAGGCCGTTGCCGCATTTTTGCCGCGTGCGACCAGCGTTGTCAAGCG 
CCGCAA 
26) pGSP ME H-H 2, T3 end. 
CCTTGCAAGAACCATCCACCTTGCGCGSTTTCTACCCAGTTGCTCGCCGGCCTGCTCGC 
GCGAGACAGGGCCAGTTCATCGGGCATGCAGCGCATCGGCGGCGGCTGCATGCGCATGA 
ATTCCGGCTCGTCGCAGGCGAGTTGCAGCAGGCCTTCGCGACTACGGCAGAACGCATGT 
CCGGCCGCTTCGAACGCGCGCCATCGCACAGCGTTATTGATAACAGGGCACGCGAGACC 
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CCGCGCCGAAGTTGTCGTCGATCGCGACCAGCATGGAACACGCCGGCCCTTGCCCGAGG 
CTTCGCTCGCAGTTCGGCATGTCGATCGATCAGCGTGACTCGCCAGCCGCGCGCGACGC 
TCGACCAGCGCGCAACCTGCCAGGCCCGCGCCGATCACGATCGCGTCGTGCGTATCGGC 
GTCGAAGGCGTGGCGTTCGTGTCGACGCAGCTTCCAGCGCGGCCGAAATTCGCCGACCA 
GCATCGCGCGCTTGCCCGCAATCCCTCCACCTTGCGATACGAAAAGCCCGCGTTTTCCA 
GGGCTCGTTTCACATCGCCGGCGCTCGTGTA 
27)pGSP ME H-E 1.7, T7 end. 
GCCGACCAGCATCGCGCGCTTGCCCGSAATCCCTCCACCTTGCGATACGAAAAGCCCGC 
GTTTTCCAGGGCTCGTTTCACATCGCCGGCGCTCGTGTAGGTGGCGACAKGGCGTGTTC 
GTCGGCCAGTTTCGCGAGCGCGCGGAACACCTCGACGGACCAGAGTTCGGCGTTGCGCG 
AGGGCGAAACCATCGAGGTTTAACGCATCGGCACGCAGCACCAGCGAGGGCAGCATCTC 
GCGCGCATCGCCGACGCGTCAGTACCACGCGCCCTGCATCGAGTTCGACGCGATGCAGC 
CCCGGCGTGAATCGGCCAGGCATCGGCGAGTTGGTCGACCAGGCTCGCCTCGATGGTTG 
TGCCCGCAACGATATGGCGAGCGGCCTTGCGCAGGTCCTCGCGCGAGAACGGATGTTTC 
TCGACCGAGACGAAATGCAGCCGCTCGCTGCGCAAGGATCCGCGCGCCAGGSCCCAGGT 
.CGCGAGGAAGTTGCAGCCGGTGCCGAAGCCGGTCTCGACGATGGTGAAGTGGCGACGCC 
GCGCCASTTCGGGCAGGCGGTTGCGCGCAGGAACACGTGCTCGGCCTGGGCGACGCGCC 
GGCGCTATGGTAGATATCGCCGT 
28)pGSP ME H-E 1.7, T3 end. 
GGTCAAATCGGGGAAAAGCGTGAAACACGTCATTCCAGCGCCCGCGAGCTTCCTCGGGA 
CGAAAAAAAACCCGCCGCGGCCGTTCACAAACGCTGGACTCAGCTTGTTCACTGCATCC 
TTGAATTGCCTTGCCAGCCGTGAACTTGACGGTCTTGTGCTGTCCGGTTATCTTGATGG 
TTTCGCCCGTCTTCGGTTGCGGCCGGTACGTGCTGCACGCTTACCCGAGCCGAAGCTGC 
CGAAGCCGATCAACTGAACCGCGTCGCCTTTCGACACGGCCTTCTTGATCACCTCGAGG 
AGCGTGTCCAGCGTTTCGCCGGTTTGAGCCTTGCTGGCGCCCGTCTGTGCGGCGACGGC 
GTCGATCAGTTCCTGTTTGTTCATTAAGGTTCCTTTCTCAGGTTAAGTTGACACGAACA 
GCGCGGACGATTATACGTGCGCAGGCCGTAGCATCGCAGTTCGCGGCGACGACCAGGCA 
TCCGGACCGCGCCGSCCTGGTACCCGCGGGTGAGCCCTGAGGCGCTTCCGCAGTACGGC 
GCTTGCTATGATA 
29) pGSP KS B-B2.2, T7 end. 
CGGCGAAATCCGCGATCTGGAAACCGCGCAGATCGCCGTGCAGCTCGCTGAGGGCCACC 
TGGTGCTGGCCACCCTGCACACCAACGACGCCGCCTCGGCGTCACGCGCCTGACCGACA 
TGGGCGTGGAGCTACCTGCTGGCTTCCTCGCTGCTCGCGTCTGGCGCAcGGCTGGTGCT 
CTGCCGCATTGCAAGGAACCGCGCGAGGAGGAAGGCCGCGTGATCTATCACCCGGTGGC 
TGCGAGAAGTGCGGCCATTCGGGCTACACGGGCCGGCGCGGTGTCTATGAACTGCTGGT 
GATCGACGACGCGATCCGCTCGCTGGTCCACCGCAACGCCCGATTCGGAAATCCTCGCC 
TCGGGCGCTCGAACGGCATGCGCACGCTGCGACGACGCCGAGCGCTGGCTCGCGCAGGG 
CAACACCTCGCTAGAGAAGTGCTGCGCGTGACGGGAGGCGCGTAGATGCCGGCATTCCG 
Appendix III 208 
TTTCGAAGCGATCGATTCCGGCGGCCGCCCCAGAAGGCGTGATCGAGGCCGACAGCGCG 
CGCGCGGCCAGTTGCGCGGCCAGGGTCTCACGCCGCTGGTGGTCGAGCCGGCCGCGAGC 
CTCGCGCGATGCSAAAGCAGCSCTGTCGATCGGCCGCAAGCTCTCGCAGCGCAGGCCAT 
CCTCACGCGCCATCGCCAGCCTCTTGACCGCCGGGCTGCCGCTCGGAAATCGCTGGCGG 
TGCTCACCGAG 
30) pGSP KS B-B2.2, T3 end. 
GCAGCCCGGGGGATCTATCCCTCGCCCTCTTCGCGGCCTTGTGCGACGGCCACCTACTG 
GGCCATCACGTCTCGGGCATCAGGCCCCGCTACCCGCCGCCGCCGCGCGCTCCCTTGCG 
CACGGAGGACGCTGCCGCGCTGTTCGGCGGGCAGTCACGCACAACCCCGTGGAGGACAT 
CCACCTGTTCGGCATCCTCGCGCTGCCAGGGSGCCGCGATCGTCGGCATCGGCGGATCC 
GGCCCGCACCATCACGCTGGGGCGACATCTCCCAGGGCACCAAGCTCGCCGAGGTCCGC 
GCCCGCTCGATCGTGATCGACCGCAACGGCGCGCATGCCGAGATCTTCCTGCCGGCCAA 
CACGCCCGGCCCCGCCATCTACGTGCGCTGAGCCGTTCCTTCCCATAACGCTCATCGCC 
GACGTTCATTCCGGCAACGGTCGCGATCGGCTTTGCCTTGCATCCCTTACTGCACCATG 
TTGTTCAGCTCGATGATCGGCAGCATCACGGCCAGCACGATCACCAGCACGATGCCGCC 
CATCGCCAGGATCAGGAGCGGCTCGAGCAGGCTGGTCATGAACATGGTGCGGCGCTCGA 
GTTCGCGCGCCTCACCTCGGCGGCGGGTCGAGCATGGTGGTGACGTCGCCGGTGGCTCG 
CCCGAGCGGATCAGGTGCACCAG 
31) pGSP KS B-B7.2, T7 end. 
TCGACCGTCATGATGTTGGTGGTGGCCGTCTCCAGCCGCGACATCGCCGCGTAGAGTGG 
TGGTCTTGCCCGAGCCGGTCGGCGGTGACCAGCACGATGCCGTCGGCGGCCGATCAGCT 
TGTCAAACTGCACCAGCGTGTCGCGCCCATGCAGCGCCTCGAGGTTCAGGCGCTGCGCA 
TCCTTTTCCAGCAGACGCAGCACCGCGCGCTCGCCGTGGCCGGTGGGCAGCGTCGAGAC 
CCGCACGTCCACCGGGCGCCGCACGCGCAATCCGGCNATCCTGCGGCAGGCGTTTCTCG 
GCGATGTCGAGCTGCGCCATGATCTTGATCCGCGAGATCAGCGCGCCGTGCAGGGCCTT 
CTTGGGCGCACCACGTCGCGCATGCCGTCGACGCGAAAGCACCACCGAGGCGTTCTCGA 
AGGGCTCGATGTGGATGTCGGAAGCCTGCTCGCGCGCGGCCTGGGTGAGCAGGGCGTTG 
ATCATGCGGATGATCGGCGCGTCGTCCTCCGATTCCAGCAGGTCCTCGACTTCCGGGAT 
GTCCTGCATCAGCCGCGACAGGTCGACCTCGCCTTCCACCTCGCCGACCACCTGCGCCG 
CGCTGCCGTCCTGGCGCGCATAGGGTGTTGATGGCCTGCGCGACGTCGTCGGCCGGCAG 
CGAGCNTCAACGCGCGAAGTTGCGTGCCACCTCGGCCAGCGCGG 
32)pGSP KS B-B7.2, T3 end. 
CATCGACCGAGGCGGGCCTSAAAGGGTTCAGTGGCGATGGACGATTTCCTCGTCGTCGT 
GATCGTCGTGCTCGTCGAGGTCCCAGGACGGAAACGGATCGGGCAGCGCGCGCCAGGCT 
TCCACGCCGGCCGCGTATTCGGCATCGTCGAGCAGGCAGGCGTCGAATTTCGCGCGCCA 
TTGCGTCCAGGCCGATGCCGATCAGCACCAGTTCCTGGCGGCGGTCGCATGCTGTCGTC 
GTCGGGCGCGCCATGCCAATCGGCGGCGATCTCCTCGAGCAGCGCCGGATCGTCGTCGG 
Appendix III 209 
GCCATTCGGCGCGGTCCTGCGGCCCACCAGAGCCCGGCCGGCCCGTGAGACGCCGCCCG 
CCTGCGAGAGAGCCGCCGATATCGTTGCGCGTGGCCAGCCAGAAGAAGCCCTTGCTGCG 
CAACGCCCTGCCATTCGTCGTGCAGCAGGGTCCAGAAACGTTGCGGATGAAACGGTCGG 
CGCGCGCGATAGACGAATTGCCGATGCCGAACTCGCCGGCCGCGTGCGTGTGCCCGCAA 
TCCTCGCCGCAATCTTCCCCGTGTTCGTGATCGTGCCGATGCTCGAGCGAGGCGAGCCA 
GCCCGGCGCGTTGGCGCTCGAAATCGAACAGGCCGGTGTCGATCACCTCGCGCAGCACC 
GCGCCGAAGCGC 
